```
?  s cathepsin adj z or CTSZ
           0   CATHEPSIN ADJ Z
          60   CTSZ
S1        60   S CATHEPSIN ADJ Z OR CTSZ

?
?  rd
>>>W:  Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S2        29   RD  (UNIQUE ITEMS)

?  t s29/free/1-29
>>>E:  Set 29 does not exist

?  t s29/3,k/1-29
>>>E:  Set 29 does not exist

?  t s1/3,k/1-29
>>>W:  KWIC option is not available in file(s): 399
 1/3,K/1 (Item 1 from file: 5)  Links
   Fulltext available through:   USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
0019601646   Biosis No.: 200700261387
Methylation markers common to breast and lung cancer segregate with breast cancer
risk in benign breast epithelial cells obtained by periareolar fine needle
aspiration (FNA).

Author: Euhus D M (Reprint); Shames D S; Lewis C M; Bu D; Minna J D
Author Address: UT SW Med Ctr, Dallas, TX USA**USA
Journal: Breast Cancer Research and Treatment   100 ( Suppl. 1 ): p S226 2006 2006
Conference/Meeting: 29th Annual San Antonio Breast Cancer Symposium   San Antonio,
TX, USA   December 14 -17, 2006; 20061214
Sponsor: San Antonio Canc Inst
Baylor Coll Med
Canc Therapy & Res Ctr
Univ Texas, Hlth Sci Ctr
ISSN: 0167-6806
Document Type: Meeting; Meeting Poster
Record Type: Citation
Language: English
DESCRIPTORS:
Gene Name: ...human CTSZ gene (Hominidae...


 1/3,K/2 (Item 2 from file: 5)  Links
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
18969215   Biosis No.: 200600314610
Gene amplification in cancer

Author: Powers Scott; Yang Jianxin
Author Address: Greenlawn, NY USA**USA
Journal: Official Gazette of the United States Patent and Trademark Office Patents
DEC 13 2005 2005
Patent Number: US 06974672  Patent Date Granted: December 13, 2005 20051213  Patent
Classification: 435-6 Patent Assignee: Amgen Inc.  Patent Country: USA
ISSN: 0098-1133
Document Type: Patent
Record Type: Abstract
Language: English
```

Abstract: ...diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the CTSZ and CD24 genes, which are amplified colon cancer and/or ovarian cancer and/or breast cancer genes. The CTSZ and CD24 genes, their expressed protein products and antibodies are used diagnostically or as targets...
DESCRIPTORS:
Gene Name: ...human CTSZ gene (Hominidae)

1/3,K/3 (Item 3 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
18688474 Biosis No.: 200600033869
Cathepsins in the ovine uterus: Regulation by pregnancy, progesterone, and interferon tau

Author: Song Gwonhwa; Spencer Thomas E; Bazer Fuller W (Reprint)
Author Address: Texas A and M Univ, Ctr Anim Biotechnol and Genom, 442 Kleberg Ctr,2471 TAMU, College Stn, TX 77843 USA**USA
Author E-mail Address: fbazer@cvm.tamu.edu
Journal: Endocrinology 146 ( 11 ): p 4825-4833 NOV 2005 2005
ISSN: 0013-7227
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ...expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant... ...tau. Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ) or progesterone and IFN tau (CTSH, CTSK, CTSS, and CTSZ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and...
DESCRIPTORS:
Gene Name: ...sheep CTSZ gene (Bovidae...

1/3,K/4 (Item 4 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
18237633 Biosis No.: 200500144698
Cyclic tetrasaccharide-synthesizing enzymes from Arthrobacter globiformis A19

Author: Mukai Kazuhisa (Reprint); Maruta Kazuhiko; Satouchi Kazuhiro; Kubota Michio ; Fukuda Shigeharu; Kurimoto Masashi; Tsujisaka Yoshio
Author Address: Amase Inst, Hayashibara Biochem Labs Inc, 7-7 Amase Minami Machi, Okayama, 7000834, Japan**Japan
Author E-mail Address: amaseken@hayashibara.co.jp
Journal: Bioscience Biotechnology and Biochemistry 68 ( 12 ): p 2529-2540 December 2004 2004
Medium: print
ISSN: 0916-8451
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...than the enzymes from strains of B. globisporus. The genes for IMT (ctsY) and 6GT (ctsZ) were cloned from the genome of A. globiformis A19. The two genes linked together in...

DESCRIPTORS:
Gene Name: ...Arthrobacter globiformis ctsZ gene (Irregular Nonsporing Gram-Positive Rods)

1/3,K/5 (Item 5 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
16983940 Biosis No.: 200200577451
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer

Author: Mahlamaki Eija H (Reprint); Barlund Maarit; Tanner Minna; Gorunova Ludmila; Hoglund Mattias; Karhu Ritva; Kallioniemi Anne
Author Address: Department of Clinical Chemistry, Tampere University Hospital, FIN-33521, P.O. Box 2000, Tampere, Finland**Finland
Journal: Genes Chromosomes and Cancer 35 ( 4 ): p 353-358 December, 2002 2002
Medium: print
ISSN: 1045-2257
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...17. In the 20q arm, the amplification frequencies varied from 32% to 83%, with the CTSZ gene at 20q13 being most frequently affected. These results illustrate that amplification of genes from...

1/3,K/6 (Item 6 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
16867043 Biosis No.: 200200460554
Cloning and sequencing of the genes encoding cyclic tetrasaccharide-synthesizing enzymes from Bacillus globisporus C11

Author: Aga Hajime (Reprint); Maruta Kazuhiko; Yamamoto Takuo; Kubota Michio; Fukuda Shigeharu; Kurimoto Masashi; Tsujisaka Yoshio
Author Address: Amase Institute, Hayashibara Biochemical Laboratories, 7-7 Amase Minami-machi, Okayama, 700-0834, Japan**Japan
Journal: Bioscience Biotechnology and Biochemistry 66 ( 5 ): p 1057-1068 May, 2002 2002
Medium: print
ISSN: 0916-8451
Document Type: Article
Record Type: Abstract
Language: English

Abstract: The genes for isomaltosyltransferase (CtsY) and 6-glucosyltransferase ( CtsZ), involved in synthesis of a cyclic tetrasaccharide from alpha-glucan, have been cloned from the... ...of 1093 residues having a signal sequence of 29 residues in its N-terminus. The ctsZ gene encodes a protein consisting of 1284 residues with a signal sequence of 35 residues...

1/3,K/7 (Item 7 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
15734468 Biosis No.: 200000452781
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Author: Bonthron David T (Reprint); Hayward Bruce E; Moran Veronica; Strain Lisa
Author Address: Molecular Medicine Unit, University of Leeds, St James's University Hospital, Clinical Sciences Building, Leeds, LS9 7TF, UK**UK
Journal: Human Genetics 107 ( 2 ): p 165-175 August, 2000 2000
Medium: print
ISSN: 0340-6717
Document Type: Article
Record Type: Abstract
Language: English
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Abstract: ...tissues, suggesting that, unlike GNAS1, TH1 is probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure... ...TH1, only 70 bp separating their polyadenylation sites. A polymorphism was again identified within the CTSZ 3' untranslated region and used to demonstrate biallelic expression in fetal tissues.
DESCRIPTORS:
Chemicals & Biochemicals: ...human CTSZ gene...

1/3,K/8 (Item 1 from file: 24) Links
CSA Life Sciences Abstracts
(c) 2007 CSA. All rights reserved.
0002874280 IP Accession No: 6458347
Cyclic Tetrasaccharide-Synthesizing Enzymes from Arthrobacter globiformis A19

Mukai, Kazuhisa; Maruta, Kazuhiko; Satouchi, Kazuhiro; Kubota, Michio; Fukuda, Shigeharu; Kurimoto, Masashi; Tsujisaka, Yoshio Amase Institute, Hayashibara Biochemical Laboratories, Inc., 7-7 Amase minami-machi, Okayama 700-0834, Japan
Bioscience, Biotechnology, and Biochemistry , v 68 , n 12 , p [np] , 2004
Publication Date: 2004

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0916-8451
File Segment: Bacteriology Abstracts (Microbiology B)

Abstract:
...than the enzymes from strains of B. globisporus. The genes for IMT (ctsY) and 6GT (ctsZ) were cloned from the genome of A. globiformis A19. The two genes linked together in...

1/3,K/9 (Item 2 from file: 24) Links
Fulltext available through: USPTO Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2007 CSA. All rights reserved.
0002450689 IP Accession No: 5569328
Cloning and Sequencing of the Genes Encoding Cyclic Tetrasaccharide-synthesizing Enzymes from Bacillus globisporus C11

Aga, Hajime; Maruta, Kazuhiko; Yamamoto, Takuo; Kubota, Michio; Fukuda, Shigeharu; Kurimoto, Masashi; Tsujisaka, Yoshio Amase Institute, Hayashibara Biochemical Laboratories, 7-7 Amase minami-machi, Okayama 700-0834, Japan, [mailto:amaseken@hayashibara.co.jp]
Bioscience, Biotechnology, and Biochemistry , v 66 , n 5 , p 1057-1068 , May 2002
Publication Date: 2002

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0916-8451
File Segment: Bacteriology Abstracts (Microbiology B)

Abstract:
The genes for isomaltosyltransferase (CtsY) and 6-glucosyltransferase ( CtsZ), involved in synthesis of a cyclic tetrasaccharide from alpha -glucan, have been cloned from the... ...of 1093 residues having a signal sequence of 29 residues in its N-terminus. The ctsZ gene encodes a protein consisting of 1284 residues with a signal sequence of 35 residues...

Descriptors: ...Aspartic acid; Gene clusters; cyclic tetrasaccharides; alpha -Glucan; 6-Glucosyltransferase; isomaltosyltransferase; glycoside hydrolase; ctsY gene; ctsZ gene; sugar transport; Bacillus globisporus; Thermococcus

1/3,K/10 (Item 1 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rights reserved.
14438813 Genuine Article#: 974IP No. References: 44
Cathepsins in the ovine uterus: Regulation by pregnancy, progesterone, and interferon tau

Author: Song GH; Spencer TE; Bazer FW (REPRINT)
Corporate Source: Texas A&M Univ,Ctr Anim Biotechnol & Genom,442 Kleberg Ctr,2471 TAMU/College Stn//TX/77843 (REPRINT); Texas A&M Univ,Ctr Anim Biotechnol & Genom,College Stn//TX/77843; Texas A&M Univ,Dept Anim Sci,College Stn//TX/77843 ( fbazer@cvm.tamu.edu )
Journal: ENDOCRINOLOGY , 2005 , V 146 , N11 ( NOV ) , P 4825-4833
ISSN: 0013-7227 Publication date: 20051100
Publisher: ENDOCRINE SOC , 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Abstract: ...intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ...expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant... ...tau. Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ) or progesterone and IFN tau (CTSH, CTSK, CTSS, and CTSZ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and...

1/3,K/11 (Item 2 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rights reserved.
13489190 Genuine Article#: 886TC No. References: 23
Cyclic tetrasaccharide-synthesizing enzymes from Arthrobacter globiformis A19

Author: Mukai K (REPRINT) ; Maruta K; Satouchi K; Kubota M; Fukuda S; Kurimoto M; Tsujisaka Y
Corporate Source: Hayashibara Biochem Labs Inc,Amase Inst,7-7 Amase Minami Machi/Okayama 7000834//Japan/ (REPRINT); Hayashibara Biochem Labs Inc,Amase Inst,Okayama 7000834//Japan/ ( amaseken@hayashibara.co.jp )
Journal: BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY , 2004 , V 68 , N12 ( DEC ) , P 2529-2540
ISSN: 0916-8451 Publication date: 20041200

Publisher: JAPAN SOC BIOSCI BIOTECHN AGROCHEM , JAPAN ACAD SOC CTR BLDG, 2-4-6 YAYOI BUNKYO-KU, TOKYO, 113, JAPAN
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Abstract: ...than the enzymes from strains of B. globisporus. The genes for IMT (ctsY) and 6GT (ctsZ) were cloned from the genome of A. globiformis A19. The two genes linked together in...

1/3,K/12 (Item 3 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rights reserved.
11124549 Genuine Article#: 608ZV No. References: 23
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer

Author: Mahlamaki EH (REPRINT) ; Barlund M; Tanner M; Gorunova L; Hoglund M; Karhu R; Kallioniemi A
Corporate Source: Tampere Univ Hosp,Dept Clin Chem, Canc Genet Lab,POB 2000/FIN-33521 Tampere//Finland/ (REPRINT); Tampere Univ Hosp,Dept Clin Chem, Canc Genet Lab,FIN-33521 Tampere//Finland/; Univ Tampere,FIN-33101 Tampere//Finland/; Univ Lund Hosp,Dept Clin Genet,S-22185 Lund//Sweden/
Journal: GENES CHROMOSOMES & CANCER , 2002 , V 35 , N4 ( DEC ) , P 353-358
ISSN: 1045-2257 Publication date: 20021200
Publisher: WILEY-LISS , DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Abstract: ...17. In the 20q arm, the amplification frequencies varied from 32% to 83%, with the CTSZ gene at 20q 13 being most frequently affected. These results illustrate that amplification of genes...

1/3,K/13 (Item 4 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rights reserved.
10692617 Genuine Article#: 557ZQ No. References: 33
Cloning and sequencing of the genes encoding cyclic tetrasaccharide-synthesizing enzymes from Bacillus globisporus C11

Author: Aga H (REPRINT) ; Maruta K; Yamamoto T; Kubota M; Fukuda S; Kurimoto M; Tsujisaka Y
Corporate Source: Amase Inst,Hayashibara Biochem Labs,77 Amase Minami Machi/Okayama 7000834//Japan/ (REPRINT); Amase Inst,Hayashibara Biochem Labs,Okayama 7000834//Japan/
Journal: BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY , 2002 , V 66 , N5 ( MAY ) , P 1057-1068
ISSN: 0916-8451 Publication date: 20020500
Publisher: JAPAN SOC BIOSCI BIOTECHN AGROCHEM , JAPAN ACAD SOC CTR BLDG, 2-4-6 YAYOI BUNKYO-KU, TOKYO, 113, JAPAN
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Abstract: The genes for isomaltosyltransferase (CtsY) and 6-glucosyltransferase ( CtsZ), involved in synthesis of a cyclic tetrasaccharide from alpha-glucan, have been cloned from the... ...of 1093 residues having a signal sequence of 29 residues in its N-terminus. The ctsZ gene encodes a protein consisting of 1284 residues with a signal sequence of 35 residues...

1/3,K/14 (Item 5 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rights reserved.
08981240 Genuine Article#: 352JV No. References: 25

Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Author: Bonthron DT (REPRINT) ; Hayward BE; Moran V; Strain L
Corporate Source: UNIV LEEDS,ST JAMESS UNIV HOSP, MOL MED UNIT, CLIN SCI BLDG/LEEDS LS9 7TF/W YORKSHIRE/ENGLAND/ (REPRINT); UNIV EDINBURGH,WESTERN GEN HOSP, HUMAN GENET UNIT/EDINBURGH EH4 2XU/MIDLOTHIAN/SCOTLAND/
Journal: HUMAN GENETICS , 2000 , V 107 , N2 ( AUG ) , P 165-175
ISSN: 0340-6717 Publication date: 20000800
Publisher: SPRINGER-VERLAG , 175 FIFTH AVE, NEW YORK, NY 10010
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13
Abstract: ...tissues, suggesting that, unlike GNAS1, TH1 is probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure... ...TH1, only 70 bp separating their polyadenylation sites. A polymorphism was again identified within the CTSZ 3' untranslated legion and used to demonstrate biallelic expression in fetal tissues.

1/3,K/15 (Item 1 from file: 50) Links
Fulltext available through: USPTO Full Text Retrieval Options
CAB Abstracts
(c) 2007 CAB International. All rights reserved.
0008943406 CAB Accession Number: 20053216008
Cathepsins in the ovine uterus: regulation by pregnancy, progesterone, and interferon tau.

Song, G. H.; Spencer, T. E.; Bazer, F. W.
Author email address: fbazer@cvm.tamu.edu
Center for Animal Biotechnology and Genomics, Department of Animal Science, Texas A&M University, College Station, TX 77843, USA.
Endocrinology vol. 146 ( 11 ): p.4825-4833
Publication Year: 2005
ISSN: 0013-7227
Digital Object Identifier: 10.1210/en.2005-0768
Publisher: Endocrine Society Bethesda , USA
Language: English Record Type: Abstract
Document Type: Journal article
... intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ... expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant... ... tau. Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ) or progesterone and IFN (CTSH, CTSK, CTSS, and CTSZ ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and ...

1/3,K/16 (Item 1 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE
(c) 2007 Elsevier B.V. All rights reserved.
03839269 2007254436
Differential Expression of Cathepsins and Cystatin C in Ovine Uteroplacental Tissues

Song G.; Bazer F.W.; Spencer T.E.
Address: T.E. Spencer, Center for Animal Biotechnology and Genomics, Department of Animal Science, Texas A and M University, 2471 TAMU, College Station, TX 77843-2471 , United States

Email: tspencer@tamu.edu
Journal : Placenta , 28/10 (1091-1098) , 2007 , United Kingdom
CODEN: PLACD
ISSN: 0143-4004
Publisher Item Identifier: S0143400407001099
Document Type: Article
Languages: English Summary Languages: English
No. of References: 34

...roles in implantation and placentation in sheep. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, CTSZ, and CST3 mRNAs was detected in ovine uteroplacental tissues with distinct temporal and/or spatial expression patterns between Days 40 and 120 of pregnancy. Of particular note, CTSB, CTSD, and CTSZ mRNAs were predominantly detected in the chorion of the placenta and were more abundant in...

1/3,K/17 (Item 2 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE
(c) 2007 Elsevier B.V. All rights reserved.
03106591 2005270752
Cathepsins in the ovine uterus: Regulation by pregnancy, progesterone, and interferon tau

Song G.; Spencer T.E.; Bazer F.W.
Address: F.W. Bazer, Center for Animal Biotechnology and Genomics, 442 Kleberg Center, Texas A and M University, College Station, TX 77843-2471 , United States
Email: fbazer@cvm.tamu.edu
Journal : Endocrinology , 146/11 (4825-4833) , 2005 , United States
CODEN: ENDOA
ISSN: 0013-7227
Document Type: Article
Languages: English Summary Languages: English
No. of References: 44

...intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ...expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant... ...tau. Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ) or progesterone and IFNtau (CTSH, CTSK, CTSS, and CTSZ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and...

1/3,K/18 (Item 3 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE
(c) 2007 Elsevier B.V. All rights reserved.
02888459 2005043458
Cyclic tetrasaccharide-synthesizing enzymes from Arthrobacter globiformis A19

Mukai K.; Maruta K.; Satouchi K.; Kubota M.; Fukuda S.; Kurimoto M.; Tsujisaka Y.
Address: K. Mukai, Amase Institute, Hayashibara Biochem. Labs., Inc., 7-7 Amase minami-machi, Okayama 700-0834 , Japan
Email: amaseken@hayashibara.co.jp
Journal : Bioscience, Biotechnology and Biochemistry , 68/12 (2529-2540) , 2004 , Japan
CODEN: BBBIE
ISSN: 0916-8451
Document Type: Article
Languages: English Summary Languages: English

No. of References: 23

...than the enzymes from strains of B. globisporus. The genes for IMT (ctsY) and 6GT (ctsZ) were cloned from the genome of A. globiformis A19. The two genes linked together in...

1/3,K/19 (Item 4 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE
(c) 2007 Elsevier B.V. All rights reserved.
02763829 2004242374
Cloning and sequencing of the genes encoding cyclic tetrasaccharide- synthesizing enzymes from Bacillus globisporus C11

Aga H.; Maruta K.; Yamamoto T.; Kubota M.; Fukuda S.; Kurimoto M.; Tsujisaka Y.
Address: H. Aga, Amase Institute, Hayashibara Biochemical Laboratories, 7-7 Amase minami-machi, Okayama 700-0834 , Japan
Email: amaseken@hayashibara.co.jp
Journal : Bioscience, Biotechnology and Biochemistry , 66/5 (1057-1068) , 2002 , Japan
CODEN: BBBIE
ISSN: 0916-8451
Document Type: Article
Languages: English Summary Languages: English
No. of References: 33

The genes for isomaltosyltransferase (CtsY) and 6-glucosyltransferase ( CtsZ), involved in synthesis of a cyclic tetrasaccharide from alpha-glucan, have been cloned from the... ...of 1093 residues having a signal sequence of 29 residues in its N-terminus. The ctsZ gene encodes a protein consisting of 1284 residues with a signal sequence of 35 residues...

1/3,K/20 (Item 5 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE
(c) 2007 Elsevier B.V. All rights reserved.
02170500 2002251489
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer

Mahlamaki E.H.; Barlund M.; Tanner M.; Gorunova L.; Hoglund M.; Karhu R.; Kallioniemi A.
Address: E.H. Mahlamaki, Department of Clinical Chemistry, Tampere University Hospital, P.O. Box 2000, FIN-33521 Tampere , Finland
Email: eija.mahlamaki@tays.fi
Journal : Genes Chromosomes and Cancer , 35/4 (353-358) , 2002 , United States
PUBLICATION DATE: December 1, 2002
CODEN: GCCAE
ISSN: 1045-2257
Document Type: Article
Languages: English Summary Languages: English
No. of References: 23

...17. In the 20q arm, the amplification frequencies varied from 32% to 83%, with the CTSZ gene at 20q 13 being most frequently affected. These results illustrate that amplification of genes...

1/3,K/21 (Item 6 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options
ELSEVIER BIOBASE

(c) 2007 Elsevier B.V. All rights reserved.
01545037 2000208279
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Bonthron D.T.; Hayward B.E.; Moran V.; Strain L.
Address: D.T. Bonthron, Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds LS9 7TF , United Kingdom
Email: D.T.Bonthron@leeds.ac.uk
Journal : Human Genetics , 107/2 (165-175) , 2000 , Germany
CODEN: HUGED
ISSN: 0340-6717
Document Type: Article
Languages: English Summary Languages: English
No. of References: 26
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

...tissues, suggesting that, unlike GNAS1, TH1 is probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure... ...TH1, only 70 bp separating their polyadenylation sites. A polymorphism was again identified within the CTSZ 3' untranslated region and used to demonstrate biallelic expression in fetal tissues.

1/3,K/22 (Item 1 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14746499 EMBASE No: 2007432049
Differential Expression of Cathepsins and Cystatin C in Ovine Uteroplacental Tissues

Song G.; Bazer F.W.; Spencer T.E.
T.E. Spencer, Center for Animal Biotechnology and Genomics, Department of Animal Science, Texas A and M University, 2471 TAMU, College Station, TX 77843-2471 United States
Author Email: tspencer@tamu.edu
Placenta ( PLACENTA ) ( United Kingdom ) 2007 , 28/10 (1091-1098)
CODEN: PLACD ISSN: 0143-4004
Publisher Item Identifier: S0143400407001099
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 34

...roles in implantation and placentation in sheep. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, CTSZ, and CST3 mRNAs was detected in ovine uteroplacental tissues with distinct temporal and/or spatial expression patterns between Days 40 and 120 of pregnancy. Of particular note, CTSB, CTSD, and CTSZ mRNAs were predominantly detected in the chorion of the placenta and were more abundant in...

1/3,K/23 (Item 2 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13422159 EMBASE No: 2005463408
Cathepsins in the ovine uterus: Regulation by pregnancy, progesterone, and interferon tau

Song G.; Spencer T.E.; Bazer F.W.
F.W. Bazer, Center for Animal Biotechnology and Genomics, 442 Kleberg Center, Texas

A and M University, College Station, TX 77843-2471 United States
Author Email: fbazer@cvm.tamu.edu
Endocrinology ( ENDOCRINOLOGY ) ( United States ) 2005 , 146/11 (4825-4833)
CODEN: ENDOA ISSN: 0013-7227
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 44

...intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ...expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant... ...tau. Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ) or progesterone and IFNtau (CTSH, CTSK, CTSS, and CTSZ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and...

1/3,K/24 (Item 3 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11819087 EMBASE No: 2002389392
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer

Mahlamaki E.H.; Barlund M.; Tanner M.; Gorunova L.; Hoglund M.; Karhu R.; Kallioniemi A.
E.H. Mahlamaki, Department of Clinical Chemistry, Tampere University Hospital, P.O. Box 2000, FIN-33521 Tampere Finland
Author Email: eija.mahlamaki@tays.fi
Genes Chromosomes and Cancer ( GENES CHROMOSOMES CANCER ) ( United States ) 01 DEC 2002 , 35/4 (353-358)
CODEN: GCCAE ISSN: 1045-2257
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 23

...17. In the 20q arm, the amplification frequencies varied from 32% to 83%, with the CTSZ gene at 20q 13 being most frequently affected. These results illustrate that amplification of genes...

1/3,K/25 (Item 4 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10839518 EMBASE No: 2000320402
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Bonthron D.T.; Hayward B.E.; Moran V.; Strain L.
D.T. Bonthron, Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds LS9 7TF United Kingdom
Author Email: D.T.Bonthron@leeds.ac.uk
Human Genetics ( HUM. GENET. ) ( Germany ) 2000 , 107/2 (165-175)
CODEN: HUGED ISSN: 0340-6717
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 26
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

...tissues, suggesting that, unlike GNAS1, TH1 is probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure... ...TH1, only 70 bp separating their polyadenylation sites. A polymorphism was again identified within the CTSZ 3' untranslated region and used to demonstrate biallelic expression in fetal tissues.

1/3,K/26 (Item 1 from file: 144) Links
Pascal
(c) 2007 INIST/CNRS. All rights reserved.

17400127 PASCAL No.: 05-0479921

Cathepsins in the ovine uterus : Regulation by pregnancy, progesterone, and interferon tau

GWONHWA SONG; SPENCER Thomas E; BAZER Fuller W
Center for Animal Biotechnology and Genomics and Department of Animal Science, Texas A&M University, College Station, Texas 77843, United States
Journal: Endocrinology : (Philadelphia), 2005, 146 (11) 4825-4833
Language: English

Copyright (c) 2005 INIST-CNRS. All rights reserved.

... intracellular proteins, and processing of prohormones. Expression of CTSB, CTSD, CTSH, CTSK, CTSL, CTSS, and CTSZ genes was detected in the endometria of cyclic and early pregnant ewes with distinct temporal... ... expression patterns. In the d 18 and 20 conceptus, expression of CTSB, CTSD, CTSL, and CTSZ mRNA was detected in the trophectoderm. Of particular note, CTSL mRNA was the most abundant...

... tau . Other endometrial CTS genes were also regulated by progesterone alone (CTSB, CTSK, CTSS, and CTSZ ) or progesterone and IFN tau (CTSH, CTSK, CTSS, and CTSZ). These results indicate that CTS of endometrial and conceptus origin may regulate endometrial remodeling and...

1/3,K/27 (Item 2 from file: 144) Links
Pascal
(c) 2007 INIST/CNRS. All rights reserved.

17078692 PASCAL No.: 05-0144052

Cyclic tetrasaccharide-synthesizing enzymes from Arthrobacter globiformis A19

MUKAI Kazuhisa; MARUTA Kazuhiko; SATOUCHI Kazuhiro; KUBOTA Michio; FUKUDA Shigeharu; KURIMOTO Masashi; TSUJISAKA Yoshio
Amase Institute, Hayashibara Biochemical Laboratories, Inc, 7-7 Amase minami-machi, Okayama 700-0834, Japan
Journal: Bioscience, biotechnology, and biochemistry , 2004, 68 (12 ) 2529-2540
Language: English

Copyright (c) 2005 INIST-CNRS. All rights reserved.

... than the enzymes from strains of B. globisporus. The genes for IMT (ctsY) and 6GT (ctsZ) were cloned from the genome of A. globiformis A19. The two genes linked together in...

1/3,K/28 (Item 3 from file: 144) Links
Pascal
(c) 2007 INIST/CNRS. All rights reserved.

15743060 PASCAL No.: 02-0454699

Cloning and sequencing of the genes encoding cyclic tetrasaccharide-synthesizing enzymes from Bacillus globisporus C11

AGA Hajime; MARUTA Kazuhiko; YAMAMOTO Takuo; KUBOTA Michio; FUKUDA Shigeharu; KURIMOTO Masashi; TSUJISAKA Yoshio
Amase Institute, Hayashibara Biochemical Laboratories, 7-7 Amase minami-machi, Okayama 700-0834, Japan
Journal: Bioscience, biotechnology, and biochemistry
, 2002, 66 (5
) 1057-1068
Language: English

Copyright (c) 2002 INIST-CNRS. All rights reserved.

The genes for isomaltosyltransferase (CtsY) and 6-glucosyltransferase ( CtsZ ), involved in synthesis of a cyclic tetrasaccharide from alpha -glucan, have been cloned from the...
... of 1093 residues having a signal sequence of 29 residues in its N-terminus. The ctsZ gene encodes a protein consisting of 1284 residues with a signal sequence of 35 residues...

1/3,K/29 (Item 4 from file: 144) Links
Pascal
(c) 2007 INIST/CNRS. All rights reserved.

14916379 PASCAL No.: 01-0066263

Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

BONTHRON David T; HAYWARD Bruce E; MORAN Veronica; STRAIN Lisa

Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James's University Hospital, Leeds, LS9 7TF, United Kingdom; Human Genetics Unit, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom
Journal: Human genetics, 2000
, 107 (2) 165-175

Language: English

Copyright (c) 2001 INIST-CNRS. All rights reserved.

Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

...tissues, suggesting that, unlike GNASI, THI is probably not imprinted. Immediately downstream of THI lies CTSZ , encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure...

... TH1, only 70 bp separating their polyadenylation sites. A polymorphism was again identified within the CTSZ 3' untranslated region and used to demonstrate biallelic expression in fetal tissues.

...French Descriptors: Chromosome F20; Sequence nucleotide; Homologie; Organisation gene; Cathepsin; Origine parentale; Gene GNAS1; Gene TH1; Gene CTSZ

```
  s cathepsin
S1      88555   S CATHEPSIN

?  s cathepsin(w)Z or CSTZ or cathepsin(w)X or cathepsin(w)P or cathepsin(w)Y
Processing
Processing
Processing
        88555   CATHEPSIN
      1099189   Z
          152   CATHEPSIN(W)Z
           10   CSTZ
        88555   CATHEPSIN
      6940523   X
          197   CATHEPSIN(W)X
        88555   CATHEPSIN
     12346779   P
           65   CATHEPSIN(W)P
        88555   CATHEPSIN
      1989729   Y
           30   CATHEPSIN(W)Y
S2        450   S CATHEPSIN(W)Z OR CSTZ OR CATHEPSIN(W)X OR CATHEPSIN(W)P OR
CATHEPSIN(W)Y

?  s s2 and compound
          450   S2
      4641049   COMPOUND
S3         67   S S2 AND COMPOUND

?  rd
>>>W:  Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S4         63   RD  (UNIQUE ITEMS)

?  t s64/3,k/1-63
>>>E:  Set 64 does not exist

?  t s4/3,k/1-63
>>>W:  KWIC option is not available in file(s): 399
 4/3,K/1 (Item 1 from file: 5)  Links
   Fulltext available through:   USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
18349334   Biosis No.: 200510043834
Defining the substrate specificity of mouse cathepsin P

Author: Puzer Luciano; Barros Nilana M T; Oliveira Vitor; Julianoa Maria Aparecida;
Lu Guizhen; Hassanein Mohamed; Juliano Luiz; Mason Robert W; Carmona Adriana K
(Reprint)
Author Address: UNIFESP, Escola Paulista Med, Dept Biophys, Rua Tres Maio 100,
BR-04044020 Sao Paulo, Brazil**Brazil
Author E-mail Address: adriana@biofis.epm.br
Journal: Archives of Biochemistry and Biophysics   435 ( 1 ): p 190-196 MAR 1 05
2005
ISSN: 0003-9861
Document Type: Article
Record Type: Abstract
Language: English
Defining the substrate specificity of mouse cathepsin P

Abstract: Cathepsin P is a recently discovered placental cysteine protease that is
structurally related to the more ubiquitously expressed, broad-specificity enzyme,
cathepsin L. We studied the substrate specificity requirements of recombinant mouse
```

cathepsin P using fluorescence resonance energy transfer (FRET) peptides derived from the lead sequence Abz-KLRSSKQ-EDDnp... ...Arg), and hydrophobic aliphatic or aromatic residues (Val, Phe). For several substrates, the activity of cathepsin P was markedly regulated by kosmotropic salts, particularly Na2SO4. No significant effect on secondary or tertiary... ...this substrate was almost two orders of magnitude higher than that of the original parent compound. These results show that cathepsin P, in contrast to other mammalian cathepsins, has a restricted catalytic specificity. (C) 2004 Elsevier Inc...
Registry Numbers: ...cathepsin P
DESCRIPTORS:
Chemicals & Biochemicals: ...cathepsin P--

4/3,K/2 (Item 1 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14746499 EMBASE No: 2007432049
Differential Expression of Cathepsins and Cystatin C in Ovine Uteroplacental Tissues

Song G.; Bazer F.W.; Spencer T.E.
T.E. Spencer, Center for Animal Biotechnology and Genomics, Department of Animal Science, Texas A and M University, 2471 TAMU, College Station, TX 77843-2471 United States
Author Email: tspencer@tamu.edu
Placenta ( PLACENTA ) ( United Kingdom ) 2007 , 28/10 (1091-1098)
CODEN: PLACD ISSN: 0143-4004
Publisher Item Identifier: S0143400407001099
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 34
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cystatin C--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin D--endogenous compound--ec;
cathepsin H--endogenous compound--ec; cathepsin K--endogenous compound--ec;
cathepsin L--endogenous compound --ec; cathepsin S--endogenous compound--ec;
messenger RNA --endogenous compound--ec; peptide hydrolase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec

4/3,K/3 (Item 2 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14643786 EMBASE No: 2007348195
Expression of Cathepsin P mRNA, Protein and Activity in the Rat Choriocarcinoma Cell Line, Rcho-1, During Giant Cell Transformation

Hassanein M.; Korant B.D.; Lu G.; Mason R.W.
R.W. Mason, Department of Biomedical Research, Alfred I duPont Hospital for Children, 1600 Rock land Road, Wilmington, DE 19803 United States
Author Email: rmason@nemours.org
Placenta ( PLACENTA ) ( United Kingdom ) 2007 , 28/8-9 (912-919)
CODEN: PLACD ISSN: 0143-4004
Publisher Item Identifier: S0143400406002773
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 44
Expression of Cathepsin P mRNA, Protein and Activity in the Rat Choriocarcinoma Cell Line, Rcho-1, During Giant Cell...

...proteases perform critical functions in protein turnover and are essential for

normal growth and development. Cathepsin P is a member of a newly discovered family of lysosomal cysteine proteases uniquely expressed in... ...L was not regulated. A specific enzyme assay was developed to show that activity of cathepsin P mirrored mRNA expression during differentiation. Cathepsin P protein co-localizes with cathepsin B, indicating that the enzyme probably functions in the endosomal ...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; peptide hydrolase--endogenous compound--ec; proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin 1--endogenous compound--ec; cathepsin 2--endogenous compound--ec; cathepsin P--endogenous compound --ec; cathepsin Q--endogenous compound--ec; cathepsin m--endogenous compound--ec; cathepsin r--endogenous compound--ec

4/3,K/4 (Item 3 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14625291 EMBASE No: 2007394692
Inflammatory processes in the aging mouse brain: Participation of dendritic cells and T-cells

Stichel C.C.; Luebbert H.
C.C. Stichel, Biofrontera Bioscience GmbH, D-51377 Leverkusen Germany
Author Email: c.stichel-gunkel@biofrontera.com
Neurobiology of Aging ( NEUROBIOL. AGING ) ( United States ) 2007 , 28/10 (1507-1521)
CODEN: NEAGD ISSN: 0197-4580
Publisher Item Identifier: S0197458006002740
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 100
DRUG DESCRIPTORS:
CD11b antigen--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin--endogenous compound--ec; integrin --endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/5 (Item 4 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14423842 EMBASE No: 2007158978
Differential expression of cathepsin X in aging and pathological central nervous system of mice

Wendt W.; Zhu X.-R.; Lubbert H.; Stichel C.C.
C.C. Stichel, Biofrontera Bioscience GmbH, D-51377 Leverkusen Germany
Author Email: c.stichel-gunkel@biofrontera.com
Experimental Neurology ( EXP. NEUROL. ) ( United States ) 2007 , 204/2 (525-540)
CODEN: EXNEA ISSN: 0014-4886 eISSN: 1090-2430
Publisher Item Identifier: S0014488607000222
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 77
Differential expression of cathepsin X in aging and pathological central nervous system of mice

...we analyzed the regional, cellular and subcellular localization and the activity of the recently discovered cathepsin X in the normal, developing and pathological mouse brain. Our results show that CATX is: (i... ...plaques in a transgenic mouse model and in Alzheimer patients. These results strongly suggest that cathepsin X is

an important player in degenerative processes during normal aging and in pathological conditions. (c...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/6 (Item 5 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14198060 EMBASE No: 2006599352
Cysteine cathepsins: Regulators of antitumour immune response

Obermajer N.; Doljak B.; Kos J.
J. Kos, University of Ljubljana, Department of Pharmaceutical Biology, Faculty of Pharmacy, Askerceva 7, SI-1000 Ljubljana Slovenia
Author Email: Janko.kos@ffa.uni-lj.si
Expert Opinion on Biological Therapy ( EXPERT OPIN. BIOL. THER. ) ( United Kingdom ) 2006 , 6/12 (1295-1309)
CODEN: EOBTA ISSN: 1471-2598
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 120
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cysteine derivative--endogenous compound--ec; cysteine proteinase --endogenous compound--ec; major histocompatibility antigen class 2 --endogenous compound--ec; cytokine--endogenous compound--ec; growth factor--endogenous compound--ec; integrin--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound --ec; cathepsin K--endogenous compound--ec; stefin A--endogenous compound--ec; stefin B--endogenous compound--ec; cystatin C --endogenous compound--ec; cystatin--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin H--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin w--endogenous compound--ec; cathepsin x --endogenous compound--ec; cystatin f--endogenous compound --ec; cathepsin o--endogenous compound--ec; cathepsin v--endogenous compound--ec

4/3,K/7 (Item 6 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14090484 EMBASE No: 2006493081
Cargo selectivity of the ERGIC-53/MCFD2 transport receptor complex

Nyfeler B.; Zhang B.; Ginsburg D.; Kaufman R.J.; Hauri H.-P.
H. Hans-Peter, Biozentrum, University of Basel, CH-4056 Basel Switzerland
Author Email: hans-peter.hauri@unibas.ch
Traffic ( TRAFFIC ) ( Denmark ) 2006 , 7/11 (1473-1481)
CODEN: TRAFF ISSN: 1398-9219 eISSN: 1600-0854
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 37

...complex in the early secretory pathway. ERGIC-53 also interacts with the two lysosomal glycoproteins cathepsin Z and cathepsin C. Here, we tested the subunit interdependence and cargo selectivity of ERGIC-53... ...yellow fluorescent protein fragment complementation. We found that MCFD2 is dispensable for the binding of cathepsin Z and cathepsin C to ERGIC-53. The results indicate that ERGIC-53 can bind cargo...
DRUG DESCRIPTORS:

* endoplasmic reticulum golgi intermediate compartment protein 53--endogenous compound--ec; *protein--endogenous compound--ec
secretory protein--endogenous compound--ec; receptor--endogenous compound--ec; blood clotting factor 5--endogenous compound --ec; blood clotting factor 8--endogenous compound--ec; lectin --endogenous compound--ec; glycoprotein; dipeptidyl peptidase I; cathepsin; protein subunit--endogenous compound--ec; small interfering RNA; yellow fluorescent protein; unclassified drug
Drug Terms (Uncontrolled): multiple coagulation factor deficiency protein 2--endogenous compound--ec

4/3,K/8 (Item 7 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14057877 EMBASE No: 2006471802
Cysteine cathepsins: Multifunctional enzymes in cancer

Mohamed M.M.; Sloane B.F.
B.F. Sloane, Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 United States
Author Email: bsloane@med.wayne.edu
Nature Reviews Cancer ( NAT. REV. CANCER ) ( United Kingdom ) 2006 , 6/10 (764-775)
CODEN: NRCAC ISSN: 1474-175X
Publisher Item Identifier: NRC1949
Document Type: Journal ; Conference Paper
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 145
DRUG DESCRIPTORS:
* cysteine--endogenous compound--ec; *cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; cathepsin H--endogenous compound --ec; cathepsin L--endogenous compound--ec; cathepsin K--endogenous compound--ec; cathepsin S--endogenous compound--ec; kininogen --endogenous compound--ec; cystatin C--endogenous compound --ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin O--endogenous compound--ec; cathepsin V--endogenous compound--ec; cathepsin W--endogenous compound--ec; cathepsin x--endogenous compound--ec; cystatin D --endogenous compound--ec; cystatin E--endogenous compound --ec; cystatin f--endogenous compound--ec; cystatin s--endogenous compound--ec; cystatin SA--endogenous compound--ec; cystatin sn--endogenous compound--ec; cystatin M--endogenous compound --ec

4/3,K/9 (Item 8 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14049123 EMBASE No: 2006446396
Molecular aspects of stromal-parenchymal interactions in malignant neoplasms

Zalatnai A.
A. Zalatnai, First Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Ulloi ut 26, H-1085 Budapest Hungary
Author Email: zalatnai@korb1.sote.hu
Current Molecular Medicine ( CURR. MOL. MED. ) ( Netherlands ) 2006 , 6/6 (685-693)
CODEN: CMMUB ISSN: 1566-5240
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 108
DRUG DESCRIPTORS:
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; enzyme

precursor--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin K--endogenous compound--ec; cathepsin--endogenous compound --ec; matrix metalloproteinase--endogenous compound--ec; CD147 antigen--endogenous compound--ec; interleukin 1alpha--endogenous compound--ec; basic fibroblast growth factor--endogenous compound--ec; gelatinase B--endogenous compound--ec; tumor necrosis factor alpha--endogenous compound--ec; transforming growth factor beta--endogenous compound--ec; gelatinase A--endogenous compound--ec; collagenase 3--endogenous compound--ec; CD68 antigen--endogenous compound--ec; stromal cell derived factor 1 --endogenous compound--ec; transforming growth factor beta1 --endogenous compound--ec; inducible nitric oxide synthase --endogenous compound--ec; gemcitabine--pharmacology--pd; matrix metalloproteinase inhibitor--clinical trial--ct; matrix metalloproteinase inhibitor--drug therapy...
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/10 (Item 9 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13924109 EMBASE No: 2006345822
Caenorhabditis elegans: Study model for animal and human cathepsins and inhibitors

Hashmi S.; Anwer K.; Bilgrami A.L.
S. Hashmi, Laboratory of Molecular Parasitology, Lindsley F. Kimbal Research Instiute, New York Blood Center, 310 East 67th Street, New York, NY 10021 United States
Author Email: shashmi@nybloodcenter.org
Current Enzyme Inhibition ( CURR. ENZYME INHIB. ) ( Netherlands ) 2006 , 2/2 (173-188)
ISSN: 1573-4080
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 236

...L enzymes in C. elegans. Besides, it also reviews the function of a recently described cathepsin Z. (c) 2006 Bentham Science Publishers Ltd.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase inhibitor --drug therapy--dt; *cysteine proteinase inhibitor--endogenous compound--ec; *cysteine proteinase inhibitor--pharmacology--pd; * cysteine proteinase inhibitor--topical drug administration--tp
cathepsin L--endogenous compound--ec; cathepsin B--endogenous compound--ec; cysteine proteinase--endogenous compound--ec; papain--endogenous compound--ec; cathepsin E--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin H--endogenous compound --ec; cathepsin K--endogenous compound--ec; stefin A--endogenous compound--ec; stefin B--endogenous compound--ec; anthelmintic agent; cyclophosphamide--drug therapy--dt; cyclophosphamide--pharmacology --pd; antineoplastic agent--drug therapy--dt; antineoplastic agent --pharmacology--pd; proteinase inhibitor--drug therapy--dt; proteinase inhibitor--endogenous compound--ec; proteinase inhibitor --pharmacology--pd; proteinase inhibitor--topical drug administration--tp; antimalarial agent--drug therapy--dt; antimalarial agent--pharmacology--pd; cystatin C--drug therapy--dt; cystatin C--endogenous compound--ec; cystatin C--pharmacology--pd; cystatin C--topical drug administration--tp; oryzacystatin--pharmacology--pd; antivirus agent--drug therapy--dt; antivirus agent--endogenous compound--ec; antivirus agent --pharmacology--pd; antivirus agent--topical drug administration--tp; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): cathepsin inhibitor--drug therapy--dt; cathepsin inhibitor--endogenous compound--ec; cathepsin inhibitor--pharmacology--pd; cathepsin inhibitor--topical drug administration--tp; cathepsin Z --endogenous compound--ec; peptide aldehyde--drug therapy--dt; peptide aldehyde--pharmacology--pd; alpha ketoamide--drug therapy--dt...

4/3,K/11 (Item 10 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13908004 EMBASE No: 2006331563
Carboxypeptidase cathepsin X mediates betaSUB2-integrin-dependent adhesion of differentiated U-937 cells

Obermajer N.; Premzl A.; Zavas(caron)nik Bergant T.; Turk B.; Kos J.
J. Kos, Faculty of Pharmacy, University of Ljubljana, As(caron)kerc(caron)eva 7, SI-1000 Ljubljana Slovenia
Author Email: janko.kos@ffa.uni-lj.si
Experimental Cell Research ( EXP. CELL RES. ) ( United States ) 01 AUG 2006 , 312/13 (2515-2527)
CODEN: ECREA ISSN: 0014-4827
Publisher Item Identifier: S0014482706001601
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 50
Carboxypeptidase cathepsin X mediates betaSUB2-integrin-dependent adhesion of differentiated U-937 cells

Cathepsin X is a lysosomal carboxypeptidase with a potential role in processes of inflammation and immune response... ...integrin-binding motifs RGD and ECD, present in the pro- and in mature forms of cathepsin X, respectively, suggest that this enzyme might have a function in cell signaling and adhesion. In... ...protease inhibitors E-64 and CA-074 and 2F12 monoclonal antibody, all of which inhibit cathepsin X activity, significantly reduced adhesion of differentiated U-937 cells to polystyrene- and fibrinogen-coated surfaces... ...whereas their binding to vitronectin, fibronectin or Matrigel was not affected. On the other hand, cathepsin X, added to differentiating U-937 cells, stimulated their adhesion. Using confocal microscopy, we demonstrated that the pro-form of cathepsin X was co-localized with betaSUB2 and betaSUB3 integrin subunits and its mature form solely with... ...U-937 cells and in co-cultures with endothelial cells. Our results indicate that active cathepsin X mediates the function of betaSUB2 integrin receptors during cell adhesion and that it could also...
DRUG DESCRIPTORS:
* carboxypeptidase--endogenous compound--ec; *beta2 integrin --endogenous compound--ec
...cysteine proteinase inhibitor; monoclonal antibody; polystyrene; fibrinogen; integrin receptor; vitronectin; fibronectin; matrigel; beta3 integrin--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; ca 074

4/3,K/12 (Item 11 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13831452 EMBASE No: 2006270160
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer

Vasiljeva O.; Papazoglou A.; Kruger A.; Brodoefel H.; Korovin M.; Deussing J.; Augustin N.; Nielsen B.S.; Almholt K.; Bogyo M.; Peters C.; Reinheckel T.
T. Reinheckel, Institut fur Molekulare Medizin und Zellforschung, Albert-Ludwigs-Universitat Freiburg, Stefan Meier Strasse 17, D-79104 Freiburg Germany
Author Email: Thomas.Reinheckel@uniklinik-freiburg.de
Cancer Research ( CANCER RES. ) ( United States ) 15 MAY 2006 , 66/10 (5242-5250)
CODEN: CNREA ISSN: 0008-5472

Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 48

...labeling of cysteine cathepsins by the active site probe DCG-04 detected up-regulation of cathepsin X on PyMT;ctsbSUP+/+ cells. Treatment of cells with a neutralizing anti-cathepsin X antibody significantly reduced Matrigel invasion of PyMT;ctsbSUP+/+ cells but did not affect invasion of PyMT;ctsbSUP+/+ or PyMT;ctsbSUP+/- cells, indicating a compensatory function of cathepsin X in CTSB-deficient tumor cells. Finally, an adoptive transfer model, in which ctsbSUP+/+, ctsbSUP+/-, and...
DRUG DESCRIPTORS:
* cathepsin B--endogenous compound--ec
virus middle T antigen--endogenous compound--ec; proteinase --endogenous compound--ec; matrigel--endogenous compound--ec; cysteine--endogenous compound--ec

4/3,K/13 (Item 12 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13797099  EMBASE No: 2006226285
Cysteine cathepsins in the immune response

Zavas(caron)nik-Bergant T.; Turk B.
B. Turk, Department of Biochemistry and Molecular Biology, J. Stefan Institute, SI-1000 Ljubljana  Slovenia
Author Email: boris.turk@ijs.si
Tissue Antigens ( TISSUE ANTIGENS ) ( United Kingdom )  2006 , 67/5 (349-355)
CODEN: TSANA  ISSN: 0001-2815  eISSN: 1399-0039
Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 50
DRUG DESCRIPTORS:
* cysteine derivative--endogenous compound--ec; *cathepsin--endogenous compound--ec
major histocompatibility antigen class 2--endogenous compound--ec; cathepsin B--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; cathepsin F--endogenous compound --ec; cathepsin H--endogenous compound--ec; cathepsin K--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin D--endogenous compound --ec; CD4 antigen--endogenous compound--ec; CD8 antigen--endogenous compound--ec; major histocompatibility antigen class 1--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; cathepsin W --endogenous compound--ec; cathepsin V--endogenous compound --ec

4/3,K/14 (Item 13 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13702260  EMBASE No: 2004344716
Protease expression in interface tissues around loose arthroplasties

Kido A.; Pap G.; Nagler D.K.; Ziomek E.; Menard R.; Neumann H.W.; Roessner A.
Dr. A. Kido, Department of Orthopedic Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522  Japan
Author Email: akirakid@naramed-u.ac.jp
Clinical Orthopaedics and Related Research ( CLIN. ORTHOP. RELAT. RES. ) ( United States )  2004 , -/425 (230-236)
CODEN: CORTB  ISSN: 0009-921X
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 35

DRUG DESCRIPTORS:
* proteinase--endogenous compound--ec
cathepsin--endogenous compound--ec; interstitial collagenase --endogenous compound--ec; cathepsin B--endogenous compound --ec; cathepsin D--endogenous compound--ec; cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/15 (Item 14 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13659084 EMBASE No: 2006135543
Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins

Roberts R.
Prof. R. Roberts, Department of Biology, Program in Biochemistry and Molecular Biology, Ursinus College, P.O. Box 1000, Collegeville, PA 19426-1000 United States

Author Email: rroberts@ursinus.edu
Drug News and Perspectives ( DRUG NEWS PERSPECT. ) ( Spain ) 2005 , 18/10 (605-614)
CODEN: DNPEE ISSN: 0214-0934
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 111
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
lysosome enzyme--endogenous compound--ec; cysteine proteinase --endogenous compound--ec; cathepsin B--endogenous compound --ec; dipeptidyl peptidase I--endogenous compound--ec; cathepsin F --endogenous compound--ec; cathepsin H--endogenous compound --ec; cathepsin K--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound--ec; n [n (3 carboxyoxirane 2 carbonyl)leucyl]agmatine--drug comparison--cm; n [n (3...
Drug Terms (Uncontrolled): cathepsin V--endogenous compound--ec; cathepsin O--endogenous compound--ec; cathepsin W--endogenous compound--ec; cathepsin x--endogenous compound--ec; ca 074--drug comparison--cm; ca 074--pharmacology--pd; morpholineurea leucine homophenylalanine vinylsulfonephenyl--drug...

4/3,K/16 (Item 15 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13558393 EMBASE No: 2006036856
An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker

Nagler D.K.; Lechner A.M.; Oettl A.; Kozaczynska K.; Scheuber H.-P.; Gippner-Steppert C.; Bogner V.; Biberthaler P.; Jochum M.
D.K. Nagler, Department of Clinical Chemistry and Clinical Biochemistry, University Hospital of Surgery-City, Ludwig-Maximilians-University, Nussbaumstr. 20, 80336 Munich Germany
Author Email: dorit.naegler@med.uni-muenchen.de
Journal of Immunological Methods ( J. IMMUNOL. METHODS ) ( Netherlands ) 20 JAN 2006 , 308/1-2 (241-250)
CODEN: JIMMB ISSN: 0022-1759
Publisher Item Identifier: S0022175905003704
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35
An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker

The human lysosomal cysteine-type carboxypeptidase cathepsin X is mainly present in monocytes and macrophages and may be released into the circulation due...
...inflammatory marker, we have developed a highly sensitive and specific sandwich-type immunoassay (ELISA) for cathepsin X permitting both intra- and extracellular detection and quantification. The dynamic range of the cathepsin X ELISA was determined to be 100 (detection limit) to 8000 pg/ml. Reproducibility of both... ...of the thiol-dependent cathepsin family was not observed. The ELISA was used to quantify cathepsin X in leukocytes as well as in plasma of healthy volunteers and patients with multiple trauma. During the first 72 h after trauma, plasma levels of cathepsin X increased significantly, particularly in patients who died during the posttraumatic period. In comparison to the well-known inflammation marker neutrophil elastase, cathepsin X levels predicted survival with a higher significance in the later posttraumatic phase. In conclusion, this report provides the first evidence of cathepsin X immunoreactivity not only in cell lysates but also in plasma samples. We suggest that the...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; elastase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/17 (Item 16 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13530117 EMBASE No: 2006015689
Endosomal proteases in antigen presentation

Chapman H.A.
H.A. Chapman, Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA 94143 United States
Author Email: hal.chapman@ucsf.edu
Current Opinion in Immunology ( CURR. OPIN. IMMUNOL. ) ( United Kingdom ) 2006 , 18/1 (78-84)
CODEN: COPIE ISSN: 0952-7915
Publisher Item Identifier: S0952791505002049
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 57
DRUG DESCRIPTORS:
* proteinase--endogenous compound--ec; *major histocompatibility antigen class 1--endogenous compound--ec; *major histocompatibility antigen class 2--endogenous compound--ec
cathepsin--endogenous compound--ec; cathepsin D--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec ; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/18 (Item 17 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13445732 EMBASE No: 2005489501
Gene expression profiles reveal increased mClca3 (Gob5) expression and mucin production in a murine model of asbestos-induced fibrogenesis

Sabo-Attwood T.; Ramos-Nino M.; Bond J.; Butnor K.J.; Heintz N.; Gruber A.D.; Steele C.; Taatjes D.J.; Vacek P.; Mossman B.T.
B.T. Mossman, University of Vermont, HSRF 218, 89 Beaumont Ave., Burlington, VT

05405 United States
Author Email: brooke.mossman@uvm.edu
American Journal of Pathology ( AM. J. PATHOL. ) ( United States ) 2005 , 167/5 (1243-1256)
CODEN: AJPAA ISSN: 0002-9440
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 63
DRUG DESCRIPTORS:
* mucin--endogenous compound--ec; *asbestos; *gene product--endogenous compound--ec chrysotile; cyclin B1--endogenous compound--ec; cell cycle protein 20--endogenous compound--ec; cyclin dependent kinase 1--endogenous compound--ec; chemokine--endogenous compound--ec; complement component C1--endogenous compound--ec; chitinase--endogenous compound--ec; tumor necrosis factor derivative--endogenous compound--ec; interleukin 1beta--endogenous compound--ec; macrophage elastase--endogenous compound--ec; stromelysin --endogenous compound--ec; integrin--endogenous compound--ec; cathepsin K--endogenous compound--ec; cathepsin--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin S--endogenous compound--ec; cytokine--endogenous compound--ec ; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): protein mCLCA3--endogenous compound--ec; protein Gob5--endogenous compound--ec; CDC28 protein kinase regulatory subunit 2--endogenous compound--ec; CCL9 chemokine--endogenous compound--ec; ccl6 chemokine--endogenous compound--ec; chitinase 3 like 3--endogenous compound--ec; tumor necrosis factor superfamily member 10 --endogenous compound--ec; integrin alphaX--endogenous compound--ec; cathepsin Z--endogenous compound --ec

4/3,K/19 (Item 18 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13365751 EMBASE No: 2005432915
Large scale real-time PCR analysis of mRNA abundance in rainbow trout eggs in relationship with egg quality and post-ovulatory ageing

Aegerter S.; Jalabert B.; Bobe J.
J. Bobe, INRA, SCRIBE, Campus de Beaulieu, F-35042 Rennes Cedex France
Author Email: Julien.Bobe@rennes.inra.fr
Molecular Reproduction and Development ( MOL. REPROD. DEV. ) ( United States ) 2005 , 72/3 (377-385)
CODEN: MREDE ISSN: 1040-452X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35

...period, eight transcripts (nucleoplasmin or Npm2, ferritin H, tubulin beta, JNK1, cyclin A1, cyclin A2, cathepsin Z, and IGF2) exhibited a differential abundance at one or several collection time(s). Interestingly, we... ...lower levels of Npm2, tubulin beta, and IGF1 transcripts. In contrast, keratins 8 and 18, cathepsin Z, and prostaglandin synthase 2 were more abundant in low quality eggs than in high quality...
DRUG DESCRIPTORS:
nucleoplasmin--endogenous compound--ec; somatomedin--endogenous compound--ec; cyclin A--endogenous compound--ec; tubulin --endogenous compound--ec; ferritin--endogenous compound--ec; stress activated protein kinase 1--endogenous compound--ec; cathepsin--endogenous compound--ec; somatomedin C--endogenous compound--ec; beta tubulin--endogenous compound--ec; keratin --endogenous compound--ec; prostaglandin synthase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cyclin a1--endogenous compound--ec; cyclin A2--endogenous compound--ec; cathepsin Z--endogenous compound --ec; keratin 8--endogenous compound--ec; keratin 18--endogenous compound--ec; prostaglandin synthase 2--endogenous compound --ec

4/3,K/20 (Item 19 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13318701 EMBASE No: 2005386832
Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer

Krueger S.; Kalinski T.; Hundertmark T.; Wex T.; Kuster D.; Peitz U.; Ebert M.; Nagler D.K.; Kellner U.; Malfertheiner P.; Naumann M.; Rocken C.; Roessner A.
S. Krueger, Department of Pathology, Otto-von-Guericke University, Leipziger Strasse 44, D-39120 Magdeburg Germany
Author Email: Sabine.Krueger@medizin.uni-magdeburg.de
Journal of Pathology ( J. PATHOL. ) ( United Kingdom ) 2005 , 207/1 (32-42)
CODEN: JPTLA ISSN: 0022-3417
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35
Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer

Recently, we identified increased cathepsin X expression in H. pylori-infected gastric mucosa. Here, we describe further up-regulation in gastric cancer and report on the role of inflammatory cytokines required for cathepsin X up-regulation in H. pylori-infected gastric mucosa, as well as on consequences for cellular...
...infected and non-infected patients. Gastric cancer samples were obtained from patients undergoing gastric surgery. Cathepsin X was detected in gastric mucosa by quantitative real-time RT-PCR, western blotting and immunohistochemistry. Induction of cathepsin X expression in epithelial and inflammatory cells caused by H. pylori infection was tested in in... ...cultures of AGS cells and monocytic cells. Patients with H. pylori gastritis showed significantly higher cathepsin X mRNA (2.5-fold) and protein (1.6-fold) expression than H. pylori-negative patients. Cathepsin X was also up-regulated in gastric cancer (3-12-fold) compared to non-neoplastic mucosa. Cathepsin X was predominantly expressed by macrophages in the mucosal stroma and in glands of the antral mucosa. In addition, tumour cells stained for cathepsin X in 26 (68%) patients with gastric carcinoma. In general, staining was significantly more common (20... ...via soluble factors in the culture medium seems to be responsible for increased expression of cathepsin X in monocytes. Using antisense oligonucleotides, cathepsin X up-regulation was directly associated with higher invasiveness in vitro. Although no correlation of cathepsin X expression and TNM stage was found, our study demonstrates that cathepsin X plays a role not only in the chronic inflammation of gastric mucosa but also in...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cytokine--endogenous compound--ec; messenger RNA--endogenous compound--ec; antisense oligonucleotide; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/21 (Item 20 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13163079 EMBASE No: 2005224520
Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues

Kos J.; Sekirnik A.; Premzl A.; Bergant V.Z.; Langerholc T.; Turk B.; Werle B.; Golouh R.; Repnik U.; Jeras M.; Turk V.
J. Kos, Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, As(caron)kerc(caron)eva 7, SI-1000 Ljubljana Slovenia
Author Email: janko.kos@krka.biz
Experimental Cell Research ( EXP. CELL RES. ) ( United States ) 15 MAY 2005 ,

306/1 (103-113)
CODEN: ECREA ISSN: 0014-4827
Publisher Item Identifier: S0014482704007220
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 42

Cathepsin X, a recently discovered lysosomal cysteine protease, shares common structural features and activity properties with cysteine... ...distribution in cells and tissues and to their possible roles in malignancy. Protein level of cathepsin X did not differ significantly between matched pairs of lung tumor and adjacent lung tissue obtained... ...6-fold higher in tumor compared to adjacent lung tissue. Immunohistochemical analysis of lung tumor cathepsin X revealed very faint staining in tumor cells but positive staining in infiltrated histiocytes, alveolar macrophages, bronchial epithelial cells, and alveolar type II cells. Cathepsin X stained positive also in CD68SUP+ cells in germinal centers of secondary follicles in lymph nodes ... ...10A neoT and MDA-MB 231, showed positive staining for cathepsin B, but negative for cathepsin X. We showed that the invasive potential of MCF-10A neoT cells can be impaired by specific inhibitor of cathepsin B but not by that of cathepsin X. Cathepsin X was found in large amounts in the pro-monocytic U-937 cell line, in monocytes and in dendritic cells, generated from monocytes in vitro. Our results show that cathepsin X is not involved in degradation of extracellular matrix, a proteolytic event leading to tumor cell...
DRUG DESCRIPTORS:
* carboxypeptidase--endogenous compound--ec; *cathepsin B--endogenous compound--ec
CD68 antigen--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/22 (Item 21 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13140612 EMBASE No: 2005207535
Capturing protein interactions in the secretory pathway of living cells

Nyfeler B.; Michnick S.W.; Hauri H.-P.
H.-P. Hauri, Dept. of Pharmacol. and Neurbiology, Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel Switzerland
Author Email: hans-peter.hauri@unibas.ch
Proceedings of the National Academy of Sciences of the United States of America ( PROC. NATL. ACAD. SCI. U. S. A. ) ( United States ) 03 MAY 2005 , 102/18 (6350-6355)
CODEN: PNASA ISSN: 0027-8424
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35

...ERGIC-53-interacting multicoagulation factor deficiency protein MCFD2, and to ERGIC-53's cargo glycoprotein cathepsin Z. YFP PCA analysis revealed the oligomerization of ERGIC-53 and its interaction with MCFD2, as well as its lectin-mediated interaction with cathepsin Z. Mutation of the lectin domain of ERGIC-53 selectively decreased YFP complementation with cathepsin Z. Using YFP PCA, we discovered a carbohydrate-mediated interaction between ERGIC-53 and cathepsin C...
DRUG DESCRIPTORS:
* endoplasmic reticulum golgi intermediate compartment protein 53--endogenous compound--ec; *cathepsin--endogenous compound--ec; *hybrid protein--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; multicoagulation factor deficiency protein--endogenous compound--ec

4/3,K/23 (Item 22 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13138770 EMBASE No: 2005198390
The human brain mannose 6-phosphate glycoproteome: A complex mixture composed of multiple isoforms of many soluble lysosomal proteins

Sleat D.E.; Lackland H.; Wang Y.; Sohar I.; Xiao G.; Li H.; Lobel P.
Dr. P. Lobel, Ctr. for Adv. Biotech. and Medicine, 679 Hoes Lane, Piscataway, NJ 08854 United States
Author Email: lobel@cabm.rutgers.edu
Proteomics ( PROTEOMICS ) ( Germany ) 2005 , 5/6 (1520-1532)
CODEN: PROTC ISSN: 1615-9853
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 41
DRUG DESCRIPTORS:
* mannose 6 phosphate--endogenous compound--ec; *lysosome enzyme --endogenous compound--ec; *proteome--endogenous compound--ec
somatomedin B receptor--endogenous compound--ec; n acetyl beta glucosaminidase--endogenous compound--ec; cathepsin S--endogenous compound--ec; deoxyribonuclease II--endogenous compound--ec; dipeptidyl peptidase--endogenous compound--ec; gamma glutamyl hydrolase--endogenous compound--ec; legumain--endogenous compound--ec; lysophospholipase--endogenous compound--ec; proline carboxypeptidase--endogenous compound--ec; clusterin --endogenous compound--ec; acetylesterase--endogenous compound--ec; alpha mannosidase--endogenous compound--ec; serine carboxypeptidase--endogenous compound--ec; ribonuclease --endogenous compound--ec; ependymin--endogenous compound--ec ; n4 (beta n acetylglucosaminyl)asparaginase--endogenous compound --ec; angiotensinogen--endogenous compound--ec; cerebroside sulfatase--endogenous compound--ec; acylsphingosine deacylase --endogenous compound--ec; palmitoyl protein thioesterase --endogenous compound--ec; cystatin C--endogenous compound --ec; cystatin B--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; cathepsin D--endogenous compound --ec; cathepsin F--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin--endogenous compound--ec; F box protein--endogenous compound--ec; ferritin--endogenous compound--ec; alpha levo fucosidase--endogenous compound--ec; alpha glucosidase--endogenous compound--ec; sulfatase--endogenous compound--ec; alpha galactosidase--endogenous compound--ec; beta galactosidase--endogenous compound--ec; beta glucuronidase --endogenous compound--ec; beta n acetylhexosaminidase A--endogenous compound--ec; beta n acetylhexosaminidase B--endogenous compound--ec; iduronate 2 sulfatase--endogenous compound--ec; levo iduronidase--endogenous compound--ec; galectin 1--endogenous compound--ec; acid lipase--endogenous compound--ec; myelin associated glycoprotein--endogenous compound--ec; beta mannosidase --endogenous compound--ec; prosaposin--endogenous compound --ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin p--endogenous compound--ec; cathepsin x --endogenous compound--ec; dipeptidyl peptidase VII--endogenous compound--ec; ribonuclease 6--endogenous compound--ec; n acetyl 6 galactosamine sulfatase--endogenous compound--ec; n acetyl glucosamine 6 sulfatase--endogenous compound--ec

4/3,K/24 (Item 23 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13138755 EMBASE No: 2005198358
Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease

Abe J.; Jibiki T.; Noma S.; Nakajima T.; Saito H.; Terai M.

Dr. J. Abe, Department of Allergy and Immunology, Natl. Res. Inst. Child Hlth./Devmt., 2-10-1 Ohkura, Setagaya-ku, Tokyo 157-8535 Japan
Author Email: jabe@nch.go.jp
Journal of Immunology ( J. IMMUNOL. ) ( United States ) 01 MAY 2005 , 174/9 (5837-5845)
CODEN: JOIMA ISSN: 0022-1767
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 53
DRUG DESCRIPTORS:
* ...dose--do; *immunoglobulin--drug therapy--dt; *immunoglobulin --intravenous drug administration--iv; *chemokine receptor CCR2--endogenous compound--ec; *protein S 100--endogenous compound--ec; *Fc receptor--endogenous compound--ec; *adrenomedullin--endogenous compound--ec
formylpeptide receptor--endogenous compound--ec; C reactive protein --endogenous compound--ec; toll like receptor 2--endogenous compound--ec; adiponectin--endogenous compound--ec; cell surface receptor--endogenous compound--ec; colony stimulating factor receptor--endogenous compound--ec; interleukin 8 receptor --endogenous compound--ec; CD39 antigen--endogenous compound --ec; CD16 antigen--endogenous compound--ec; colony stimulating factor 1--endogenous compound--ec; protein tyrosine phosphatase --endogenous compound--ec; protein p57--endogenous compound --ec; interleukin 3--endogenous compound--ec; versican--endogenous compound--ec; immunoglobulin kappa chain--endogenous compound --ec; APRIL protein--endogenous compound--ec; dysferlin--endogenous compound--ec; chimerin--endogenous compound--ec; hematopoietic cell kinase--endogenous compound--ec; phosphatase --endogenous compound--ec; RGS2 protein--endogenous compound --ec; Rab protein--endogenous compound--ec; transcription factor --endogenous compound--ec; protein v fos--endogenous compound --ec; early growth response factor 1--endogenous compound--ec; calreticulin--endogenous compound--ec; major histocompatibility antigen class 2--endogenous compound--ec; hexokinase--endogenous compound--ec; 5 aminolevulinate synthase--endogenous compound --ec; oxidoreductase--endogenous compound--ec; cytochrome P450 1B1 --endogenous compound--ec; long chain fatty acid coenzyme A ligase --endogenous compound--ec; histidine ammonialyase--endogenous compound--ec; microsomal aminopeptidase--endogenous compound --ec; spermidine--endogenous compound--ec; acyltransferase --endogenous compound--ec; cathepsin--endogenous compound--ec ; collapsin response mediator protein--endogenous compound--ec; ribosome protein--endogenous compound--ec; aquaporin 9--endogenous compound--ec; carrier protein--endogenous compound--ec; scramblase--endogenous compound--ec; heat shock protein 70 --endogenous compound--ec; protein disulfide isomerase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): protein S100A9--endogenous compound--ec; protein S100A12--endogenous compound--ec; protein S100A8--endogenous compound--ec; adiponectin receptor 1--endogenous compound--ec; leukocyte immunoglobulin receptor B1--endogenous compound--ec; leukocyte immunoglobulin receptor B2--endogenous compound--ec; leukocyte immunoglobulin like receptor B3--endogenous compound--ec; stabilin 1 --endogenous compound--ec; S phase response protein--endogenous compound--ec; growth arrest specific protein 7--endogenous compound--ec; cold autoinflammatory syndrome 1 protein--endogenous compound--ec; pre B cell colony enhancing factor--endogenous compound--ec; proapoptotic caspase adaptor protein--endogenous compound--ec; chimerin 2--endogenous compound--ec; dual specificity phosphatase 1--endogenous compound--ec; Rab31 protein --endogenous compound--ec; kruppel like factor 4--endogenous compound--ec; cold shock domain protein A--endogenous compound--ec; SFFV proviral integration 1 protein--endogenous compound--ec; transcription factor 7 like 2--endogenous compound--ec; hexokinase 3--endogenous compound--ec; guanosine phosphate reductase--endogenous compound--ec; biliverdin reductase B--endogenous compound--ec; gamma interferon inducible protein 30--endogenous compound--ec; flavoprotein oxidoreductase --endogenous compound--ec; neutrophil cytosolic factor 2--endogenous compound--ec; spermine n1 acetyltransferase--endogenous compound--ec; cathepsin Z--endogenous compound --ec; mitochondrial solute carrier protein--endogenous compound--ec

4/3,K/25 (Item 24 from file: 73) Links

Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13086504 EMBASE No: 2005147588
Pancreatic beta-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58SUPIPK

Ladiges W.C.; Knoblaugh S.E.; Morton J.F.; Korth M.J.; Sopher B.L.; Baskin C.R.; MacAuley A.; Goodman A.G.; LeBoeuf R.C.; Katze M.G.
W.C. Ladiges, Department of Comparative Medicine, Box 357190, University of Washington, Seattle, WA 98195 United States
Author Email: wladiges@u.washington.edu
Diabetes ( DIABETES ) ( United States ) 2005 , 54/4 (1074-1081)
CODEN: DIAEA ISSN: 0012-1797
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 26
DRUG DESCRIPTORS:
* chaperone--endogenous compound--ec; *protein p58--endogenous compound--ec glucose; initiation factor 2alpha--endogenous compound--ec; cathepsin L--endogenous compound--ec; protein p53--endogenous compound--ec; lymphotoxin beta--endogenous compound--ec; cathepsin D--endogenous compound--ec; cathepsin B--endogenous compound--ec; serine proteinase Omi--endogenous compound--ec; FAS ligand--endogenous compound--ec; cathepsin--endogenous compound--ec; annexin--endogenous compound--ec; cytochrome c --endogenous compound--ec; STAT3 protein--endogenous compound --ec; beta arrestin--endogenous compound--ec; immunoglobulin enhancer binding protein--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec

4/3,K/26 (Item 25 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12666149 EMBASE No: 2004261313
Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa

Buhling F.; Peitz U.; Kruger S.; Kuster D.; Vieth M.; Gebert I.; Roessner A.; Weber E.; Malfertheiner P.; Wex T.
T. Wex, Dept. of Gastroenterology, Dept. of Infectious Disease, Leipziger Str. 44, D-39120 Magdeburg Germany
Author Email: thomas.wex@medizin.uni-magdeburg.de
Biological Chemistry ( BIOL. CHEM. ) ( Germany ) 2004 , 385/5 (439-445)
CODEN: BICHF ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 28

...was expressed at very low levels. Infection by Helicobacter pylori caused a significant induction of cathepsin X ($p<0.008$), whereas the other cathepsins were not or only locally affected by H. pylori infection or reflux disease. Immunohistochemistry revealed specific expression of cathepsin X (macrophages), cathepsin K (parietal cells) and cathepsin W (lymphocytes), whereas cathepsins B and L were...
DRUG DESCRIPTORS:
* cathepsin K--endogenous compound--ec; *cathepsin L--endogenous compound--ec; *cathepsin B--endogenous compound--ec; * cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; cathepsin w --endogenous compound--ec

4/3,K/27 (Item 26 from file: 73) Links

Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12657426 EMBASE No: 2004255824
Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia

Nagler D.K.; Kruger S.; Kellner A.; Ziomek E.; Menard R.; Buhtz P.; Krams M.; Roessner A.; Kellner U.
D.K. Nagler, Dept. of Clin. Chem./Clin. Biochem., University Hospital of Surgery-City, Ludwig-Maximilians-University, Nussbaumstr. 20, 80336 Munich Germany

Author Email: dorit.naegler@clinbio.med.uni-muenchen.de
Prostate ( PROSTATE ) ( United States ) 01 JUL 2004 , 60/2 (109-119)
CODEN: PRSTD ISSN: 0270-4137
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 36
Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec cathepsin F--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; genomic DNA--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/28 (Item 27 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12605998 EMBASE No: 2004197020
Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner

Lautwein A.; Kraus M.; Reich M.; Burster T.; Brandenburg J.; Overkleeft H.S.; Schwarz G.; Kammer W.; Weber E.; Kalbacher H.; Nordheim A.; Driessen C.
C. Driessen, MNF Universitat Tubingen, Ob dein Himmelreich 7, 72074 Tubingen Germany
Author Email: christoph.driessen@med.uni-tuebingen.de
Journal of Leukocyte Biology ( J. LEUKOCYTE BIOL. ) ( United States ) 2004 , 75/5 (844-855)
CODEN: JLBIE ISSN: 0741-5400
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 56
DRUG DESCRIPTORS:
* major histocompatibility antigen class 2--endogenous compound--ec; * cathepsin--endogenous compound--ec; *cathepsin S--endogenous compound--ec proteinase--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin D--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; HLA DM antigen; vinyl derivative; phenol derivative; unclassified drug
Drug Terms (Uncontrolled): asparagine specific endoprotease--endogenous compound--ec; cathepsin Z; leucine homophenylalanine vinylsulfone phenol

4/3,K/29 (Item 28 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.

12535984 EMBASE No: 2004129918
Expression and characterization of cathepsin P

Mason R.W.; Bergman C.A.; Lu G.; Frenck Holbrook J.; Sol-Church K.
R.W. Mason, Department of Biomedical Research, Alfred I. duPont Hosp. for Children, 1600 Rockland Road, Wilmington, DE 19803 United States
Author Email: mason@medsci.udel.edu
Biochemical Journal ( BIOCHEM. J. ) ( United Kingdom ) 01 MAR 2004 , 378/2 (657-663)
CODEN: BIJOA ISSN: 0264-6021
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 24
Expression and characterization of cathepsin P

...in placental tissues of all mammalian species. In the present study, it was shown that cathepsin P can be expressed in Pichia pastoris as an inactive zymogen that can be activated with proteinase K, chymotrypsin or pancreatic elastase at neutral pH. Unlike other mammalian cathepsins, cathepsin P could also be autoactivated at neutral pH, but not at acidic pH. The activated enzyme... ...SUB2SOSUB4 and hyaluronate stimulated the activity of the protease against peptidyl substrates. The properties of cathepsin P appear to be quite distinct from those of cathepsin L, indicating that the duplication that gave rise to cathepsin P has probably not yielded an enzyme that provides a subfunction of cathepsin L in rodents. It seems probable that cathepsin P has evolved to perform a function that is performed by an evolutionarily unrelated protease in...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cathepsin L--endogenous compound--ec
messenger RNA--endogenous compound--ec; proteinase K; chymotrypsin; pancreatic elastase; peptide derivative--endogenous compound--ec; protein derivative--endogenous compound--ec; transferrin--endogenous compound--ec; inorganic salt; sodium sulfate; hyaluronic acid; unclassified drug
Drug Terms (Uncontrolled): cathepsin p--endogenous compound--ec; azocasein --endogenous compound--ec

4/3,K/30 (Item 29 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12534119 EMBASE No: 2004127448
Cysteine proteases as disease markers

Berdowska I.
I. Berdowska, Department of Medical Biochemistry, Wroclaw Medical University, 10 Chalubinskiego, 50-368 Wroclaw Poland
Author Email: iza@bioch.am.wroc.pl
Clinica Chimica Acta ( CLIN. CHIM. ACTA ) ( Netherlands ) 2004 , 342/1-2 (41-69)
CODEN: CCATA ISSN: 0009-8981
Publisher Item Identifier: S0009898103006041
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 248
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *tumor marker --endogenous compound--ec
peptidase--endogenous compound--ec; papain--endogenous compound--ec; cysteine derivative--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin K--endogenous compound --ec; cathepsin F--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; protein precursor--endogenous compound--ec; enzyme precursor--endogenous compound--ec; hormone precursor--endogenous compound--ec; major histocompatibility

antigen class 2--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cysteine cathepsin derivative--endogenous compound--ec; cathepsin v --endogenous compound--ec; cathepsin x--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin o--endogenous compound--ec

4/3,K/31 (Item 30 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12503843 EMBASE No: 2004098453
Myxobolus cerebralis: Identification of a cathepsin Z-like protease gene (MyxCP-1) expressed during parasite development in rainbow trout, Oncorhynchus mykiss

Kelley G.O.; Adkison M.A.; Leutenegger C.M.; Hedrick R.P.
G.O. Kelley, Dept. of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616 United States
Author Email: gokelley@ucdavis.edu
Experimental Parasitology ( EXP. PARASITOL. ) ( United States ) 2003 , 105/3-4 (201-210)
CODEN: EXPAA ISSN: 0014-4894
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 54
Myxobolus cerebralis: Identification of a cathepsin Z-like protease gene (MyxCP-1) expressed during parasite development in rainbow trout, Oncorhynchus mykiss

...cysteine proteases. MyxCP-1 features a propeptide region and sequence insertions that are characteristics of cathepsin Z proteases. Phylogenetic comparisons of M. cerebralis to other eukaryotes based on full-length cathepsin-like genes show that MyxCP-1 is the earliest lineage in the cathepsin Z group and separated from cathepsin L, B, and C-like proteases. Using TaqMan PCR differential levels of transcription of the cathepsin Z-like protease were found in earlier and later developmental stages of the parasite in experimentally...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z like protease--endogenous compound--ec

4/3,K/32 (Item 31 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12487347 EMBASE No: 2004079961
The Caenorhabditis elegans Cathepsin Z-like Cysteine Protease, Ce-CPZ-1, Has a Multifunctional Role during the Worms' Development

Hashmi S.; Zhang J.; Oksov Y.; Lustigman S.
S. Hashmi, Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Inst., New York Blood Center, 310 E. 67th St., New York, NY 10021 United States
Author Email: shashmi@nybloodcenter.org
Journal of Biological Chemistry ( J. BIOL. CHEM. ) ( United States ) 13 FEB 2004 , 279/7 (6035-6045)
CODEN: JBCHA ISSN: 0021-9258
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 60
The Caenorhabditis elegans Cathepsin Z-like Cysteine Protease, Ce-CPZ-1, Has a Multifunctional Role during the Worms' Development

We have analyzed the expression and function of Ce-cpz-1, a Caenorhabditis elegans cathepsin Z-like cysteine protease gene, during development of the worm. The cpz-1 gene is expressed... ...are degraded prior to shedding and ecdysis. The similar

localization of the related Onchocerca volvulus cathepsin Z protein suggests that the function of CPZ-1 during molting might be conserved in other... ...basement membrane extracellular matrix assembly process. The present findings have defined a critical role for cathepsin Z in nematode biology.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin Z like cysteine proteinase--endogenous compound--ec

4/3,K/33 (Item 32 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12409511 EMBASE No: 2004009245
Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes

Rumpler G.; Becker B.; Hafner C.; McClelland M.; Stolz W.; Landthaler M.; Schmitt R.; Bosserhoff A.; Vogt T.
Dr. T. Vogt, Department of Dermatology, University of Regensburg, D-93042 Regensburg Germany
Author Email: thomas.vogt@klinik.uni-regensburg.de
Experimental Dermatology ( EXP. DERMATOL. ) ( United Kingdom ) 2003 , 12/6 (761-771)
CODEN: EXDEE ISSN: 0906-6705
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 46

...migration inhibiting factor (MIF), an important modulator of both cell cycle progression and angiogenesis, and cathepsin Z, a novel member of the family of matrix degrading proteinases. (c) Blackwell Munksgaard, 2003.
DRUG DESCRIPTORS:
* complementary DNA--endogenous compound--ec; *osteonectin--endogenous compound--ec; *macrophage migration inhibition factor--endogenous compound--ec; *cathepsin--endogenous compound--ec; * proteinase--endogenous compound--ec reduced nicotinamide adenine dinucleotide dehydrogenase (ubiquinone) --endogenous compound--ec; ubiquitin--endogenous compound--ec ; selenoprotein--endogenous compound--ec; tumor protein--endogenous compound--ec; guanine nucleotide binding protein--endogenous compound--ec; HLA antigen class 2--endogenous compound--ec; laminin binding protein--endogenous compound--ec; protein --endogenous compound--ec; polyadenylic acid binding protein --endogenous compound--ec; DNA binding protein--endogenous compound--ec; initiation factor 2--endogenous compound--ec; heat shock protein 90--endogenous compound--ec; cytochrome b --endogenous compound--ec; protein lysine 6 oxidase--endogenous compound--ec; adenosine triphosphatase--endogenous compound --ec; receptor--endogenous compound--ec; phospholipid transfer protein--endogenous compound--ec; beta galactosidase--endogenous compound--ec; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; Wilm tumor related protein--endogenous compound--ec; guanine nucleotide binding protein beta subunit like protein--endogenous compound--ec; eukaryotic translation elongation factor 1 gamma--endogenous compound--ec; glia derived nexin--endogenous compound--ec; folic acid receptor 1--endogenous compound--ec

4/3,K/34 (Item 33 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12290413 EMBASE No: 2003402858
Phylogeny of antigen-processing enzymes: Cathepsins of a cephalochordate, an

agnathan and a bony fish

Uinuk-Ool T.S.; Takezaki N.; Kuroda N.; Figueroa F.; Sato A.; Samonte I.E.; Mayer W.E.; Klein J.
T.S. Uinuk-Ool, Max-Planck-Inst. fur Biologie, Abteilung Immungenetik, Corrensstrasse 42, D-72076 Tubingen Germany
Author Email: tanya@tuebingen.mpg.de
Scandinavian Journal of Immunology ( SCAND. J. IMMUNOL. ) ( United Kingdom ) 01 OCT 2003 , 58/4 (436-448)
CODEN: SJIMA ISSN: 0300-9475
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 71
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin F--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; cathepsin S --endogenous compound--ec; cathepsin K--endogenous compound --ec; complementary DNA; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin O --endogenous compound--ec

4/3,K/35 (Item 34 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11901450 EMBASE No: 2003014131
Determination of the mRNA sequence of cathepsin Y, a cysteine endopeptidase from rat spleen, and confirmation of its ubiquitous expression

Nakazono E.; Kamata Y.; Yamafuji K.
K. Yamafuji, Division of Food and Nutrition, Nakamura Gakuen University, Befu 5-7-1, Jonan-ku, Fukuoka 814-0198 Japan
Biological Chemistry ( BIOL. CHEM. ) ( Germany ) 01 DEC 2002 , 383/12 (1971-1975)
CODEN: BICHF ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 14
Determination of the mRNA sequence of cathepsin Y, a cysteine endopeptidase from rat spleen, and confirmation of its ubiquitous expression

...by its action of producing kinin-potentiating peptide from a plasma protein. We named it cathepsin Y due to its localization, acidic pH optimum and the presence of the same set of... ...the mRNA sequence resulted in the omission of the strangely attached C-terminal peptide from cathepsin Y.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
messenger RNA--endogenous compound--ec; cysteine proteinase --endogenous compound--ec; amino acid--endogenous compound --ec; thiol--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Y--endogenous compound--ec

4/3,K/36 (Item 35 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11309979 EMBASE No: 2001324286
Lysosomal cysteine proteases: Facts and opportunities

Turk V.; Turk B.; Turk D.
V. Turk, Department of Biochemistry, J. Stefan Institute, Ljubljana Slovenia

Author Email: vito.turk@ijs.si
EMBO Journal ( EMBO J. ) ( United Kingdom )  03 SEP 2001 , 20/17 (4629-4633)
CODEN: EMJOD  ISSN: 0261-4189
Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 45
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *cathepsin--endogenous compound--ec enzyme precursor--endogenous compound--ec; amino acid; cathepsin L --endogenous compound--ec; cathepsin S--endogenous compound --ec; cathepsin K--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin V--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin o--endogenous compound--ec; cathepsin x--endogenous compound--ec

4/3,K/37 (Item 36 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11229615  EMBASE No: 2001244434
Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design

Menard R.; Therrien C.; Lachance P.; Sulea T.; Qi H.; Alvarez-Hernandez A.; Roush W.R.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Que. H4P 2R2  Canada
Biological Chemistry ( BIOL. CHEM. ) ( Germany )  2001 , 382/5 (839-845)
CODEN: BICHF  ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 21

...share similar activity profiles against substrates and inhibitors. Using quenched fluorogenic substrates, we show that cathepsin X preferentially cleaves substrates through a monopeptidyl carboxypeptidase pathway, while cathepsin B displays a preference for... ...approximately 2 orders of magnitude. Cleavage of a C-terminal dipeptide of a substrate by cathepsin X can be observed under conditions that preclude efficient monopeptidyl carboxypeptidase activity. In addition, an inhibitor designed to exploit the unique structural features responsible for the carboxypeptidase activity of cathepsin X has been synthesized and tested against cathepsins X, B and L. Although of moderate potency, this E-64 derivative is the first reported example of a cathepsin X-specific inhibitor. By comparison, CA074 was found to inactivate cathepsin B at least 34 000-fold more efficiently than cathepsin X.
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *cathepsin B --endogenous compound--ec; *enzyme inhibitor--drug development--dv; *enzyme inhibitor--pharmacology--pd
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; ca 074--drug development--dv; ca 074--pharmacology--pd

4/3,K/38 (Item 37 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11062658  EMBASE No: 2001079403
Human cathepsin X: A novel cysteine protease with unique specificity

Menard R.; Nagler D.K.; Zhang R.; Tam W.; Sulea T.; Purisima E.O.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Avenue Royalmount, Montreal, Que. H4P 2R2 Canada
Advances in Experimental Medicine and Biology ( ADV. EXP. MED. BIOL. ) ( United States ) 2000 , 477/- (317-322)
CODEN: AEMBA ISSN: 0065-2598
Document Type: Journal ; Conference Paper
Language: ENGLISH
Number Of References: 14
Human cathepsin X: A novel cysteine protease with unique specificity
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/39 (Item 38 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11062650 EMBASE No: 2001079395
Review: Novel cysteine proteases of the papain family

Buhling F.; Fengler A.; Brandt W.; Welte T.; Ansorge S.; Nagler D.K.
F. Buhling, Institue of Immunology, Otto von Guericke Univ. Magdeburg, Magdeburg Germany
Advances in Experimental Medicine and Biology ( ADV. EXP. MED. BIOL. ) ( United States ) 2000 , 477/- (241-254)
CODEN: AEMBA ISSN: 0065-2598
Document Type: Journal ; Conference Paper
Language: ENGLISH
Number Of References: 69
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *papain--endogenous compound--ec
cathepsin F--endogenous compound--ec; cathepsin K--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin o--endogenous compound--ec; cathepsin V--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin x--endogenous compound--ec

4/3,K/40 (Item 39 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11023122 EMBASE No: 2000123291
Proteolytic signals from Magdeburg

Ansorge S.; Langner J.; Buhling F.; Lendeckel U.
S. Ansorge, Inst. of Experimental Internal Med., Otto-von-Guericke University, D-39120 Magdeburg Germany
Immunology Today ( IMMUNOL. TODAY ) ( United Kingdom ) 2000 , 21/4 (166-167)
CODEN: IMTOD ISSN: 0167-5699
Publisher Item Identifier: S0167569900015863
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
DRUG DESCRIPTORS:
* microsomal aminopeptidase--endogenous compound--ec; *dipeptidyl peptidase IV--endogenous compound--ec; *enzyme inhibitor--drug development--dv; *enzyme inhibitor--pharmacology--pd; *cathepsin --endogenous compound--ec
cathepsin S--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin K--endogenous compound --ec; cathepsin D--endogenous compound--ec; unclassified drug

Drug Terms (Uncontrolled): peptidase inhibitor--drug development--dv; peptidase inhibitor --pharmacology--pd; cathepsin w--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin x--endogenous compound--ec

4/3,K/41 (Item 40 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10939353 EMBASE No: 2000429272
Flow cytometric analysis of enzymes in live spermatozoa before and after cryostorage

Schaller J.; Glander H.-J.
Dr. J. Schaller, Dermatohistological Unit, Department of Dermatology, St. Barbara Hospital, Barbarastr. 67, 47167 Duisburg Germany
Andrologia ( ANDROLOGIA ) ( Germany ) 2000 , 32/6 (357-364)
CODEN: ANDRD ISSN: 0303-4569
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 27

...for butyryl esterase (P<0.05), prolyl-aminopeptidase (P<0.001) and val-lys-(VK)-cathepsin (P<0.001) most probably due to elevated enzyme activities. The activities of FDA-esterase (P...
DRUG DESCRIPTORS:
* peptidase--endogenous compound--ec; *proteinase--endogenous compound--ec; *esterase--endogenous compound--ec; *elastase --endogenous compound--ec; *collagenase--endogenous compound --ec
fluorescein; rhodamine 110; microsomal aminopeptidase--endogenous compound--ec; subtilisin--endogenous compound--ec; dipeptidyl peptidase--endogenous compound--ec; proline iminopeptidase --endogenous compound--ec; cathepsin--endogenous compound--ec

4/3,K/42 (Item 41 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10839518 EMBASE No: 2000320402
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Bonthron D.T.; Hayward B.E.; Moran V.; Strain L.
D.T. Bonthron, Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds LS9 7TF United Kingdom
Author Email: D.T.Bonthron@leeds.ac.uk
Human Genetics ( HUM. GENET. ) ( Germany ) 2000 , 107/2 (165-175)
CODEN: HUGED ISSN: 0340-6717
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 26

...probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure of this gene; it has six exons spanning...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin z--endogenous compound--ec

4/3,K/43 (Item 42 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE

(c) 2007 Elsevier B.V. All rights reserved.
10834786 EMBASE No: 2000316209
Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase

Klemencic I.; Carmona A.K.; Cezari M.H.S.; Juliano M.A.; Juliano L.; Guncar G.; Turk D.; Krizaj I.; Turk V.; Turk B.
B. Turk, Dept. of Biochemistry/Molec. Biol., Josef Stefan Institute, Jamova 39, 1000 Ljubljana Slovenia
Author Email: boris.turk@ijs.si
European Journal of Biochemistry ( EUR. J. BIOCHEM. ) ( United Kingdom ) 2000 , 267/17 (5404-5412)
CODEN: EJBCA ISSN: 0014-2956
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 44
Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase

Cathepsin X, purified to homogeneity from human liver, is a single chain glycoprotein with a molecular mass of approx. eq. 33 kDa and pI 5.1-5.3. Cathepsin X was inhibited by stefin A, cystatin C and chicken cystatin (K(i) = 1.7-15... ...was also inhibited by two specific synthetic cathepsin B inhibitors, CA-074 and GFG-semicarbazone. Cathepsin X was similar to cathepsin B and found to be a carboxypeptidase with preference for a positively charged Arg in P1 position. Contrary to the preference of cathepsin B, cathepsin X normally acts as a carboxymonopeptidase. However, the preference for Arg in the P1 position is so strong that cathepsin X cleaves substrates with Arg in antepenultimate position, acting also as a carboxydipeptidase. A large hydrophobic... ...P1' position, although the enzyme cleaved all P1' residues investigated (Trp, Phe, Ala, Arg, Pro). Cathepsin X also cleaved substrates with amide-blocked C-terminal carboxyl group with rates similar to those of the unblocked substrates. In contrast, no endopeptidase activity of cathepsin X could be detected on a series of o-aminobenzoic acid-peptidyl-N-[2,-dinitrophenyl]ethylenediamine...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *carboxypeptidase--endogenous compound--ec; *dipeptidase--endogenous compound--ec
liver enzyme--endogenous compound--ec; stefin A; cystatin C; stefin B; kininogen; semicarbazone; cathepsin B; tryptophan; phenylalanine; arginine; proline...

4/3,K/44 (Item 43 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10728641 EMBASE No: 2000138039
Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages

Shi G.-P.; Bryant R.A.R.; Riese R.; Verhelst S.; Driessen C.; Li Z.; Bromme D.; Ploegh H.L.; Chapman H.A.
H.A. Chapman, Pulmonary and Critical Care Div., University of California, 505 Parnassus Ave., San Francisco, CA 94143-0111 United States
Author Email: halchap@itsa.ucsf.edu
Journal of Experimental Medicine ( J. EXP. MED. ) ( United States ) 03 APR 2000 , 191/7 (1177-1185)
CODEN: JEMEA ISSN: 0022-1007
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 42

...and dendritic cells revealed two enzymes expressed exclusively in macrophages, cathepsins Z and F. Recombinant cathepsin Z did not generate CLIP from Ii-MHC class

II complexes, whereas cathepsin F was as...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *major histocompatibility antigen class 2--endogenous compound--ec; *cell membrane protein --endogenous compound--ec
cysteine proteinase--endogenous compound--ec; recombinant enzyme; cathepsin S; unclassified drug
Drug Terms (Uncontrolled): cathepsin F--endogenous compound--ec; class ii associated invariant chain peptide--endogenous compound--ec; cathepsin z

4/3,K/45 (Item 44 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10703930 EMBASE No: 2000192563
The new subfamily of cathepsin-Z-like protease genes includes Tc-cpz-1, a cysteine protease gene expressed in Toxocara canis adults and infective stage larvae

Falcone F.H.; Tetteh K.K.A.; Hunt P.; Blaxter M.L.; Loukas A.; Maizels R.M.
R.M. Maizels, Inst. Cell Animal/Population Biol., University of Edinburgh, West Mains Road, Edinburgh EH9 3JT United Kingdom
Author Email: r.maizels@ed.ac.uk
Experimental Parasitology ( EXP. PARASITOL. ) ( United States ) 2000 , 94/3 (201-207)
CODEN: EXPAA ISSN: 0014-4894
Document Type: Journal ; Article
Language: ENGLISH
Number Of References: 32
The new subfamily of cathepsin-Z-like protease genes includes Tc-cpz-1, a cysteine protease gene expressed in Toxocara canis...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin tc cpz 1--endogenous compound--ec

4/3,K/46 (Item 45 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10651123 EMBASE No: 2000116176
Mouse cathepsin M, a placenta-specific lysosomal cysteine protease related to cathepsins L and P

Sol-Church K.; Frenck J.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I.du Pont Hosp. for Children, P.O. Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochimica et Biophysica Acta - Gene Structure and Expression ( BIOCHIM. BIOPHYS. ACTA GENE STRUCT. EXPR. ) ( Netherlands ) 25 APR 2000 , 1491/1-3 (289-294)
CODEN: BBGSD ISSN: 0167-4781
Publisher Item Identifier: S0167478100000300
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 34
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *complementary DNA--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin m--endogenous compound--ec; cathepsin p --endogenous compound--ec

4/3,K/47 (Item 46 from file: 73) Links

Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10651103 EMBASE No: 2000116156
Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization

Deussing J.; Von Olshausen I.; Peters C.
C. Peters, Institut Molekular Medizin, Klinikum, Albert-Ludwig-Universitat, Hugstetter Strasse 55, 79106 Freiburg Germany
Author Email: peters@mm11.ukl.uni-freiburg.de
Biochimica et Biophysica Acta - Gene Structure and Expression ( BIOCHIM. BIOPHYS. ACTA GENE STRUCT. EXPR. ) ( Netherlands ) 25 APR 2000 , 1491/1-3 (93-106)
CODEN: BBGSD ISSN: 0167-4781
Publisher Item Identifier: S016747810000021X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 53
Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization

...encoding a predicted polypeptide of 306 amino acids was characterized. The new protease, tentatively named cathepsin Z, exhibits all features characteristics of a papain-like cysteine protease, including the highly conserved residues of the 'catalytic triad'. Cathepsin Z shares only 26-35% overall homology with previously described mammalian papain-like cysteine peptidases and... ...within the family of papain-like cysteine peptidases. Genomic clones covering the murine and human cathepsin Z genes were isolated. They comprise six exons and five introns spanning a 12-kb region of genomic DNA, respectively. Murine cathepsin Z was mapped to chromosome 2, a region with synteny homology to a region of human chromosome 20 to which human cathepsin Z has been mapped previously. Northern blot analysis revealed ubiquitous expression of murine cathepsin Z. Multiple transcriptional start sites were identified for the murine cathepsin Z gene and together with the absence of a TATA box, a high G+C content... ...CpG island and the presence of several Sp1-binding sites in the promoter region, murine cathepsin Z may be classified as a 'housekeeping' gene. Copyright (C) 2000 Elsevier Science B.V.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
complementary DNA--endogenous compound--ec

4/3,K/48 (Item 47 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10633942 EMBASE No: 2000099482
Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease

Guncar G.; Klemencic I.; Turk B.; Turk V.; Karaoglanovic-Carmona A.; Juliano L.; Turk D.
D. Turk, Dept. of Biochem./Molecular Biology, Jozef Stefan Institute, Jamova 39, 1000 Ljubljana Slovenia
Author Email: dusan.turk@ijs.si
Structure ( STRUCTURE ) ( United Kingdom ) 15 MAR 2000 , 8/3 (305-313)
CODEN: STRUE ISSN: 0969-2126
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 54
Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity...

Background: Cathepsin X is a widespread, abundantly expressed papain- like mammalian

lysosomal cysteine protease. It exhibits carboxy-monopeptidase... ...of the two enzyme activities has actually been monitored. Results: The crystal structure of human cathepsin X has been determined at 2.67 Angstrom resolution. The structure shares the common features of... ...like enzyme fold, but with a unique active site. The most pronounced feature of the cathepsin X structure is the mini-loop that includes a short three- residue insertion protruding into the... ...terminal carboxyl group of a substrate in two different sidechain conformations. Conclusions: The structure of cathepsin X exhibits a binding surface that will assist in the design of specific inhibitors of cathepsin X as well as of cathepsin B and thereby help to clarify the physiological roles of...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *histidine--endogenous compound--ec; *peptidase--endogenous compound--ec; * proteinase--endogenous compound--ec

4/3,K/49 (Item 48 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10601951 EMBASE No: 2000067209
Cathepsin Q, a novel lysosomal cysteine protease highly expressed in placenta

Sol-Church K.; Frenck J.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I. duPont Hospital Children, PO Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochemical and Biophysical Research Communications ( BIOCHEM. BIOPHYS. RES. COMMUN. ) ( United States ) 27 JAN 2000 , 267/3 (791-795)
CODEN: BBRCA ISSN: 0006-291X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 22

...is predicted that cathepsin Q will differ in catalytic specificity to another placental-specific protease, cathepsin P, indicating that these enzymes will have unique proteolytic functions in extra-embryonic tissues. (C) 2000...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec; *lysosome enzyme--endogenous compound--ec

4/3,K/50 (Item 49 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10531360 EMBASE No: 1999415968
Cathepsin Y (a novel thiol enzyme) produces kinin potentiating peptide from the component protein of rat plasma

Sakamoto E.; Sakao Y.; Taniguchi Y.; Yamafuji K.
E. Sakamoto, Department of Food and Nutrition, Nakamura Gakuen University, Jonan-ku, Fukuoka 814-0198 Japan
Immunopharmacology ( IMMUNOPHARMACOLOGY ) ( Netherlands ) 1999 , 45/1-3 (207-214)
CODEN: IMMUD ISSN: 0162-3109
Publisher Item Identifier: S016231099900079X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 18
Cathepsin Y (a novel thiol enzyme) produces kinin potentiating peptide from the component protein of rat plasma

Rat spleen cathepsin Y (a novel enzyme) that produces bradykinin (BK) potentiating peptide (BPP) from rat plasma was isolated... ...from cDNA cloned by reverse

transcription-polymerase chain reaction (RT-PCR). We propose the name cathepsin Y for this enzyme considering its origin, characteristics and the amino acid sequence. BPP potentiates not... ...when the level is doubled. The precursor proteins that produce BPP by the action of cathepsin Y are eluted into two fractions when the heated plasma was applied to a negative ion... ...this paper, we report on the characteristics and the amino acid sequence of rat spleen cathepsin Y, its structure and the potentiating activity of BPP, and isolation of the precursor protein.
Copyright...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *bradykinin--endogenous compound--ec; *thiol proteinase--endogenous compound--ec; * kinin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin y--endogenous compound--ec

4/3,K/51 (Item 50 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07906071 EMBASE No: 1999379729
Cathepsin P, a novel protease in mouse placenta

Sol-Church K.; Frenck J.; Troeber D.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I. duPont Hospital Children, PO Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochemical Journal ( BIOCHEM. J. ) ( United Kingdom ) 15 OCT 1999 , 343/2 (307-309)
CODEN: BIJOA ISSN: 0264-6021
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 13
Cathepsin P, a novel protease in mouse placenta

The complete cDNA nucleotide sequence of a novel cathepsin derived from mouse placenta, termed cathepsin P, was determined. mRNA for cathepsin P was expressed in placenta and at lower levels in visceral yolk sac, but could not...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
proteinase--endogenous compound--ec; complementary DNA--endogenous compound--ec; messenger RNA--endogenous compound--ec

4/3,K/52 (Item 51 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07863831 EMBASE No: 1999344211
Human cathepsin X: A cysteine protease with unique carboxypeptidase activity

Nagler D.K.; Zhang R.; Tam W.; Sulea T.; Purisima E.O.; Menard R.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount Ave., Montreal, Que. H4P 2R2 Canada
Author Email: robert.menard@nrc.ca
Biochemistry ( BIOCHEMISTRY ) ( United States ) 28 SEP 1999 , 38/39 (12648-12654)
CODEN: BICHA ISSN: 0006-2960
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 40
Human cathepsin X: A cysteine protease with unique carboxypeptidase activity

Cathepsin X is a novel cysteine protease which was identified recently from the EST (expressed sequence tags) database. In a homology model of the mature cathepsin X, a unique three residue insertion between the Gln22 of the oxyanion hole and the

active... ...verify this hypothesis, human procathepsin X was expressed in Pichia pastoris and converted to mature cathepsin X using small amounts of human cathepsin L. Cathepsin X was found to display excellent carboxypeptidase activity against the substrate Abz-FRF(4NOinf 2), with... ...1 ssup -sup 1 at the optimal pH of 5.0. However, the activity of cathepsin X against the substrates Cbz-FR-MCA and Abz-AFRSAAQ-EDDnp was found to be extremely... ...k(cat)/K(M) values lower than 70 Msup -sup 1 ssup -sup 1. Therefore, cathepsin X displays a stricter exopeptidase activity than cathepsin B. No inhibition of cathepsin X by cystatin C could be detected up to a concentration of 4 muM of inhibitor... ...the bound carboxypeptidase substrate is predicted to establish a number of favorable contacts within the cathepsin X binding site, in particular with residues His23 and Tyr27 from the mini-loop. The presence ... ...substrates in the primed subsites of the protease. The marked structural and functional differences of cathepsin X relative to other members of the papain family of cysteine proteases will be of great...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec; *carboxypeptidase--endogenous compound--ec; * cathepsin l--endogenous compound--ec; *cathepsin b--endogenous compound--ec
histidine--endogenous compound--ec; tyrosine--endogenous compound--ec; cystatin c--endogenous compound--ec; cysteine
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/53 (Item 52 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07403528 EMBASE No: 1998297006
Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insertions

Nagler D.K.; Menard R.
R. Menard, Biotechnology Research Institute, National Research Council Canada, 6100 Avenue Royalmount, Montreal, Que. H4P 2R2 Canada
FEBS Letters ( FEBS LETT. ) ( Netherlands ) 1998 , 434/1-2 (135-139)
CODEN: FEBLA ISSN: 0014-5793
Publisher Item Identifier: S0014579398009648
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 40
Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique...

A novel cDNA encoding a cysteine protease of the papain family named cathepsin X was obtained by PCR amplification from a human ovary cDNA library. The cathepsin X cDNA is ubiquitously expressed in human tissues and contains an open reading frame of 912... ...highly conserved regions in papain-like cysteine proteases including the catalytic residues are present in cathepsin X. The mature part of cathepsin X is 26-32% identical to human cathepsins B, C, H, K, L, O, S and W. The cathepsin X sequence contains several unique features: (i) a very short proregion; (ii) a three amino acid...
DRUG DESCRIPTORS:
* cathepsin; *papain--endogenous compound--ec; *cysteine proteinase --endogenous compound--ec
cathepsin s--endogenous compound--ec; cathepsin b--endogenous compound--ec

4/3,K/54 (Item 53 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07356252 EMBASE No: 1998227542
Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a

unique chromosomal location

Santamaria I.; Velasco G.; Pendas A.M.; Fueyo A.; Lopez-Otin C.
C. Lopez-Otin, Depto. de Bioquimica/Biologia Molec., Facultad de Medicina, Universidad de Oviedo, 33006 Oviedo Spain
Author Email: CLO@DWARF1.QUIMICA.UNIOVI.ES
Journal of Biological Chemistry ( J. BIOL. CHEM. ) ( United States ) 03 JUL 1998 , 273/27 (16816-16823)
CODEN: JBCHA ISSN: 0021-9258
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 62
Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location

...revealed that the isolated cDNA codes for a polypeptide of 303 amino acids, tentatively called cathepsin Z, that exhibits structural features characteristic of cysteine proteinases. Fluorescent in situ hybridization experiments revealed that the human cathepsin Z gene maps to chromosome 20q13, a location that differs from all cysteine proteinase genes mapped to date. The cDNA encoding cathepsin Z was expressed in Escherichia coli as a fusion protein with glutathione S- transferase, and after... ...amido-4- methylcoumarin, used as a substrate for cysteine proteinases. Northern blot analysis demonstrated that cathepsin Z is widely expressed in human tissues, suggesting that this enzyme could be involved in the normal intracellular protein degradation taking place in all cell types. Cathepsin Z is also ubiquitously distributed in cancer cell lines and in primary tumors from different sources... ...unusual short propeptide, together with its unique chromosomal location among cysteine proteinases, we propose that cathepsin Z may be the first representative of a novel subfamily of this class of proteolytic enzymes.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin z--endogenous compound--ec

4/3,K/55 (Item 54 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
06200066 EMBASE No: 1995231005
Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas

Li Y.-P.; Alexander M.; Wucherpfennig A.L.; Yelick P.; Chen W.; Stashenko P.
Forsyth Dental Center, 140 Fenway,Boston, MA 02115 United States
Journal of Bone and Mineral Research ( J. BONE MINER. RES. ) ( United States ) 1995 , 10/8 (1197-1202)
CODEN: JBMRE ISSN: 0884-0431
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH

...has been identified by differential screening of a human osteoclastoma cDNA library. This molecule, termed cathepsin X, appears to represent the human homolog of the osteoclast-expressed rabbit cathepsin OC-2. Cathepsin X (GenBank accession number U20280) is 93.9% identical to OC-2 at the amino acid level, and is 92% identical at the nucleotide level within the coding region. Cathepsin X is 52.2 and 46.9% identical to cathepsins S and L, respectively, and is therefore clearly distinct from these enzymes. Cathepsin X mRNA was localized to multinucleated giant cells within the osteoclastoma tumor by in situ hybridization. These data strongly support the hypothesis that cathepsin X represents a novel cysteine proteinase which is expressed at high levels in osteoclasts.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cysteine proteinase--endogenous compound--ec; unclassified drug

Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/56 (Item 1 from file: 35) Links
Dissertation Abs Online
(c) 2007 ProQuest Info&Learning. All rights reserved.
01980017 ORDER NO: AADAA-IMQ83852
The design of substrates for cathepsin X

Author: Devanathan, Gopal
Degree: M.Sc.
Year: 2003
Corporate Source/Institution: Concordia University (Canada) ( 0228 )
Source: Volume 42/03 of MASTERS ABSTRACTS. of Dissertations Abstracts International.

PAGE 941 . 90 PAGES
ISBN: 0-612-83852-8
The design of substrates for cathepsin X

...diseases such as arthritis, Alzheimer's, and cancer, they are attractive targets for inhibitor design. Cathepsin X is a cysteine protease that was only recently discovered. The primary structure of cathepsin X contains several unique features that clearly distinguish it from the other human cysteine proteases. The... ...a systematic study on the S2, S1, and S1<super>′</super> subsites of the cathepsin X active site and to gain a detailed understanding of the enzyme's substrate specificity.

Three libraries of compounds have been synthesized based on the parent compound 2-Abz-Phe-Arg-Phe(4NO<sub>2</sub>). In each library, the 20 natural... ...prime;</super> sites respectively, while keeping the other positions fixed. In reference to the parent compound, P2 is occupied by Phe, P1 by Arg, and P1<super>′</super> by Phe... ...by docking 2-Abz-Phe-Arg-Phe(4NO<sub>2</sub>) and analogues to the cathepsin X active site in order to gain a detailed understanding of factors underlying substrate specificity. Knowledge...

4/3,K/57 (Item 1 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0377298 DBA Accession No.: 2005-23004 PATENT
Identification of a compound capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence and presence of the compound involving vector-mediated gene transfer and expression in host cell for therapy

Author: SALTZMAN A G; TANG Z; PALEJWALA V; CAVALLO J
Patent Assignee: AVENTIS PHARM INC 2005
Patent Number: WO 200565693 Patent Date: 20050721 WPI Accession No.: 2005-533570 ( 200554 )
Priority Application Number: US 533330 Application Date: 20031230
National Application Number: WO 2004US41815 Application Date: 20041214
Language: English
Identification of a compound capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence and presence of the compound involving vector-mediated gene transfer and expression in host cell for therapy
Abstract: DERWENT ABSTRACT: NOVELTY - Identification of a compound (I) capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence of a candidate compound; introducing the candidate compound; and measuring the cell's level of cathepsin Z activity in the presence of the candidate compound. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) the compound (I) capable of modulating activity of cathepsin Z; and (2) a pharmaceutical comprising (I) and excipient for treating an inflammatory. ACTIVITY - Antiinflammatory; Immunosuppressive; Antiarthritic;

Antirheumatic; Neuroprotective. MECHANISM OF ACTION - Cathepsin Z modulator. Test details are described but no results given. USE - (I) is useful to treat...
Descriptors: recombinant cathepsin-Z prep., isol., vector-mediated gene transfer, expression in host cell, appl., inflammatory disease, autoimmune disease...

4/3,K/58 (Item 2 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0338230 DBA Accession No.: 2004-10522 PATENT
Use of polynucleotide sequence encoding Cathespin Y protein for identification of therapeutic agent useful for treating stroke e.g. ischemic stroke vector-mediated cathespin-Y gene transfer, expression in host cell and antisense oligonucleotide for drug screening and gene therapy

Author: LUBBERT H; ZWILLING S; ENGELS P
Patent Assignee: LUBBERT H; ZWILLING S; ENGELS P 2003
Patent Number: US 20030232740 Patent Date: 20031218 WPI Accession No.: 2004-142033 ( 200414 )
Priority Application Number: US 392809 Application Date: 20030319
National Application Number: US 392809 Application Date: 20030319
Language: English
Abstract: ...of potential therapeutic agent for treating stroke involves contacting a cell capable of expressing a Cathepsin Y gene or homologues or fragments with the potential therapeutic agent; detecting a level of expression of the Cathepsin Y gene in the test cell; comparing expression in the test cell to a reference cell... ...of potential therapeutic agent for treating stroke involves contacting a cell capable of expressing a Cathepsin Y gene or homologues or fragments with the potential therapeutic agent; detecting a level of expression of the Cathepsin Y gene in the test cell; comparing the level of expression of the Cathepsin Y gene in the test cell to a level of expression of the Cathepsin Y gene in a reference cell whose disease stage is known; and identifying the difference in the expression level of the Cathepsin Y gene in the test cell and the reference cell. INDEPENDENT CLAIMS are included for the following: (a) a composition comprising a compound of formula (I) or its salt; (b) a composition comprising a nucleic acid sequence (S1) which is an antisense sequence compared to a nucleic acid sequence (S2) encoding Cathepsin Y, its homologue or fragment. (S2) Has sequence of 1140 or 1500 nucleotide bases as given... ...is 0, then R4 is other than -N(CH3)OCH3. ACTIVITY - Cerebroprotective. MECHANISM OF ACTION - Cathepsin Y protein inhibitor. Test details are described, but no results are given. USE - For identifying potential...

4/3,K/59 (Item 3 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0335363 DBA Accession No.: 2004-07655 PATENT
New antisense compound targeted to nucleic acid molecules encoding cathepsin Z, useful for treating diseases associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder involving vector-mediated gene transfer and expression in host cell for use in therapy

Author: DOBIE K W
Patent Assignee: ISIS PHARM INC 2003
Patent Number: US 20030224511 Patent Date: 20031204 WPI Accession No.: 2004-060543 ( 200406 )
Priority Application Number: US 159266 Application Date: 20020531
National Application Number: US 159266 Application Date: 20020531
Language: English
New antisense compound targeted to nucleic acid molecules encoding cathepsin Z, useful for treating diseases associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder involving vector-mediated gene transfer and expression...
Abstract: DERWENT ABSTRACT: NOVELTY - A compound (I) 8-80 nucleobases in length

targeted to a nucleic acid molecule encoding cathepsin Z, is new. DETAILED DESCRIPTION - A compound (I) 8-80 nucleobases in length targeted to a nucleic acid molecule encoding cathepsin Z, is new. The compound specifically hybridizes with the nucleic acid molecule encoding cathepsin Z and inhibits the expression of cathepsin Z, or specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding cathepsin Z. INDEPENDENT CLAIMS are included for the following: (1) a composition comprising (I) and a pharmaceutical carrier or diluent; (2) a method of inhibiting the expression of cathepsin Z in cells or tissues comprising contacting the cells or tissues with (I); and (3) a method of treating an animal having a disease or condition associated with cathepsin Z comprising administering to the animal a therapeutic or prophylactic amount of (I) so that expression of cathepsin Z is inhibited. BIOTECHNOLOGY - Preparation: The antisense compounds are produced by solid phase synthesis. Preferred Compound: The compound is an antisense oligonucleotide, preferably a chimeric oligonucleotide. The antisense oligonucleotide comprises: (a) at least... ...Inhibitor Z. USE - The antisense oligonucleotides and compounds are useful for inhibiting the expression of cathepsin Z, and for treating diseases or conditions associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder, such as cancer (all claimed). The antisense... Descriptors: recombinant cathepsin-Z prep., isol., vector-mediated gene transfer, expression in host cell, antisense oligonucleotide, appl. encephalitis, virus...

4/3,K/60 (Item 4 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0334375 DBA Accession No.: 2004-06667 PATENT
Composition useful for treating pain e.g. neuropathic pain comprises polynucleotide sequence sense and antisense sequence for use in disease therapy and gene therapy

Author: LUBBERT H; ENGELS P; SCHMITZ B
Patent Assignee: LUBBERT H; ENGELS P; SCHMITZ B 2003
Patent Number: US 20030212003 Patent Date: 20031113 WPI Accession No.: 2004-041675 ( 200404 )
Priority Application Number: US 369386 Application Date: 20030214
National Application Number: US 369386 Application Date: 20030214
Language: English
Abstract: ...therapeutic agents for treating pain involving: (a) contacting a test cell capable of expressing a Cathepsin Y gene, its homologues or fragments with the potential therapeutic agent; (b) detecting a level of expression of the Cathepsin Y gene in the test cell; (c) comparing the level of expression of the Cathepsin Y gene in the test cell to that in a reference cell; and (d) identifying the difference in the expression levels of the Cathepsin Y gene in the test cell and reference cell; (2) identification of a therapeutic agent for treating pain involving: (a) incubating a sample comprising a Cathepsin Y protein, a test compound/agent and a polypeptide which is a target of Cathepsin Y protein proteolysis; (b) determining an aminoterminal amino acid of a peptide resulting from the proteolysis... ...nucleic acid sequence is an antisense sequence compared to a nucleic acid sequence that encodes Cathepsin Y and has a sequence of 1387 or 1500 nucleotide bases. BIOTECHNOLOGY - Preferred Method: The expression of the Cathepsin Y gene is determined by at least one method selected from PCR of a cDNA, hybridizing a sample DNA and detecting a Cathepsin Y protein. ACTIVITY - Analgesic; Antidiabetic; Neuroprotective; Virucide; Vulnerary; Cardiant. MECHANISM OF ACTION - Cathepsin Y protein inhibitor. No biological data given. USE - The compound is useful for treating pain e.g. neuropathic pain (claimed), diabetic neuropathy, post-herpetic neuralgia... ...reflex sympathetic dystrophy and causalgia, myocardial syndromes or idiopathic pain. ADVANTAGE - The composition efficiently downregulates Cathepsin Y activity and hence treats pain. EXAMPLE - No relevant example given. (22 pages) Descriptors: polynucleotide composition, cathepsin Y gene, antisense sequence, polymerase chain reaction, appl. pain, neuropathic pain, diabetic neuropathy, post-herpetic neuralgia...

4/3,K/61 (Item 5 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0328457 DBA Accession No.: 2004-00749 PATENT
Developing medicament used for treating pain comprises using polynucleotide sequence encoding cathepsin Y involving vector-mediated gene transfer and expression in host cell for use in neuropathic pain therapy

Author: LUEBBERT H; SCHMITZ B
Patent Assignee: BIOFRONTERA PHARM AG 2003
Patent Number: EP 1336847 Patent Date: 20030820 WPI Accession No.: 2003-814978 ( 2003 )
Priority Application Number: EP 20023400 Application Date: 20020214
National Application Number: EP 20023400 Application Date: 20020214
Language: English
Developing medicament used for treating pain comprises using polynucleotide sequence encoding cathepsin Y involving vector-mediated gene transfer and expression in host cell for use in neuropathic pain...
Abstract: DERWENT ABSTRACT: NOVELTY - Developing a medicament for treating pain comprises using a polynucleotide sequence encoding cathepsin Y. DETAILED DESCRIPTION - Developing a medicament for treating pain, for diagnosing pain status outside of a... ...efficacy of pain treatment outside of a living body, comprises using a polynucleotide sequence encoding cathepsin Y or homologs or fragments or the corresponding protein or peptide. INDEPENDENT CLAIMS are also included for: (1) the use of a compound downregulating cathepsin Y expression or activity for manufacture of a medicament for treatment of pain; (2) a diagnostic... ...isolated nucleic acid sequence comprising an 'antisense' sequence compared to a nucleic acid sequence encoding cathepsin Y or a fragment of the nucleic acid sequence as a medicament; and (4) a transgenic animal where the gene encoding cathepsin Y is manipulated in the animal in comparison to the wild type. ACTIVITY - Analgesic. MECHANISM OF ACTION - Cathepsin Y inhibitor. Tests are described, but no results are given. USE - Used for treating pain, particularly...
Descriptors: recombinant cathepsin-Y prep., isol., vector-mediated gene transfer, expression in host cell, polymerase chain reaction, appl. neuropathic...

4/3,K/62 (Item 6 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0313249 DBA Accession No.: 2003-14389 PATENT
New transgenic mice comprising a disruption in a cathepsin Z (CTSZ) useful as models for diseases or conditions associated with phenotypes relating to a disruption in a CTSZ gene, and in identifying drugs for treating a disease vector-mediated mutant gene transfer and expression in embryonic stem cell for transgenic mouse construction for use as an animal model in disease therapy

Author: WISOTZKEY R G; KIRK C J
Patent Assignee: DELTAGEN INC 2003
Patent Number: WO 200326403 Patent Date: 20030403 WPI Accession No.: 2003-354621 ( 200333 )
Priority Application Number: US 324639 Application Date: 20010924
National Application Number: WO 2002US30506 Application Date: 20020924
Language: English
New transgenic mice comprising a disruption in a cathepsin Z (CTSZ) useful as models for diseases or conditions associated with phenotypes relating to a disruption...
Abstract: DERWENT ABSTRACT: NOVELTY - A transgenic mouse comprising a disruption in a cathepsin Z (CTSZ) gene, where there is no native expression of endogenous CTSZ gene, is new. DETAILED... ...a pharmaceutical composition for a condition associated with a function of CTSZ, comprises identifying a compound that modulates CTSZ, synthesizing the identified compound, and incorporating the compound into a pharmaceutical carrier. USE - The transgenic mouse is useful as a model for diseases... ...symptoms; and in testing and developing new treatments relating to behavioral phenotypes. EXAMPLE - Disruptions in cathepsin Z (CTSZ) genes were

produced by homologous recombination. Transgenic mice comprising disruptions in CTSZ genes were...
Descriptors: transgenic mouse construction, vector-mediated mutant cathepsin- Z gene transfer, expression in embryonic stem cell, phenotyping, animal model, antagonist, agonist, database, homologous recombination...

4/3,K/63 (Item 7 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0257611 DBA Accession No.: 2000-12101 PATENT
New human cathepsin-Y protein, a gene encoding it and its application - diagnosis, therapy, gene therapy and drug screening

Corporate Source: Japan.
Patent Assignee: Fuji-Pharm. 2000
Patent Number: JP 2000157263 Patent Date: 20000613 WPI Accession No.: 2000-468198 ( 2041 )
Priority Application Number: JP 98352110 Application Date: 19981126
National Application Number: JP 98352110 Application Date: 19981126
Language: Japanese
New human cathepsin-Y protein, a gene encoding it and its application
Abstract: A human-derived cathepsin-Y protein (I) or a new human-derived cathepsin-Y protein which has at least 49% homology to the protein sequence of (I) has a...
...I) or its salts, peptides, etc., the DNA or the antibody; a drug containing a compound promoting or inhibiting biological activity of one of the claimed proteins, their partial peptides or...
Descriptors: human recombinant cathepsin-Y prep., cysteine protease act., monoclonal antibody, vector expression in host cell, DNA probe hybridization, appl...

```
?  s cathepsin
S1       88555   S CATHEPSIN

?  s cathepsin(w)Z or CSTZ or cathepsin(w)X or cathepsin(w)P or cathepsin(w)Y
Processing
Processing
Processing
         88555   CATHEPSIN
       1099189   Z
           152   CATHEPSIN(W)Z
            10   CSTZ
         88555   CATHEPSIN
       6940523   X
           197   CATHEPSIN(W)X
         88555   CATHEPSIN
      12346779   P
            65   CATHEPSIN(W)P
         88555   CATHEPSIN
       1989729   Y
            30   CATHEPSIN(W)Y
S2         450   S CATHEPSIN(W)Z OR CSTZ OR CATHEPSIN(W)X OR CATHEPSIN(W)P OR
CATHEPSIN(W)Y

?  s s2 and compound
           450   S2
       4641049   COMPOUND
S3          67   S S2 AND COMPOUND

?  rd
>>>W:  Duplicate detection is not supported for File 393.
```

Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S4 63 RD (UNIQUE ITEMS)

? t s64/3,k/1-63
>>>E: Set 64 does not exist

? t s4/3,k/1-63
>>>W: KWIC option is not available in file(s): 399
4/3,K/1 (Item 1 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
18349334 Biosis No.: 200510043834
Defining the substrate specificity of mouse cathepsin P

Author: Puzer Luciano; Barros Nilana M T; Oliveira Vitor; Julianoa Maria Aparecida; Lu Guizhen; Hassanein Mohamed; Juliano Luiz; Mason Robert W; Carmona Adriana K (Reprint)
Author Address: UNIFESP, Escola Paulista Med, Dept Biophys, Rua Tres Maio 100, BR-04044020 Sao Paulo, Brazil**Brazil
Author E-mail Address: adriana@biofis.epm.br
Journal: Archives of Biochemistry and Biophysics 435 ( 1 ): p 190-196 MAR 1 05 2005
ISSN: 0003-9861
Document Type: Article
Record Type: Abstract
Language: English
Defining the substrate specificity of mouse cathepsin P

Abstract: Cathepsin P is a recently discovered placental cysteine protease that is structurally related to the more ubiquitously expressed, broad-specificity enzyme, cathepsin L. We studied the substrate specificity requirements of recombinant mouse cathepsin P using fluorescence resonance energy transfer (FRET) peptides derived from the lead sequence Abz-KLRSSKQ-EDDnp... ...Arg), and hydrophobic aliphatic or aromatic residues (Val, Phe). For several substrates, the activity of cathepsin P was markedly regulated by kosmotropic salts, particularly Na2SO4. No significant effect on secondary or tertiary... ...this substrate was almost two orders of magnitude higher than that of the original parent compound. These results show that cathepsin P, in contrast to other mammalian cathepsins, has a restricted catalytic specificity. (C) 2004 Elsevier Inc...
Registry Numbers: ...cathepsin P
DESCRIPTORS:
Chemicals & Biochemicals: ...cathepsin P--

4/3,K/2 (Item 1 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14746499 EMBASE No: 2007432049
Differential Expression of Cathepsins and Cystatin C in Ovine Uteroplacental Tissues

Song G.; Bazer F.W.; Spencer T.E.
T.E. Spencer, Center for Animal Biotechnology and Genomics, Department of Animal Science, Texas A and M University, 2471 TAMU, College Station, TX 77843-2471 United States
Author Email: tspencer@tamu.edu
Placenta ( PLACENTA ) ( United Kingdom ) 2007 , 28/10 (1091-1098)
CODEN: PLACD ISSN: 0143-4004
Publisher Item Identifier: S0143400407001099
Document Type: Journal ; Article

Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 34
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cystatin C--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin D--endogenous compound--ec;
cathepsin H--endogenous compound--ec; cathepsin K--endogenous compound--ec;
cathepsin L--endogenous compound --ec; cathepsin S--endogenous compound--ec;
messenger RNA --endogenous compound--ec; peptide hydrolase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec

4/3,K/3 (Item 2 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14643786 EMBASE No: 2007348195
Expression of Cathepsin P mRNA, Protein and Activity in the Rat Choriocarcinoma Cell Line, Rcho-1, During Giant Cell Transformation

Hassanein M.; Korant B.D.; Lu G.; Mason R.W.
R.W. Mason, Department of Biomedical Research, Alfred I duPont Hospital for Children, 1600 Rock land Road, Wilmington, DE 19803 United States
Author Email: rmason@nemours.org
Placenta ( PLACENTA ) ( United Kingdom ) 2007 , 28/8-9 (912-919)
CODEN: PLACD ISSN: 0143-4004
Publisher Item Identifier: S0143400406002773
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 44
Expression of Cathepsin P mRNA, Protein and Activity in the Rat Choriocarcinoma Cell Line, Rcho-1, During Giant Cell...

...proteases perform critical functions in protein turnover and are essential for normal growth and development. Cathepsin P is a member of a newly discovered family of lysosomal cysteine proteases uniquely expressed in... ...L was not regulated. A specific enzyme assay was developed to show that activity of cathepsin P mirrored mRNA expression during differentiation. Cathepsin P protein co-localizes with cathepsin B, indicating that the enzyme probably functions in the endosomal ...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; peptide hydrolase--endogenous compound--ec; proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin 1--endogenous compound--ec; cathepsin 2--endogenous compound--ec; cathepsin P--endogenous compound --ec; cathepsin Q--endogenous compound--ec; cathepsin m--endogenous compound--ec; cathepsin r--endogenous compound--ec

4/3,K/4 (Item 3 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14625291 EMBASE No: 2007394692
Inflammatory processes in the aging mouse brain: Participation of dendritic cells and T-cells

Stichel C.C.; Luebbert H.
C.C. Stichel, Biofrontera Bioscience GmbH, D-51377 Leverkusen Germany
Author Email: c.stichel-gunkel@biofrontera.com
Neurobiology of Aging ( NEUROBIOL. AGING ) ( United States ) 2007 , 28/10 (1507-1521)
CODEN: NEAGD ISSN: 0197-4580
Publisher Item Identifier: S0197458006002740

Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 100
DRUG DESCRIPTORS:
CD11b antigen--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin--endogenous compound--ec; integrin --endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/5 (Item 4 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14423842 EMBASE No: 2007158978
Differential expression of cathepsin X in aging and pathological central nervous system of mice

Wendt W.; Zhu X.-R.; Lubbert H.; Stichel C.C.
C.C. Stichel, Biofrontera Bioscience GmbH, D-51377 Leverkusen Germany
Author Email: c.stichel-gunkel@biofrontera.com
Experimental Neurology ( EXP. NEUROL. ) ( United States ) 2007 , 204/2 (525-540)
CODEN: EXNEA ISSN: 0014-4886 eISSN: 1090-2430
Publisher Item Identifier: S0014488607000222
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 77
Differential expression of cathepsin X in aging and pathological central nervous system of mice

...we analyzed the regional, cellular and subcellular localization and the activity of the recently discovered cathepsin X in the normal, developing and pathological mouse brain. Our results show that CATX is: (i... ...plaques in a transgenic mouse model and in Alzheimer patients. These results strongly suggest that cathepsin X is an important player in degenerative processes during normal aging and in pathological conditions. (c...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/6 (Item 5 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14198060 EMBASE No: 2006599352
Cysteine cathepsins: Regulators of antitumour immune response

Obermajer N.; Doljak B.; Kos J.
J. Kos, University of Ljubljana, Department of Pharmaceutical Biology, Faculty of Pharmacy, Askerceva 7, SI-1000 Ljubljana Slovenia
Author Email: Janko.kos@ffa.uni-lj.si
Expert Opinion on Biological Therapy ( EXPERT OPIN. BIOL. THER. ) ( United Kingdom ) 2006 , 6/12 (1295-1309)
CODEN: EOBTA ISSN: 1471-2598
Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 120
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cysteine derivative--endogenous compound--ec; cysteine proteinase --endogenous compound--ec; major histocompatibility antigen class 2 --endogenous compound--ec; cytokine--endogenous compound--ec; growth factor--endogenous compound--ec; integrin--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin

L--endogenous compound--ec; cathepsin S--endogenous compound --ec; cathepsin K--endogenous compound--ec; stefin A--endogenous compound--ec; stefin B--endogenous compound--ec; cystatin C --endogenous compound--ec; cystatin--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin H--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin w--endogenous compound--ec; cathepsin x --endogenous compound--ec; cystatin f--endogenous compound --ec; cathepsin o--endogenous compound--ec; cathepsin v--endogenous compound--ec

4/3,K/7 (Item 6 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14090484 EMBASE No: 2006493081
Cargo selectivity of the ERGIC-53/MCFD2 transport receptor complex

Nyfeler B.; Zhang B.; Ginsburg D.; Kaufman R.J.; Hauri H.-P.
H. Hans-Peter, Biozentrum, University of Basel, CH-4056 Basel Switzerland
Author Email: hans-peter.hauri@unibas.ch
Traffic ( TRAFFIC ) ( Denmark ) 2006 , 7/11 (1473-1481)
CODEN: TRAFF ISSN: 1398-9219 eISSN: 1600-0854
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 37

...complex in the early secretory pathway. ERGIC-53 also interacts with the two lysosomal glycoproteins cathepsin Z and cathepsin C. Here, we tested the subunit interdependence and cargo selectivity of ERGIC-53... ...yellow fluorescent protein fragment complementation. We found that MCFD2 is dispensable for the binding of cathepsin Z and cathepsin C to ERGIC-53. The results indicate that ERGIC-53 can bind cargo...
DRUG DESCRIPTORS:
* endoplasmic reticulum golgi intermediate compartment protein 53--endogenous compound--ec; *protein--endogenous compound--ec
secretory protein--endogenous compound--ec; receptor--endogenous compound--ec; blood clotting factor 5--endogenous compound --ec; blood clotting factor 8--endogenous compound--ec; lectin --endogenous compound--ec; glycoprotein; dipeptidyl peptidase I; cathepsin; protein subunit--endogenous compound--ec; small interfering RNA; yellow fluorescent protein; unclassified drug
Drug Terms (Uncontrolled): multiple coagulation factor deficiency protein 2--endogenous compound--ec

4/3,K/8 (Item 7 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14057877 EMBASE No: 2006471802
Cysteine cathepsins: Multifunctional enzymes in cancer

Mohamed M.M.; Sloane B.F.
B.F. Sloane, Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 United States
Author Email: bsloane@med.wayne.edu
Nature Reviews Cancer ( NAT. REV. CANCER ) ( United Kingdom ) 2006 , 6/10 (764-775)
CODEN: NRCAC ISSN: 1474-175X
Publisher Item Identifier: NRC1949
Document Type: Journal ; Conference Paper
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 145
DRUG DESCRIPTORS:

* cysteine--endogenous compound--ec; *cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; dipeptidyl peptidase I --endogenous
compound--ec; cathepsin H--endogenous compound --ec; cathepsin L--endogenous
compound--ec; cathepsin K--endogenous compound--ec; cathepsin S--endogenous
compound--ec; kininogen --endogenous compound--ec; cystatin C--endogenous compound
--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin O--endogenous compound--ec; cathepsin
V--endogenous compound--ec; cathepsin W--endogenous compound--ec; cathepsin
x--endogenous compound--ec; cystatin D --endogenous compound--ec; cystatin
E--endogenous compound --ec; cystatin f--endogenous compound--ec; cystatin
s--endogenous compound--ec; cystatin SA--endogenous compound--ec; cystatin
sn--endogenous compound--ec; cystatin M--endogenous compound --ec

4/3,K/9 (Item 8 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14049123 EMBASE No: 2006446396
Molecular aspects of stromal-parenchymal interactions in malignant neoplasms

Zalatnai A.
A. Zalatnai, First Department of Pathology and Experimental Cancer Research,
Semmelweis University, Faculty of Medicine, Ulloi ut 26, H-1085 Budapest Hungary
Author Email: zalatnai@korb1.sote.hu
Current Molecular Medicine ( CURR. MOL. MED. ) ( Netherlands ) 2006 , 6/6
(685-693)
CODEN: CMMUB ISSN: 1566-5240
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 108
DRUG DESCRIPTORS:
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; enzyme
precursor--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin
F--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin
K--endogenous compound--ec; cathepsin--endogenous compound --ec; matrix
metalloproteinase--endogenous compound--ec; CD147 antigen--endogenous compound--ec;
interleukin 1alpha--endogenous compound--ec; basic fibroblast growth
factor--endogenous compound--ec; gelatinase B--endogenous compound--ec; tumor
necrosis factor alpha--endogenous compound--ec; transforming growth factor
beta--endogenous compound--ec; gelatinase A--endogenous compound--ec; collagenase
3--endogenous compound--ec; CD68 antigen--endogenous compound--ec; stromal cell
derived factor 1 --endogenous compound--ec; transforming growth factor beta1
--endogenous compound--ec; inducible nitric oxide synthase --endogenous
compound--ec; gemcitabine--pharmacology--pd; matrix metalloproteinase
inhibitor--clinical trial--ct; matrix metalloproteinase inhibitor--drug therapy...
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/10 (Item 9 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13924109 EMBASE No: 2006345822
Caenorhabditis elegans: Study model for animal and human cathepsins and inhibitors

Hashmi S.; Anwer K.; Bilgrami A.L.
S. Hashmi, Laboratory of Molecular Parasitology, Lindsley F. Kimbal Research
Instiute, New York Blood Center, 310 East 67th Street, New York, NY 10021 United
States
Author Email: shashmi@nybloodcenter.org
Current Enzyme Inhibition ( CURR. ENZYME INHIB. ) ( Netherlands ) 2006 , 2/2
(173-188)

ISSN: 1573-4080
Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 236

...L enzymes in C. elegans. Besides, it also reviews the function of a recently described cathepsin Z. (c) 2006 Bentham Science Publishers Ltd.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase inhibitor --drug therapy--dt; *cysteine proteinase inhibitor--endogenous compound--ec; *cysteine proteinase inhibitor--pharmacology--pd; * cysteine proteinase inhibitor--topical drug administration--tp
cathepsin L--endogenous compound--ec; cathepsin B--endogenous compound--ec; cysteine proteinase--endogenous compound--ec; papain--endogenous compound--ec; cathepsin E--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin H--endogenous compound --ec; cathepsin K--endogenous compound--ec; stefin A--endogenous compound--ec; stefin B--endogenous compound--ec; anthelmintic agent; cyclophosphamide--drug therapy--dt; cyclophosphamide--pharmacology --pd; antineoplastic agent--drug therapy--dt; antineoplastic agent --pharmacology--pd; proteinase inhibitor--drug therapy--dt; proteinase inhibitor--endogenous compound--ec; proteinase inhibitor --pharmacology--pd; proteinase inhibitor--topical drug administration--tp; antimalarial agent--drug therapy--dt; antimalarial agent--pharmacology--pd; cystatin C--drug therapy--dt; cystatin C--endogenous compound--ec; cystatin C--pharmacology--pd; cystatin C--topical drug administration--tp; oryzacystatin--pharmacology--pd; antivirus agent--drug therapy--dt; antivirus agent--endogenous compound--ec; antivirus agent --pharmacology--pd; antivirus agent--topical drug administration--tp; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): cathepsin inhibitor--drug therapy--dt; cathepsin inhibitor--endogenous compound--ec; cathepsin inhibitor--pharmacology--pd; cathepsin inhibitor--topical drug administration--tp; cathepsin Z --endogenous compound--ec; peptide aldehyde--drug therapy--dt; peptide aldehyde--pharmacology--pd; alpha ketoamide--drug therapy--dt...

4/3,K/11 (Item 10 from file: 73)  Links
Fulltext available through:  USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13908004  EMBASE No: 2006331563
Carboxypeptidase cathepsin X mediates betaSUB2-integrin-dependent adhesion of differentiated U-937 cells

Obermajer N.; Premzl A.; Zavas(caron)nik Bergant T.; Turk B.; Kos J.
J. Kos, Faculty of Pharmacy, University of Ljubljana, As(caron)kerc(caron)eva 7, SI-1000 Ljubljana  Slovenia
Author Email: janko.kos@ffa.uni-lj.si
Experimental Cell Research ( EXP. CELL RES. ) ( United States )  01 AUG 2006 , 312/13 (2515-2527)
CODEN: ECREA  ISSN: 0014-4827
Publisher Item Identifier: S0014482706001601
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 50
Carboxypeptidase cathepsin X mediates betaSUB2-integrin-dependent adhesion of differentiated U-937 cells

Cathepsin X is a lysosomal carboxypeptidase with a potential role in processes of inflammation and immune response... ...integrin-binding motifs RGD and ECD, present in the pro- and in mature forms of cathepsin X, respectively, suggest that this enzyme might have a function in cell signaling and adhesion. In... ...protease inhibitors E-64 and CA-074 and 2F12 monoclonal antibody, all of which inhibit cathepsin X activity, significantly reduced adhesion of differentiated U-937 cells

to polystyrene- and fibrinogen-coated surfaces... ...whereas their binding to vitronectin, fibronectin or Matrigel was not affected. On the other hand, cathepsin X, added to differentiating U-937 cells, stimulated their adhesion. Using confocal microscopy, we demonstrated that the pro-form of cathepsin X was co-localized with betaSUB2 and betaSUB3 integrin subunits and its mature form solely with... ...U-937 cells and in co-cultures with endothelial cells. Our results indicate that active cathepsin X mediates the function of betaSUB2 integrin receptors during cell adhesion and that it could also...
DRUG DESCRIPTORS:
* carboxypeptidase--endogenous compound--ec; *beta2 integrin --endogenous compound--ec
...cysteine proteinase inhibitor; monoclonal antibody; polystyrene; fibrinogen; integrin receptor; vitronectin; fibronectin; matrigel; beta3 integrin--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; ca 074

4/3,K/12 (Item 11 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13831452 EMBASE No: 2006270160
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer

Vasiljeva O.; Papazoglou A.; Kruger A.; Brodoefel H.; Korovin M.; Deussing J.; Augustin N.; Nielsen B.S.; Almholt K.; Bogyo M.; Peters C.; Reinheckel T.
T. Reinheckel, Institut fur Molekulare Medizin und Zellforschung, Albert-Ludwigs-Universitat Freiburg, Stefan Meier Strasse 17, D-79104 Freiburg Germany
Author Email: Thomas.Reinheckel@uniklinik-freiburg.de
Cancer Research ( CANCER RES. ) ( United States ) 15 MAY 2006 , 66/10 (5242-5250)
CODEN: CNREA ISSN: 0008-5472
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 48

...labeling of cysteine cathepsins by the active site probe DCG-04 detected up-regulation of cathepsin X on PyMT;ctsbSUP+/+ cells. Treatment of cells with a neutralizing anti-cathepsin X antibody significantly reduced Matrigel invasion of PyMT;ctsbSUP+/+ cells but did not affect invasion of PyMT;ctsbSUP+/+ or PyMT;ctsbSUP+/- cells, indicating a compensatory function of cathepsin X in CTSB-deficient tumor cells. Finally, an adoptive transfer model, in which ctsbSUP+/+, ctsbSUP+/-, and...
DRUG DESCRIPTORS:
* cathepsin B--endogenous compound--ec
virus middle T antigen--endogenous compound--ec; proteinase --endogenous compound--ec; matrigel--endogenous compound--ec; cysteine--endogenous compound--ec

4/3,K/13 (Item 12 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13797099 EMBASE No: 2006226285
Cysteine cathepsins in the immune response

Zavas(caron)nik-Bergant T.; Turk B.
B. Turk, Department of Biochemistry and Molecular Biology, J. Stefan Institute, SI-1000 Ljubljana Slovenia
Author Email: boris.turk@ijs.si
Tissue Antigens ( TISSUE ANTIGENS ) ( United Kingdom ) 2006 , 67/5 (349-355)
CODEN: TSANA ISSN: 0001-2815 eISSN: 1399-0039

Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 50
DRUG DESCRIPTORS:
* cysteine derivative--endogenous compound--ec; *cathepsin--endogenous compound--ec
major histocompatibility antigen class 2--endogenous compound--ec; cathepsin
B--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec;
cathepsin F--endogenous compound --ec; cathepsin H--endogenous compound--ec;
cathepsin K--endogenous compound--ec; cathepsin L--endogenous compound--ec;
cathepsin S--endogenous compound--ec; cathepsin D--endogenous compound --ec; CD4
antigen--endogenous compound--ec; CD8 antigen--endogenous compound--ec; major
histocompatibility antigen class 1--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; cathepsin W
--endogenous compound--ec; cathepsin V--endogenous compound --ec

4/3,K/14 (Item 13 from file: 73)  Links
  Fulltext available through:  USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13702260  EMBASE No: 2004344716
Protease expression in interface tissues around loose arthroplasties

Kido A.; Pap G.; Nagler D.K.; Ziomek E.; Menard R.; Neumann H.W.; Roessner A.
Dr. A. Kido, Department of Orthopedic Surgery, Nara Medical University, 840
Shijo-cho, Kashihara, Nara 634-8522  Japan
Author Email: akirakid@naramed-u.ac.jp
Clinical Orthopaedics and Related Research ( CLIN. ORTHOP. RELAT. RES. ) ( United
States )  2004 , -/425 (230-236)
CODEN: CORTB  ISSN: 0009-921X
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 35
DRUG DESCRIPTORS:
* proteinase--endogenous compound--ec
cathepsin--endogenous compound--ec; interstitial collagenase --endogenous
compound--ec; cathepsin B--endogenous compound --ec; cathepsin D--endogenous
compound--ec; cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/15 (Item 14 from file: 73)  Links
  Fulltext available through:  USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13659084  EMBASE No: 2006135543
Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins

Roberts R.
Prof. R. Roberts, Department of Biology, Program in Biochemistry and Molecular
Biology, Ursinus College, P.O. Box 1000, Collegeville, PA 19426-1000  United States

Author Email: rroberts@ursinus.edu
Drug News and Perspectives ( DRUG NEWS PERSPECT. ) ( Spain )  2005 , 18/10
(605-614)
CODEN: DNPEE  ISSN: 0214-0934
Document Type: Journal ; Review
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 111
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
lysosome enzyme--endogenous compound--ec; cysteine proteinase --endogenous
compound--ec; cathepsin B--endogenous compound --ec; dipeptidyl peptidase

I--endogenous compound--ec; cathepsin F --endogenous compound--ec; cathepsin H--endogenous compound --ec; cathepsin K--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound--ec; n [n (3 carboxyoxirane 2 carbonyl)leucyl]agmatine--drug comparison--cm; n [n (3...
Drug Terms (Uncontrolled): cathepsin V--endogenous compound--ec; cathepsin O--endogenous compound--ec; cathepsin W--endogenous compound--ec; cathepsin x--endogenous compound--ec; ca 074--drug comparison--cm; ca 074--pharmacology--pd; morpholineurea leucine homophenylalanine vinylsulfonephenyl--drug...

4/3,K/16 (Item 15 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13558393 EMBASE No: 2006036856
An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker

Nagler D.K.; Lechner A.M.; Oettl A.; Kozaczynska K.; Scheuber H.-P.; Gippner-Steppert C.; Bogner V.; Biberthaler P.; Jochum M.
D.K. Nagler, Department of Clinical Chemistry and Clinical Biochemistry, University Hospital of Surgery-City, Ludwig-Maximilians-University, Nussbaumstr. 20, 80336 Munich Germany
Author Email: dorit.naegler@med.uni-muenchen.de
Journal of Immunological Methods ( J. IMMUNOL. METHODS ) ( Netherlands ) 20 JAN 2006 , 308/1-2 (241-250)
CODEN: JIMMB ISSN: 0022-1759
Publisher Item Identifier: S0022175905003704
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35
An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker

The human lysosomal cysteine-type carboxypeptidase cathepsin X is mainly present in monocytes and macrophages and may be released into the circulation due...
...inflammatory marker, we have developed a highly sensitive and specific sandwich-type immunoassay (ELISA) for cathepsin X permitting both intra- and extracellular detection and quantification. The dynamic range of the cathepsin X ELISA was determined to be 100 (detection limit) to 8000 pg/ml. Reproducibility of both... ...of the thiol-dependent cathepsin family was not observed. The ELISA was used to quantify cathepsin X in leukocytes as well as in plasma of healthy volunteers and patients with multiple trauma. During the first 72 h after trauma, plasma levels of cathepsin X increased significantly, particularly in patients who died during the posttraumatic period. In comparison to the well-known inflammation marker neutrophil elastase, cathepsin X levels predicted survival with a higher significance in the later posttraumatic phase. In conclusion, this report provides the first evidence of cathepsin X immunoreactivity not only in cell lysates but also in plasma samples. We suggest that the...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; elastase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/17 (Item 16 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13530117 EMBASE No: 2006015689
Endosomal proteases in antigen presentation

Chapman H.A.
H.A. Chapman, Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA 94143 United States
Author Email: hal.chapman@ucsf.edu
Current Opinion in Immunology ( CURR. OPIN. IMMUNOL. ) ( United Kingdom ) 2006 , 18/1 (78-84)
CODEN: COPIE ISSN: 0952-7915
Publisher Item Identifier: S0952791505002049
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 57
DRUG DESCRIPTORS:
* proteinase--endogenous compound--ec; *major histocompatibility antigen class 1--endogenous compound--ec; *major histocompatibility antigen class 2--endogenous compound--ec
cathepsin--endogenous compound--ec; cathepsin D--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec ; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/18 (Item 17 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13445732 EMBASE No: 2005489501
Gene expression profiles reveal increased mClca3 (Gob5) expression and mucin production in a murine model of asbestos-induced fibrogenesis

Sabo-Attwood T.; Ramos-Nino M.; Bond J.; Butnor K.J.; Heintz N.; Gruber A.D.; Steele C.; Taatjes D.J.; Vacek P.; Mossman B.T.
B.T. Mossman, University of Vermont, HSRF 218, 89 Beaumont Ave., Burlington, VT 05405 United States
Author Email: brooke.mossman@uvm.edu
American Journal of Pathology ( AM. J. PATHOL. ) ( United States ) 2005 , 167/5 (1243-1256)
CODEN: AJPAA ISSN: 0002-9440
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 63
DRUG DESCRIPTORS:
* mucin--endogenous compound--ec; *asbestos; *gene product--endogenous compound--ec
chrysotile; cyclin B1--endogenous compound--ec; cell cycle protein 20--endogenous compound--ec; cyclin dependent kinase 1--endogenous compound--ec; chemokine--endogenous compound--ec; complement component C1--endogenous compound--ec; chitinase--endogenous compound--ec; tumor necrosis factor derivative--endogenous compound--ec; interleukin 1beta--endogenous compound--ec; macrophage elastase--endogenous compound--ec; stromelysin --endogenous compound--ec; integrin--endogenous compound--ec; cathepsin K--endogenous compound--ec; cathepsin--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin S--endogenous compound--ec; cytokine--endogenous compound--ec ; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): protein mCLCA3--endogenous compound--ec; protein Gob5--endogenous compound--ec; CDC28 protein kinase regulatory subunit 2--endogenous compound--ec; CCL9 chemokine--endogenous compound--ec; ccl6 chemokine--endogenous compound--ec; chitinase 3 like 3--endogenous compound--ec; tumor necrosis factor superfamily member 10 --endogenous compound--ec; integrin alphaX--endogenous compound--ec; cathepsin Z--endogenous compound --ec

4/3,K/19 (Item 18 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options

EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13365751 EMBASE No: 2005432915
Large scale real-time PCR analysis of mRNA abundance in rainbow trout eggs in relationship with egg quality and post-ovulatory ageing

Aegerter S.; Jalabert B.; Bobe J.
J. Bobe, INRA, SCRIBE, Campus de Beaulieu, F-35042 Rennes Cedex France
Author Email: Julien.Bobe@rennes.inra.fr
Molecular Reproduction and Development ( MOL. REPROD. DEV. ) ( United States )
2005 , 72/3 (377-385)
CODEN: MREDE ISSN: 1040-452X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35

...period, eight transcripts (nucleoplasmin or Npm2, ferritin H, tubulin beta, JNK1, cyclin A1, cyclin A2, cathepsin Z, and IGF2) exhibited a differential abundance at one or several collection time(s). Interestingly, we... ...lower levels of Npm2, tubulin beta, and IGF1 transcripts. In contrast, keratins 8 and 18, cathepsin Z, and prostaglandin synthase 2 were more abundant in low quality eggs than in high quality...
DRUG DESCRIPTORS:
nucleoplasmin--endogenous compound--ec; somatomedin--endogenous compound--ec; cyclin A--endogenous compound--ec; tubulin --endogenous compound--ec; ferritin--endogenous compound--ec; stress activated protein kinase 1--endogenous compound--ec; cathepsin--endogenous compound--ec; somatomedin C--endogenous compound--ec; beta tubulin--endogenous compound--ec; keratin --endogenous compound--ec; prostaglandin synthase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cyclin a1--endogenous compound--ec; cyclin A2--endogenous compound--ec; cathepsin Z--endogenous compound --ec; keratin 8--endogenous compound--ec; keratin 18--endogenous compound--ec; prostaglandin synthase 2--endogenous compound --ec

4/3,K/20 (Item 19 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13318701 EMBASE No: 2005386832
Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer

Krueger S.; Kalinski T.; Hundertmark T.; Wex T.; Kuster D.; Peitz U.; Ebert M.; Nagler D.K.; Kellner U.; Malfertheiner P.; Naumann M.; Rocken C.; Roessner A.
S. Krueger, Department of Pathology, Otto-von-Guericke University, Leipziger Strasse 44, D-39120 Magdeburg Germany
Author Email: Sabine.Krueger@medizin.uni-magdeburg.de
Journal of Pathology ( J. PATHOL. ) ( United Kingdom ) 2005 , 207/1 (32-42)
CODEN: JPTLA ISSN: 0022-3417
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35
Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer

Recently, we identified increased cathepsin X expression in H. pylori-infected gastric mucosa. Here, we describe further up-regulation in gastric cancer and report on the role of inflammatory cytokines required for cathepsin X up-regulation in H. pylori-infected gastric mucosa, as well as on consequences for cellular... ...infected and non-infected patients. Gastric cancer samples were obtained from patients undergoing gastric surgery. Cathepsin X was detected in gastric mucosa by quantitative real-time RT-PCR, western blotting and immunohistochemistry. Induction of cathepsin X expression in epithelial and inflammatory cells caused by H. pylori infection was tested in in... ...cultures of AGS cells and monocytic cells. Patients

with H. pylori gastritis showed significantly higher cathepsin X mRNA (2.5-fold) and protein (1.6-fold) expression than H. pylori-negative patients. Cathepsin X was also up-regulated in gastric cancer (3-12-fold) compared to non-neoplastic mucosa. Cathepsin X was predominantly expressed by macrophages in the mucosal stroma and in glands of the antral mucosa. In addition, tumour cells stained for cathepsin X in 26 (68%) patients with gastric carcinoma. In general, staining was significantly more common (20... ...via soluble factors in the culture medium seems to be responsible for increased expression of cathepsin X in monocytes. Using antisense oligonucleotides, cathepsin X up-regulation was directly associated with higher invasiveness in vitro. Although no correlation of cathepsin X expression and TNM stage was found, our study demonstrates that cathepsin X plays a role not only in the chronic inflammation of gastric mucosa but also in...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cytokine--endogenous compound--ec; messenger RNA--endogenous compound--ec; antisense oligonucleotide; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/21 (Item 20 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13163079 EMBASE No: 2005224520
Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues

Kos J.; Sekirnik A.; Premzl A.; Bergant V.Z.; Langerholc T.; Turk B.; Werle B.; Golouh R.; Repnik U.; Jeras M.; Turk V.
J. Kos, Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, As(caron)kerc(caron)eva 7, SI-1000 Ljubljana Slovenia
Author Email: janko.kos@krka.biz
Experimental Cell Research ( EXP. CELL RES. ) ( United States ) 15 MAY 2005 , 306/1 (103-113)
CODEN: ECREA ISSN: 0014-4827
Publisher Item Identifier: S0014482704007220
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 42

Cathepsin X, a recently discovered lysosomal cysteine protease, shares common structural features and activity properties with cysteine... ...distribution in cells and tissues and to their possible roles in malignancy. Protein level of cathepsin X did not differ significantly between matched pairs of lung tumor and adjacent lung tissue obtained... ...6-fold higher in tumor compared to adjacent lung tissue. Immunohistochemical analysis of lung tumor cathepsin X revealed very faint staining in tumor cells but positive staining in infiltrated histiocytes, alveolar macrophages, bronchial epithelial cells, and alveolar type II cells. Cathepsin X stained positive also in CD68SUP+ cells in germinal centers of secondary follicles in lymph nodes ... ...10A neoT and MDA-MB 231, showed positive staining for cathepsin B, but negative for cathepsin X. We showed that the invasive potential of MCF-10A neoT cells can be impaired by specific inhibitor of cathepsin B but not by that of cathepsin X. Cathepsin X was found in large amounts in the pro-monocytic U-937 cell line, in monocytes and in dendritic cells, generated from monocytes in vitro. Our results show that cathepsin X is not involved in degradation of extracellular matrix, a proteolytic event leading to tumor cell...
DRUG DESCRIPTORS:
* carboxypeptidase--endogenous compound--ec; *cathepsin B--endogenous compound--ec
CD68 antigen--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/22 (Item 21 from file: 73) Links

Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13140612 EMBASE No: 2005207535
Capturing protein interactions in the secretory pathway of living cells

Nyfeler B.; Michnick S.W.; Hauri H.-P.
H.-P. Hauri, Dept. of Pharmacol. and Neurbiology, Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel Switzerland
Author Email: hans-peter.hauri@unibas.ch
Proceedings of the National Academy of Sciences of the United States of America ( PROC. NATL. ACAD. SCI. U. S. A. ) ( United States ) 03 MAY 2005 , 102/18 (6350-6355)
CODEN: PNASA ISSN: 0027-8424
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 35

...ERGIC-53-interacting multicoagulation factor deficiency protein MCFD2, and to ERGIC-53's cargo glycoprotein cathepsin Z. YFP PCA analysis revealed the oligomerization of ERGIC-53 and its interaction with MCFD2, as well as its lectin-mediated interaction with cathepsin Z. Mutation of the lectin domain of ERGIC-53 selectively decreased YFP complementation with cathepsin Z. Using YFP PCA, we discovered a carbohydrate-mediated interaction between ERGIC-53 and cathepsin C...
DRUG DESCRIPTORS:
* endoplasmic reticulum golgi intermediate compartment protein 53--endogenous compound--ec; *cathepsin--endogenous compound--ec; *hybrid protein--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; multicoagulation factor deficiency protein--endogenous compound--ec

4/3,K/23 (Item 22 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13138770 EMBASE No: 2005198390
The human brain mannose 6-phosphate glycoproteome: A complex mixture composed of multiple isoforms of many soluble lysosomal proteins

Sleat D.E.; Lackland H.; Wang Y.; Sohar I.; Xiao G.; Li H.; Lobel P.
Dr. P. Lobel, Ctr. for Adv. Biotech. and Medicine, 679 Hoes Lane, Piscataway, NJ 08854 United States
Author Email: lobel@cabm.rutgers.edu
Proteomics ( PROTEOMICS ) ( Germany ) 2005 , 5/6 (1520-1532)
CODEN: PROTC ISSN: 1615-9853
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 41
DRUG DESCRIPTORS:
* mannose 6 phosphate--endogenous compound--ec; *lysosome enzyme --endogenous compound--ec; *proteome--endogenous compound--ec
somatomedin B receptor--endogenous compound--ec; n acetyl beta glucosaminidase--endogenous compound--ec; cathepsin S--endogenous compound--ec; deoxyribonuclease II--endogenous compound--ec; dipeptidyl peptidase--endogenous compound--ec; gamma glutamyl hydrolase--endogenous compound--ec; legumain--endogenous compound--ec; lysophospholipase--endogenous compound--ec; proline carboxypeptidase--endogenous compound--ec; clusterin --endogenous compound--ec; acetylesterase--endogenous compound--ec; alpha mannosidase--endogenous compound--ec; serine carboxypeptidase--endogenous compound--ec; ribonuclease --endogenous compound--ec; ependymin--endogenous compound--ec ; n4 (beta n acetylglucosaminyl)asparaginase--endogenous compound --ec;

angiotensinogen--endogenous compound--ec; cerebroside sulfatase--endogenous compound--ec; acylsphingosine deacylase --endogenous compound--ec; palmitoyl protein thioesterase --endogenous compound--ec; cystatin C--endogenous compound --ec; cystatin B--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; cathepsin D--endogenous compound --ec; cathepsin F--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin--endogenous compound--ec; F box protein--endogenous compound--ec; ferritin--endogenous compound--ec; alpha levo fucosidase--endogenous compound--ec; alpha glucosidase--endogenous compound--ec; sulfatase--endogenous compound--ec; alpha galactosidase--endogenous compound--ec; beta galactosidase--endogenous compound--ec; beta glucuronidase --endogenous compound--ec; beta n acetylhexosaminidase A--endogenous compound--ec; beta n acetylhexosaminidase B--endogenous compound--ec; iduronate 2 sulfatase--endogenous compound--ec; levo iduronidase--endogenous compound--ec; galectin 1--endogenous compound--ec; acid lipase--endogenous compound--ec; myelin associated glycoprotein--endogenous compound--ec; beta mannosidase --endogenous compound--ec; prosaposin--endogenous compound --ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin p--endogenous compound--ec; cathepsin x --endogenous compound--ec; dipeptidyl peptidase VII--endogenous compound--ec; ribonuclease 6--endogenous compound--ec; n acetyl 6 galactosamine sulfatase--endogenous compound--ec; n acetyl glucosamine 6 sulfatase--endogenous compound--ec

4/3,K/24 (Item 23 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13138755 EMBASE No: 2005198358
Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease

Abe J.; Jibiki T.; Noma S.; Nakajima T.; Saito H.; Terai M.
Dr. J. Abe, Department of Allergy and Immunology, Natl. Res. Inst. Child Hlth./Devmt., 2-10-1 Ohkura, Setagaya-ku, Tokyo 157-8535 Japan
Author Email: jabe@nch.go.jp
Journal of Immunology ( J. IMMUNOL. ) ( United States ) 01 MAY 2005 , 174/9 (5837-5845)
CODEN: JOIMA ISSN: 0022-1767
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 53
DRUG DESCRIPTORS:
* ...dose--do; *immunoglobulin--drug therapy--dt; *immunoglobulin --intravenous drug administration--iv; *chemokine receptor CCR2--endogenous compound--ec; *protein S 100--endogenous compound--ec; *Fc receptor--endogenous compound--ec; *adrenomedullin--endogenous compound--ec
formylpeptide receptor--endogenous compound--ec; C reactive protein --endogenous compound--ec; toll like receptor 2--endogenous compound--ec; adiponectin--endogenous compound--ec; cell surface receptor--endogenous compound--ec; colony stimulating factor receptor--endogenous compound--ec; interleukin 8 receptor --endogenous compound--ec; CD39 antigen--endogenous compound --ec; CD16 antigen--endogenous compound--ec; colony stimulating factor 1--endogenous compound--ec; protein tyrosine phosphatase --endogenous compound--ec; protein p57--endogenous compound --ec; interleukin 3--endogenous compound--ec; versican--endogenous compound--ec; immunoglobulin kappa chain--endogenous compound --ec; APRIL protein--endogenous compound--ec; dysferlin--endogenous compound--ec; chimerin--endogenous compound--ec; hematopoietic cell kinase--endogenous compound--ec; phosphatase --endogenous compound--ec; RGS2 protein--endogenous compound --ec; Rab protein--endogenous compound--ec; transcription factor --endogenous compound--ec; protein v fos--endogenous compound --ec; early growth response factor 1--endogenous compound--ec; calreticulin--endogenous compound--ec; major histocompatibility antigen class 2--endogenous compound--ec; hexokinase--endogenous compound--ec; 5

aminolevulinate synthase--endogenous compound --ec; oxidoreductase--endogenous compound--ec; cytochrome P450 1B1 --endogenous compound--ec; long chain fatty acid coenzyme A ligase --endogenous compound--ec; histidine ammonialyase--endogenous compound--ec; microsomal aminopeptidase--endogenous compound --ec; spermidine--endogenous compound--ec; acyltransferase --endogenous compound--ec; cathepsin--endogenous compound--ec ; collapsin response mediator protein--endogenous compound--ec; ribosome protein--endogenous compound--ec; aquaporin 9--endogenous compound--ec; carrier protein--endogenous compound--ec; scramblase--endogenous compound--ec; heat shock protein 70 --endogenous compound--ec; protein disulfide isomerase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): protein S100A9--endogenous compound--ec; protein S100A12--endogenous compound--ec; protein S100A8--endogenous compound--ec; adiponectin receptor 1--endogenous compound--ec; leukocyte immunoglobulin receptor B1--endogenous compound--ec; leukocyte immunoglobulin receptor B2--endogenous compound--ec; leukocyte immunoglobulin like receptor B3--endogenous compound--ec; stabilin 1 --endogenous compound--ec; S phase response protein--endogenous compound--ec; growth arrest specific protein 7--endogenous compound--ec; cold autoinflammatory syndrome 1 protein--endogenous compound--ec; pre B cell colony enhancing factor--endogenous compound--ec; proapoptotic caspase adaptor protein--endogenous compound--ec; chimerin 2--endogenous compound--ec; dual specificity phosphatase 1--endogenous compound--ec; Rab31 protein --endogenous compound--ec; kruppel like factor 4--endogenous compound--ec; cold shock domain protein A--endogenous compound--ec; SFFV proviral integration 1 protein--endogenous compound--ec; transcription factor 7 like 2--endogenous compound--ec; hexokinase 3--endogenous compound--ec; guanosine phosphate reductase--endogenous compound--ec; biliverdin reductase B--endogenous compound--ec; gamma interferon inducible protein 30--endogenous compound--ec; flavoprotein oxidoreductase --endogenous compound--ec; neutrophil cytosolic factor 2--endogenous compound--ec; spermine n1 acetyltransferase--endogenous compound--ec; cathepsin Z--endogenous compound --ec; mitochondrial solute carrier protein--endogenous compound--ec

4/3,K/25 (Item 24 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
13086504 EMBASE No: 2005147588
Pancreatic beta-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58SUPIPK

Ladiges W.C.; Knoblaugh S.E.; Morton J.F.; Korth M.J.; Sopher B.L.; Baskin C.R.; MacAuley A.; Goodman A.G.; LeBoeuf R.C.; Katze M.G.
W.C. Ladiges, Department of Comparative Medicine, Box 357190, University of Washington, Seattle, WA 98195 United States
Author Email: wladiges@u.washington.edu
Diabetes ( DIABETES ) ( United States ) 2005 , 54/4 (1074-1081)
CODEN: DIAEA ISSN: 0012-1797
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 26
DRUG DESCRIPTORS:
* chaperone--endogenous compound--ec; *protein p58--endogenous compound--ec glucose; initiation factor 2alpha--endogenous compound--ec; cathepsin L--endogenous compound--ec; protein p53--endogenous compound--ec; lymphotoxin beta--endogenous compound--ec; cathepsin D--endogenous compound--ec; cathepsin B--endogenous compound--ec; serine proteinase Omi--endogenous compound--ec; FAS ligand--endogenous compound--ec; cathepsin--endogenous compound--ec; annexin--endogenous compound--ec; cytochrome c --endogenous compound--ec; STAT3 protein--endogenous compound --ec; beta arrestin--endogenous compound--ec; immunoglobulin enhancer binding protein--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec

4/3,K/26 (Item 25 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12666149 EMBASE No: 2004261313
Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa

Buhling F.; Peitz U.; Kruger S.; Kuster D.; Vieth M.; Gebert I.; Roessner A.; Weber E.; Malfertheiner P.; Wex T.
T. Wex, Dept. of Gastroenterology, Dept. of Infectious Disease, Leipziger Str. 44, D-39120 Magdeburg Germany
Author Email: thomas.wex@medizin.uni-magdeburg.de
Biological Chemistry ( BIOL. CHEM. ) ( Germany ) 2004 , 385/5 (439-445)
CODEN: BICHF ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 28

...was expressed at very low levels. Infection by Helicobacter pylori caused a significant induction of cathepsin X ($p<0.008$), whereas the other cathepsins were not or only locally affected by H. pylori infection or reflux disease. Immunohistochemistry revealed specific expression of cathepsin X (macrophages), cathepsin K (parietal cells) and cathepsin W (lymphocytes), whereas cathepsins B and L were...
DRUG DESCRIPTORS:
* cathepsin K--endogenous compound--ec; *cathepsin L--endogenous compound--ec; *cathepsin B--endogenous compound--ec; * cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; cathepsin w --endogenous compound--ec

4/3,K/27 (Item 26 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12657426 EMBASE No: 2004255824
Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia

Nagler D.K.; Kruger S.; Kellner A.; Ziomek E.; Menard R.; Buhtz P.; Krams M.; Roessner A.; Kellner U.
D.K. Nagler, Dept. of Clin. Chem./Clin. Biochem., University Hospital of Surgery-City, Ludwig-Maximilians-University, Nussbaumstr. 20, 80336 Munich Germany

Author Email: dorit.naegler@clinbio.med.uni-muenchen.de
Prostate ( PROSTATE ) ( United States ) 01 JUL 2004 , 60/2 (109-119)
CODEN: PRSTD ISSN: 0270-4137
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 36
Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec cathepsin F--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; genomic DNA--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/28 (Item 27 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options

EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12605998 EMBASE No: 2004197020
Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner

Lautwein A.; Kraus M.; Reich M.; Burster T.; Brandenburg J.; Overkleeft H.S.; Schwarz G.; Kammer W.; Weber E.; Kalbacher H.; Nordheim A.; Driessen C.
C. Driessen, MNF Universitat Tubingen, Ob dein Himmelreich 7, 72074 Tubingen Germany
Author Email: christoph.driessen@med.uni-tuebingen.de
Journal of Leukocyte Biology ( J. LEUKOCYTE BIOL. ) ( United States ) 2004 , 75/5 (844-855)
CODEN: JLBIE ISSN: 0741-5400
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 56
DRUG DESCRIPTORS:
* major histocompatibility antigen class 2--endogenous compound--ec; * cathepsin--endogenous compound--ec; *cathepsin S--endogenous compound--ec proteinase--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin D--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; HLA DM antigen; vinyl derivative; phenol derivative; unclassified drug
Drug Terms (Uncontrolled): asparagine specific endoprotease--endogenous compound--ec; cathepsin Z; leucine homophenylalanine vinylsulfone phenol

4/3,K/29 (Item 28 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12535984 EMBASE No: 2004129918
Expression and characterization of cathepsin P

Mason R.W.; Bergman C.A.; Lu G.; Frenck Holbrook J.; Sol-Church K.
R.W. Mason, Department of Biomedical Research, Alfred I. duPont Hosp. for Children, 1600 Rockland Road, Wilmington, DE 19803 United States
Author Email: mason@medsci.udel.edu
Biochemical Journal ( BIOCHEM. J. ) ( United Kingdom ) 01 MAR 2004 , 378/2 (657-663)
CODEN: BIJOA ISSN: 0264-6021
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 24
Expression and characterization of cathepsin P

...in placental tissues of all mammalian species. In the present study, it was shown that cathepsin P can be expressed in Pichia pastoris as an inactive zymogen that can be activated with proteinase K, chymotrypsin or pancreatic elastase at neutral pH. Unlike other mammalian cathepsins, cathepsin P could also be autoactivated at neutral pH, but not at acidic pH. The activated enzyme... ...SUB2SOSUB4 and hyaluronate stimulated the activity of the protease against peptidyl substrates. The properties of cathepsin P appear to be quite distinct from those of cathepsin L, indicating that the duplication that gave rise to cathepsin P has probably not yielded an enzyme that provides a subfunction of cathepsin L in rodents. It seems probable that cathepsin P has evolved to perform a function that is performed by an evolutionarily unrelated protease in...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cathepsin L--endogenous compound--ec messenger RNA--endogenous compound--ec; proteinase K; chymotrypsin; pancreatic elastase; peptide derivative--endogenous compound--ec; protein

derivative--endogenous compound--ec; transferrin--endogenous compound--ec; inorganic salt; sodium sulfate; hyaluronic acid; unclassified drug
Drug Terms (Uncontrolled): cathepsin p--endogenous compound--ec; azocasein --endogenous compound--ec

4/3,K/30 (Item 29 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12534119 EMBASE No: 2004127448
Cysteine proteases as disease markers

Berdowska I.
I. Berdowska, Department of Medical Biochemistry, Wroclaw Medical University, 10 Chalubinskiego, 50-368 Wroclaw Poland
Author Email: iza@bioch.am.wroc.pl
Clinica Chimica Acta ( CLIN. CHIM. ACTA ) ( Netherlands ) 2004 , 342/1-2 (41-69)
CODEN: CCATA ISSN: 0009-8981
Publisher Item Identifier: S0009898103006041
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 248
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *tumor marker --endogenous compound--ec
peptidase--endogenous compound--ec; papain--endogenous compound--ec; cysteine derivative--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin S--endogenous compound--ec; cathepsin K--endogenous compound --ec; cathepsin F--endogenous compound--ec; dipeptidyl peptidase I --endogenous compound--ec; protein precursor--endogenous compound--ec; enzyme precursor--endogenous compound--ec; hormone precursor--endogenous compound--ec; major histocompatibility antigen class 2--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cysteine cathepsin derivative--endogenous compound--ec; cathepsin v --endogenous compound--ec; cathepsin x--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin o--endogenous compound--ec

4/3,K/31 (Item 30 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12503843 EMBASE No: 2004098453
Myxobolus cerebralis: Identification of a cathepsin Z-like protease gene (MyxCP-1) expressed during parasite development in rainbow trout, Oncorhynchus mykiss

Kelley G.O.; Adkison M.A.; Leutenegger C.M.; Hedrick R.P.
G.O. Kelley, Dept. of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616 United States
Author Email: gokelley@ucdavis.edu
Experimental Parasitology ( EXP. PARASITOL. ) ( United States ) 2003 , 105/3-4 (201-210)
CODEN: EXPAA ISSN: 0014-4894
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 54
Myxobolus cerebralis: Identification of a cathepsin Z-like protease gene (MyxCP-1) expressed during parasite development in rainbow trout, Oncorhynchus mykiss

...cysteine proteases. MyxCP-1 features a propeptide region and sequence insertions that are characteristics of cathepsin Z proteases. Phylogenetic comparisons of M. cerebralis to other eukaryotes based on full-length cathepsin-like genes show that

MyxCP-1 is the earliest lineage in the cathepsin Z group and separated from cathepsin L, B, and C-like proteases. Using TaqMan PCR differential levels of transcription of the cathepsin Z-like protease were found in earlier and later developmental stages of the parasite in experimentally...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z like protease--endogenous compound--ec

4/3,K/32 (Item 31 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12487347 EMBASE No: 2004079961
The Caenorhabditis elegans Cathepsin Z-like Cysteine Protease, Ce-CPZ-1, Has a Multifunctional Role during the Worms' Development

Hashmi S.; Zhang J.; Oksov Y.; Lustigman S.
S. Hashmi, Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Inst., New York Blood Center, 310 E. 67th St., New York, NY 10021 United States
Author Email: shashmi@nybloodcenter.org
Journal of Biological Chemistry ( J. BIOL. CHEM. ) ( United States ) 13 FEB 2004 , 279/7 (6035-6045)
CODEN: JBCHA ISSN: 0021-9258
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 60
The Caenorhabditis elegans Cathepsin Z-like Cysteine Protease, Ce-CPZ-1, Has a Multifunctional Role during the Worms' Development

We have analyzed the expression and function of Ce-cpz-1, a Caenorhabditis elegans cathepsin Z-like cysteine protease gene, during development of the worm. The cpz-1 gene is expressed... ...are degraded prior to shedding and ecdysis. The similar localization of the related Onchocerca volvulus cathepsin Z protein suggests that the function of CPZ-1 during molting might be conserved in other... ...basement membrane extracellular matrix assembly process. The present findings have defined a critical role for cathepsin Z in nematode biology.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin Z like cysteine proteinase--endogenous compound--ec

4/3,K/33 (Item 32 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12409511 EMBASE No: 2004009245
Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes

Rumpler G.; Becker B.; Hafner C.; McClelland M.; Stolz W.; Landthaler M.; Schmitt R.; Bosserhoff A.; Vogt T.
Dr. T. Vogt, Department of Dermatology, University of Regensburg, D-93042 Regensburg Germany
Author Email: thomas.vogt@klinik.uni-regensburg.de
Experimental Dermatology ( EXP. DERMATOL. ) ( United Kingdom ) 2003 , 12/6 (761-771)
CODEN: EXDEE ISSN: 0906-6705
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 46

...migration inhibiting factor (MIF), an important modulator of both cell cycle progression and angiogenesis, and cathepsin Z, a novel member of the family of matrix degrading proteinases. (c) Blackwell Munksgaard, 2003.
DRUG DESCRIPTORS:
* complementary DNA--endogenous compound--ec; *osteonectin--endogenous compound--ec; *macrophage migration inhibition factor--endogenous compound--ec; *cathepsin--endogenous compound--ec; * proteinase--endogenous compound--ec reduced nicotinamide adenine dinucleotide dehydrogenase (ubiquinone) --endogenous compound--ec; ubiquitin--endogenous compound--ec ; selenoprotein--endogenous compound--ec; tumor protein--endogenous compound--ec; guanine nucleotide binding protein--endogenous compound--ec; HLA antigen class 2--endogenous compound--ec; laminin binding protein--endogenous compound--ec; protein --endogenous compound--ec; polyadenylic acid binding protein --endogenous compound--ec; DNA binding protein--endogenous compound--ec; initiation factor 2--endogenous compound--ec; heat shock protein 90--endogenous compound--ec; cytochrome b --endogenous compound--ec; protein lysine 6 oxidase--endogenous compound--ec; adenosine triphosphatase--endogenous compound --ec; receptor--endogenous compound--ec; phospholipid transfer protein--endogenous compound--ec; beta galactosidase--endogenous compound--ec; unindexed drug; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; Wilm tumor related protein--endogenous compound--ec; guanine nucleotide binding protein beta subunit like protein--endogenous compound--ec; eukaryotic translation elongation factor 1 gamma--endogenous compound--ec; glia derived nexin--endogenous compound--ec; folic acid receptor 1--endogenous compound--ec

4/3,K/34 (Item 33 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
12290413 EMBASE No: 2003402858
Phylogeny of antigen-processing enzymes: Cathepsins of a cephalochordate, an agnathan and a bony fish

Uinuk-Ool T.S.; Takezaki N.; Kuroda N.; Figueroa F.; Sato A.; Samonte I.E.; Mayer W.E.; Klein J.
T.S. Uinuk-Ool, Max-Planck-Inst. fur Biologie, Abteilung Immungenetik, Corrensstrasse 42, D-72076 Tubingen Germany
Author Email: tanya@tuebingen.mpg.de
Scandinavian Journal of Immunology ( SCAND. J. IMMUNOL. ) ( United Kingdom ) 01 OCT 2003 , 58/4 (436-448)
CODEN: SJIMA ISSN: 0300-9475
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 71
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cathepsin B--endogenous compound--ec; cathepsin L--endogenous compound--ec; cathepsin F--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; cathepsin S --endogenous compound--ec; cathepsin K--endogenous compound --ec; complementary DNA; unclassified drug
Drug Terms (Uncontrolled): cathepsin Z--endogenous compound--ec; cathepsin O --endogenous compound--ec

4/3,K/35 (Item 34 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11901450 EMBASE No: 2003014131
Determination of the mRNA sequence of cathepsin Y, a cysteine.endopeptidase from rat spleen, and confirmation of its ubiquitous expression

Nakazono E.; Kamata Y.; Yamafuji K.
K. Yamafuji, Division of Food and Nutrition, Nakamura Gakuen University, Befu 5-7-1, Jonan-ku, Fukuoka 814-0198 Japan
Biological Chemistry ( BIOL. CHEM. ) ( Germany ) 01 DEC 2002 , 383/12 (1971-1975)
CODEN: BICHF ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 14
Determination of the mRNA sequence of cathepsin Y, a cysteine endopeptidase from rat spleen, and confirmation of its ubiquitous expression

...by its action of producing kinin-potentiating peptide from a plasma protein. We named it cathepsin Y due to its localization, acidic pH optimum and the presence of the same set of.....the mRNA sequence resulted in the omission of the strangely attached C-terminal peptide from cathepsin Y.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
messenger RNA--endogenous compound--ec; cysteine proteinase --endogenous compound--ec; amino acid--endogenous compound --ec; thiol--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin Y--endogenous compound--ec

4/3,K/36 (Item 35 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11309979 EMBASE No: 2001324286
Lysosomal cysteine proteases: Facts and opportunities

Turk V.; Turk B.; Turk D.
V. Turk, Department of Biochemistry, J. Stefan Institute, Ljubljana Slovenia
Author Email: vito.turk@ijs.si
EMBO Journal ( EMBO J. ) ( United Kingdom ) 03 SEP 2001 , 20/17 (4629-4633)
CODEN: EMJOD ISSN: 0261-4189
Document Type: Journal ; Review
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 45
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *cathepsin--endogenous compound--ec enzyme precursor--endogenous compound--ec; amino acid; cathepsin L --endogenous compound--ec; cathepsin S--endogenous compound --ec; cathepsin K--endogenous compound--ec; cathepsin F--endogenous compound--ec; cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec; dipeptidyl peptidase I--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin V--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin o--endogenous compound--ec; cathepsin x--endogenous compound--ec

4/3,K/37 (Item 36 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11229615 EMBASE No: 2001244434
Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design

Menard R.; Therrien C.; Lachance P.; Sulea T.; Qi H.; Alvarez-Hernandez A.; Roush W.R.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Que. H4P 2R2 Canada

Biological Chemistry ( BIOL. CHEM. ) ( Germany )  2001 , 382/5 (839-845)
CODEN: BICHF  ISSN: 1431-6730
Document Type: Journal ; Article
Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 21

...share similar activity profiles against substrates and inhibitors. Using quenched fluorogenic substrates, we show that cathepsin X preferentially cleaves substrates through a monopeptidyl carboxypeptidase pathway, while cathepsin B displays a preference for... ...approximately 2 orders of magnitude. Cleavage of a C-terminal dipeptide of a substrate by cathepsin X can be observed under conditions that preclude efficient monopeptidyl carboxypeptidase activity. In addition, an inhibitor designed to exploit the unique structural features responsible for the carboxypeptidase activity of cathepsin X has been synthesized and tested against cathepsins X, B and L. Although of moderate potency, this E-64 derivative is the first reported example of a cathepsin X-specific inhibitor. By comparison, CA074 was found to inactivate cathepsin B at least 34 000-fold more efficiently than cathepsin X.
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *cathepsin B --endogenous compound--ec; *enzyme inhibitor--drug development--dv; *enzyme inhibitor--pharmacology--pd
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec; ca 074--drug development--dv; ca 074--pharmacology--pd

4/3,K/38 (Item 37 from file: 73)  Links
  Fulltext available through:  USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11062658  EMBASE No: 2001079403
Human cathepsin X: A novel cysteine protease with unique specificity

Menard R.; Nagler D.K.; Zhang R.; Tam W.; Sulea T.; Purisima E.O.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Avenue Royalmount, Montreal, Que. H4P 2R2  Canada
Advances in Experimental Medicine and Biology ( ADV. EXP. MED. BIOL. ) ( United States )  2000 , 477/- (317-322)
CODEN: AEMBA  ISSN: 0065-2598
Document Type: Journal ; Conference Paper
Language: ENGLISH
Number Of References: 14
Human cathepsin X: A novel cysteine protease with unique specificity
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/39 (Item 38 from file: 73)  Links
  Fulltext available through:  USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11062650  EMBASE No: 2001079395
Review: Novel cysteine proteases of the papain family

Buhling F.; Fengler A.; Brandt W.; Welte T.; Ansorge S.; Nagler D.K.
F. Buhling, Institue of Immunology, Otto von Guericke Univ. Magdeburg, Magdeburg Germany
Advances in Experimental Medicine and Biology ( ADV. EXP. MED. BIOL. ) ( United States )  2000 , 477/- (241-254)
CODEN: AEMBA  ISSN: 0065-2598
Document Type: Journal ; Conference Paper
Language: ENGLISH

Number Of References: 69
DRUG DESCRIPTORS:
* cysteine proteinase--endogenous compound--ec; *papain--endogenous compound--ec
cathepsin F--endogenous compound--ec; cathepsin K--endogenous compound--ec;
unclassified drug
Drug Terms (Uncontrolled): cathepsin o--endogenous compound--ec; cathepsin
V--endogenous compound--ec; cathepsin w--endogenous compound--ec; cathepsin
x--endogenous compound--ec

4/3,K/40 (Item 39 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
11023122 EMBASE No: 2000123291
Proteolytic signals from Magdeburg

Ansorge S.; Langner J.; Buhling F.; Lendeckel U.
S. Ansorge, Inst. of Experimental Internal Med., Otto-von-Guericke University,
D-39120 Magdeburg Germany
Immunology Today ( IMMUNOL. TODAY ) ( United Kingdom ) 2000 , 21/4 (166-167)
CODEN: IMTOD ISSN: 0167-5699
Publisher Item Identifier: S0167569900015863
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
DRUG DESCRIPTORS:
* microsomal aminopeptidase--endogenous compound--ec; *dipeptidyl peptidase
IV--endogenous compound--ec; *enzyme inhibitor--drug development--dv; *enzyme
inhibitor--pharmacology--pd; *cathepsin --endogenous compound--ec
cathepsin S--endogenous compound--ec; cathepsin L--endogenous compound--ec;
cathepsin B--endogenous compound--ec; cathepsin H--endogenous compound--ec;
cathepsin K--endogenous compound --ec; cathepsin D--endogenous compound--ec;
unclassified drug
Drug Terms (Uncontrolled): peptidase inhibitor--drug development--dv; peptidase
inhibitor --pharmacology--pd; cathepsin w--endogenous compound--ec; cathepsin
F--endogenous compound--ec; cathepsin x--endogenous compound--ec

4/3,K/41 (Item 40 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10939353 EMBASE No: 2000429272
Flow cytometric analysis of enzymes in live spermatozoa before and after cryostorage

Schaller J.; Glander H.-J.
Dr. J. Schaller, Dermatohistological Unit, Department of Dermatology, St. Barbara
Hospital, Barbarastr. 67, 47167 Duisburg Germany
Andrologia ( ANDROLOGIA ) ( Germany ) 2000 , 32/6 (357-364)
CODEN: ANDRD ISSN: 0303-4569
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 27

...for butyryl esterase (P<0.05), prolyl-aminopeptidase (P<0.001) and
val-lys-(VK)-cathepsin (P<0.001) most probably due to elevated enzyme activities.
The activities of FDA-esterase (P...
DRUG DESCRIPTORS:
* peptidase--endogenous compound--ec; *proteinase--endogenous compound--ec;
*esterase--endogenous compound--ec; *elastase --endogenous compound--ec;
*collagenase--endogenous compound --ec
fluorescein; rhodamine 110; microsomal aminopeptidase--endogenous compound--ec;

subtilisin--endogenous compound--ec; dipeptidyl peptidase--endogenous compound--ec; proline iminopeptidase --endogenous compound--ec; cathepsin--endogenous compound--ec

4/3,K/42 (Item 41 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10839518 EMBASE No: 2000320402
Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13

Bonthron D.T.; Hayward B.E.; Moran V.; Strain L.
D.T. Bonthron, Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds LS9 7TF United Kingdom
Author Email: D.T.Bonthron@leeds.ac.uk
Human Genetics ( HUM. GENET. ) ( Germany ) 2000 , 107/2 (165-175)
CODEN: HUGED ISSN: 0340-6717
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 26

...probably not imprinted. Immediately downstream of TH1 lies CTSZ, encoding the recently described cysteine protease, cathepsin Z. We have also elucidated the genomic structure of this gene; it has six exons spanning...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin z--endogenous compound--ec

4/3,K/43 (Item 42 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10834786 EMBASE No: 2000316209
Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase

Klemencic I.; Carmona A.K.; Cezari M.H.S.; Juliano M.A.; Juliano L.; Guncar G.; Turk D.; Krizaj I.; Turk V.; Turk B.
B. Turk, Dept. of Biochemistry/Molec. Biol., Josef Stefan Institute, Jamova 39, 1000 Ljubljana Slovenia
Author Email: boris.turk@ijs.si
European Journal of Biochemistry ( EUR. J. BIOCHEM. ) ( United Kingdom ) 2000 , 267/17 (5404-5412)
CODEN: EJBCA ISSN: 0014-2956
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 44
Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase

Cathepsin X, purified to homogeneity from human liver, is a single chain glycoprotein with a molecular mass of approx. eq. 33 kDa and pI 5.1-5.3. Cathepsin X was inhibited by stefin A, cystatin C and chicken cystatin (K(i) = 1.7-15... ...was also inhibited by two specific synthetic cathepsin B inhibitors, CA-074 and GFG-semicarbazone. Cathepsin X was similar to cathepsin B and found to be a carboxypeptidase with preference for a positively charged Arg in P1 position. Contrary to the preference of cathepsin B, cathepsin X normally acts as a carboxymonopeptidase. However, the preference for Arg in the P1 position is so strong that cathepsin X cleaves substrates with Arg in antepenultimate position, acting also as a carboxydipeptidase. A large hydrophobic... ...P1' position, although the enzyme cleaved all P1' residues investigated (Trp, Phe, Ala, Arg, Pro).

Cathepsin X also cleaved substrates with amide-blocked C-terminal carboxyl group with rates similar to those of the unblocked substrates. In contrast, no endopeptidase activity of cathepsin X could be detected on a series of o-aminobenzoic acid-peptidyl-N-[2,-dinitrophenyl]ethylenediamine...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *carboxypeptidase--endogenous compound--ec; *dipeptidase--endogenous compound--ec
liver enzyme--endogenous compound--ec; stefin A; cystatin C; stefin B; kininogen; semicarbazone; cathepsin B; tryptophan; phenylalanine; arginine; proline...

4/3,K/44 (Item 43 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10728641 EMBASE No: 2000138039
Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages

Shi G.-P.; Bryant R.A.R.; Riese R.; Verhelst S.; Driessen C.; Li Z.; Bromme D.; Ploegh H.L.; Chapman H.A.
H.A. Chapman, Pulmonary and Critical Care Div., University of California, 505 Parnassus Ave., San Francisco, CA 94143-0111 United States
Author Email: halchap@itsa.ucsf.edu
Journal of Experimental Medicine ( J. EXP. MED. ) ( United States ) 03 APR 2000 , 191/7 (1177-1185)
CODEN: JEMEA ISSN: 0022-1007
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 42

...and dendritic cells revealed two enzymes expressed exclusively in macrophages, cathepsins Z and F. Recombinant cathepsin Z did not generate CLIP from Ii-MHC class II complexes, whereas cathepsin F was as...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *major histocompatibility antigen class 2--endogenous compound--ec; *cell membrane protein --endogenous compound--ec
cysteine proteinase--endogenous compound--ec; recombinant enzyme; cathepsin S; unclassified drug
Drug Terms (Uncontrolled): cathepsin F--endogenous compound--ec; class ii associated invariant chain peptide--endogenous compound--ec; cathepsin z

4/3,K/45 (Item 44 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10703930 EMBASE No: 2000192563
The new subfamily of cathepsin-Z-like protease genes includes Tc-cpz-1, a cysteine protease gene expressed in Toxocara canis adults and infective stage larvae

Falcone F.H.; Tetteh K.K.A.; Hunt P.; Blaxter M.L.; Loukas A.; Maizels R.M.
R.M. Maizels, Inst. Cell Animal/Population Biol., University of Edinburgh, West Mains Road, Edinburgh EH9 3JT United Kingdom
Author Email: r.maizels@ed.ac.uk
Experimental Parasitology ( EXP. PARASITOL. ) ( United States ) 2000 , 94/3 (201-207)
CODEN: EXPAA ISSN: 0014-4894
Document Type: Journal ; Article
Language: ENGLISH
Number Of References: 32
The new subfamily of cathepsin-Z-like protease genes includes Tc-cpz-1, a cysteine protease gene expressed in Toxocara canis...

DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin tc cpz 1--endogenous compound--ec

4/3,K/46 (Item 45 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10651123 EMBASE No: 2000116176
Mouse cathepsin M, a placenta-specific lysosomal cysteine protease related to cathepsins L and P

Sol-Church K.; Frenck J.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I.du Pont Hosp. for Children, P.O. Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochimica et Biophysica Acta - Gene Structure and Expression ( BIOCHIM. BIOPHYS. ACTA GENE STRUCT. EXPR. ) ( Netherlands ) 25 APR 2000 , 1491/1-3 (289-294)
CODEN: BBGSD ISSN: 0167-4781
Publisher Item Identifier: S0167478100000300
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 34
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *complementary DNA--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec
cathepsin L--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin m--endogenous compound--ec; cathepsin p --endogenous compound--ec

4/3,K/47 (Item 46 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10651103 EMBASE No: 2000116156
Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization

Deussing J.; Von Olshausen I.; Peters C.
C. Peters, Institut Molekular Medizin, Klinikum, Albert-Ludwig-Universitat, Hugstetter Strasse 55, 79106 Freiburg Germany
Author Email: peters@mm11.ukl.uni-freiburg.de
Biochimica et Biophysica Acta - Gene Structure and Expression ( BIOCHIM. BIOPHYS. ACTA GENE STRUCT. EXPR. ) ( Netherlands ) 25 APR 2000 , 1491/1-3 (93-106)
CODEN: BBGSD ISSN: 0167-4781
Publisher Item Identifier: S016747810000021X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 53
Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization

...encoding a predicted polypeptide of 306 amino acids was characterized. The new protease, tentatively named cathepsin Z, exhibits all features characteristics of a papain-like cysteine protease, including the highly conserved residues of the 'catalytic triad'. Cathepsin Z shares only 26-35% overall homology with previously described mammalian papain-like cysteine peptidases and... ...within the family of papain-like cysteine peptidases. Genomic clones covering the murine and human cathepsin Z genes were isolated. They comprise six exons and five introns spanning a 12-kb region of genomic DNA, respectively. Murine cathepsin Z was mapped to chromosome 2, a region with synteny homology to a region of human chromosome 20 to

which human cathepsin Z has been mapped previously. Northern blot analysis revealed ubiquitous expression of murine cathepsin Z. Multiple transcriptional start sites were identified for the murine cathepsin Z gene and together with the absence of a TATA box, a high G+C content... ...CpG island and the presence of several Sp1-binding sites in the promoter region, murine cathepsin Z may be classified as a 'housekeeping' gene. Copyright (C) 2000 Elsevier Science B.V.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec complementary DNA--endogenous compound--ec

4/3,K/48 (Item 47 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10633942 EMBASE No: 2000099482
Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease

Guncar G.; Klemencic I.; Turk B.; Turk V.; Karaoglanovic-Carmona A.; Juliano L.; Turk D.
D. Turk, Dept. of Biochem./Molecular Biology, Jozef Stefan Institute, Jamova 39, 1000 Ljubljana Slovenia
Author Email: dusan.turk@ijs.si
Structure ( STRUCTURE ) ( United Kingdom ) 15 MAR 2000 , 8/3 (305-313)
CODEN: STRUE ISSN: 0969-2126
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 54
Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity...

Background: Cathepsin X is a widespread, abundantly expressed papain- like mammalian lysosomal cysteine protease. It exhibits carboxy-monopeptidase... ...of the two enzyme activities has actually been monitored. Results: The crystal structure of human cathepsin X has been determined at 2.67 Angstrom resolution. The structure shares the common features of... ...like enzyme fold, but with a unique active site. The most pronounced feature of the cathepsin X structure is the mini-loop that includes a short three- residue insertion protruding into the... ...terminal carboxyl group of a substrate in two different sidechain conformations. Conclusions: The structure of cathepsin X exhibits a binding surface that will assist in the design of specific inhibitors of cathepsin X as well as of cathepsin B and thereby help to clarify the physiological roles of...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *histidine--endogenous compound--ec; *peptidase--endogenous compound--ec; * proteinase--endogenous compound--ec

4/3,K/49 (Item 48 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10601951 EMBASE No: 2000067209
Cathepsin Q, a novel lysosomal cysteine protease highly expressed in placenta

Sol-Church K.; Frenck J.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I. duPont Hospital Children, PO Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochemical and Biophysical Research Communications ( BIOCHEM. BIOPHYS. RES. COMMUN. ) ( United States ) 27 JAN 2000 , 267/3 (791-795)
CODEN: BBRCA ISSN: 0006-291X
Document Type: Journal ; Article

Language: ENGLISH  Summary Language: ENGLISH
Number Of References: 22

...is predicted that cathepsin Q will differ in catalytic specificity to another placental-specific protease, cathepsin P, indicating that these enzymes will have unique proteolytic functions in extra-embryonic tissues. (C) 2000...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec; *lysosome enzyme--endogenous compound--ec

4/3,K/50 (Item 49 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
10531360 EMBASE No: 1999415968
Cathepsin Y (a novel thiol enzyme) produces kinin potentiating peptide from the component protein of rat plasma

Sakamoto E.; Sakao Y.; Taniguchi Y.; Yamafuji K.
E. Sakamoto, Department of Food and Nutrition, Nakamura Gakuen University, Jonan-ku, Fukuoka 814-0198 Japan
Immunopharmacology (IMMUNOPHARMACOLOGY ) ( Netherlands ) 1999 , 45/1-3 (207-214)
CODEN: IMMUD ISSN: 0162-3109
Publisher Item Identifier: S016231099900079X
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 18
Cathepsin Y (a novel thiol enzyme) produces kinin potentiating peptide from the component protein of rat plasma

Rat spleen cathepsin Y (a novel enzyme) that produces bradykinin (BK) potentiating peptide (BPP) from rat plasma was isolated... ...from cDNA cloned by reverse transcription-polymerase chain reaction (RT-PCR). We propose the name cathepsin Y for this enzyme considering its origin, characteristics and the amino acid sequence. BPP potentiates not... ...when the level is doubled. The precursor proteins that produce BPP by the action of cathepsin Y are eluted into two fractions when the heated plasma was applied to a negative ion... ...this paper, we report on the characteristics and the amino acid sequence of rat spleen cathepsin Y, its structure and the potentiating activity of BPP, and isolation of the precursor protein. Copyright...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *bradykinin--endogenous compound--ec; *thiol proteinase--endogenous compound--ec; * kinin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin y--endogenous compound--ec

4/3,K/51 (Item 50 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07906071 EMBASE No: 1999379729
Cathepsin P, a novel protease in mouse placenta

Sol-Church K.; Frenck J.; Troeber D.; Mason R.W.
R.W. Mason, Laboratory of Enzymology, Department of Research, Alfred I. duPont Hospital Children, PO Box 269, Wilmington, DE 19899 United States
Author Email: rmason@nemours.org
Biochemical Journal ( BIOCHEM. J. ) ( United Kingdom ) 15 OCT 1999 , 343/2 (307-309)
CODEN: BIJOA ISSN: 0264-6021
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH

Number Of References: 13
Cathepsin P, a novel protease in mouse placenta

The complete cDNA nucleotide sequence of a novel cathepsin derived from mouse placenta, termed cathepsin P, was determined. mRNA for cathepsin P was expressed in placenta and at lower levels in visceral yolk sac, but could not...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
proteinase--endogenous compound--ec; complementary DNA--endogenous compound--ec; messenger RNA--endogenous compound--ec

4/3,K/52 (Item 51 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07863831 EMBASE No: 1999344211
Human cathepsin X: A cysteine protease with unique carboxypeptidase activity

Nagler D.K.; Zhang R.; Tam W.; Sulea T.; Purisima E.O.; Menard R.
R. Menard, Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount Ave., Montreal, Que. H4P 2R2 Canada
Author Email: robert.menard@nrc.ca
Biochemistry ( BIOCHEMISTRY ) ( United States ) 28 SEP 1999 , 38/39 (12648-12654)
CODEN: BICHA ISSN: 0006-2960
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 40
Human cathepsin X: A cysteine protease with unique carboxypeptidase activity

Cathepsin X is a novel cysteine protease which was identified recently from the EST (expressed sequence tags) database. In a homology model of the mature cathepsin X, a unique three residue insertion between the Gln22 of the oxyanion hole and the active... ...verify this hypothesis, human procathepsin X was expressed in Pichia pastoris and converted to mature cathepsin X using small amounts of human cathepsin L. Cathepsin X was found to display excellent carboxypeptidase activity against the substrate Abz-FRF(4NOinf 2), with... ...1 ssup -sup 1 at the optimal pH of 5.0. However, the activity of cathepsin X against the substrates Cbz-FR-MCA and Abz-AFRSAAQ-EDDnp was found to be extremely... ...k(cat)/K(M) values lower than 70 Msup -sup 1 ssup -sup 1. Therefore, cathepsin X displays a stricter exopeptidase activity than cathepsin B. No inhibition of cathepsin X by cystatin C could be detected up to a concentration of 4 muM of inhibitor... ...the bound carboxypeptidase substrate is predicted to establish a number of favorable contacts within the cathepsin X binding site, in particular with residues His23 and Tyr27 from the mini-loop. The presence ... ...substrates in the primed subsites of the protease. The marked structural and functional differences of cathepsin X relative to other members of the papain family of cysteine proteases will be of great...
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec; *cysteine proteinase--endogenous compound--ec; *carboxypeptidase--endogenous compound--ec; * cathepsin l--endogenous compound--ec; *cathepsin b--endogenous compound--ec
histidine--endogenous compound--ec; tyrosine--endogenous compound--ec; cystatin c--endogenous compound--ec; cysteine
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/53 (Item 52 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07403528 EMBASE No: 1998297006
Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insertions

Nagler D.K.; Menard R.
R. Menard, Biotechnology Research Institute, National Research Council Canada, 6100 Avenue Royalmount, Montreal, Que. H4P 2R2 Canada
FEBS Letters ( FEBS LETT. ) ( Netherlands ) 1998 , 434/1-2 (135-139)
CODEN: FEBLA ISSN: 0014-5793
Publisher Item Identifier: S0014579398009648
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 40
Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique...

A novel cDNA encoding a cysteine protease of the papain family named cathepsin X was obtained by PCR amplification from a human ovary cDNA library. The cathepsin X cDNA is ubiquitously expressed in human tissues and contains an open reading frame of 912... ...highly conserved regions in papain-like cysteine proteases including the catalytic residues are present in cathepsin X. The mature part of cathepsin X is 26-32% identical to human cathepsins B, C, H, K, L, O, S and W. The cathepsin X sequence contains several unique features: (i) a very short proregion; (ii) a three amino acid...
DRUG DESCRIPTORS:
* cathepsin; *papain--endogenous compound--ec; *cysteine proteinase --endogenous compound--ec
cathepsin s--endogenous compound--ec; cathepsin b--endogenous compound--ec

4/3,K/54 (Item 53 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
07356252 EMBASE No: 1998227542
Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location

Santamaria I.; Velasco G.; Pendas A.M.; Fueyo A.; Lopez-Otin C.
C. Lopez-Otin, Depto. de Bioquimica/Biologia Molec., Facultad de Medicina, Universidad de Oviedo, 33006 Oviedo Spain
Author Email: CLO@DWARF1.QUIMICA.UNIOVI.ES
Journal of Biological Chemistry ( J. BIOL. CHEM. ) ( United States ) 03 JUL 1998 , 273/27 (16816-16823)
CODEN: JBCHA ISSN: 0021-9258
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 62
Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location

...revealed that the isolated cDNA codes for a polypeptide of 303 amino acids, tentatively called cathepsin Z, that exhibits structural features characteristic of cysteine proteinases. Fluorescent in situ hybridization experiments revealed that the human cathepsin Z gene maps to chromosome 20q13, a location that differs from all cysteine proteinase genes mapped to date. The cDNA encoding cathepsin Z was expressed in Escherichia coli as a fusion protein with glutathione S- transferase, and after... ...amido-4- methylcoumarin, used as a substrate for cysteine proteinases. Northern blot analysis demonstrated that cathepsin Z is widely expressed in human tissues, suggesting that this enzyme could be involved in the normal intracellular protein degradation taking place in all cell types. Cathepsin Z is also ubiquitously distributed in cancer cell lines and in primary tumors from different sources... ...unusual short propeptide, together with its unique chromosomal location among cysteine proteinases, we propose that cathepsin Z may be the first representative of a novel subfamily of this class of proteolytic enzymes.
DRUG DESCRIPTORS:

* cathepsin--endogenous compound--ec
Drug Terms (Uncontrolled): cathepsin z--endogenous compound--ec

4/3,K/55 (Item 54 from file: 73) Links
Fulltext available through: USPTO Full Text Retrieval Options
EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
06200066 EMBASE No: 1995231005
Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas

Li Y.-P.; Alexander M.; Wucherpfennig A.L.; Yelick P.; Chen W.; Stashenko P.
Forsyth Dental Center, 140 Fenway,Boston, MA 02115 United States
Journal of Bone and Mineral Research ( J. BONE MINER. RES. ) ( United States )
1995 , 10/8 (1197-1202)
CODEN: JBMRE ISSN: 0884-0431
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH

...has been identified by differential screening of a human osteoclastoma cDNA library. This molecule, termed cathepsin X, appears to represent the human homolog of the osteoclast-expressed rabbit cathepsin OC-2. Cathepsin X (GenBank accession number U20280) is 93.9% identical to OC-2 at the amino acid level, and is 92% identical at the nucleotide level within the coding region. Cathepsin X is 52.2 and 46.9% identical to cathepsins S and L, respectively, and is therefore clearly distinct from these enzymes. Cathepsin X mRNA was localized to multinucleated giant cells within the osteoclastoma tumor by in situ hybridization. These data strongly support the hypothesis that cathepsin X represents a novel cysteine proteinase which is expressed at high levels in osteoclasts.
DRUG DESCRIPTORS:
* cathepsin--endogenous compound--ec
cysteine proteinase--endogenous compound--ec; unclassified drug
Drug Terms (Uncontrolled): cathepsin x--endogenous compound--ec

4/3,K/56 (Item 1 from file: 35) Links
Dissertation Abs Online
(c) 2007 ProQuest Info&Learning. All rights reserved.
01980017 ORDER NO: AADAA-IMQ83852
The design of substrates for cathepsin X

Author: Devanathan, Gopal
Degree: M.Sc.
Year: 2003
Corporate Source/Institution: Concordia University (Canada) ( 0228 )
Source: Volume 42/03 of MASTERS ABSTRACTS. of Dissertations Abstracts International.

PAGE 941 . 90 PAGES
ISBN: 0-612-83852-8
The design of substrates for cathepsin X

...diseases such as arthritis, Alzheimer's, and cancer, they are attractive targets for inhibitor design. Cathepsin X is a cysteine protease that was only recently discovered. The primary structure of cathepsin X contains several unique features that clearly distinguish it from the other human cysteine proteases. The...
...a systematic study on the S2, S1, and S1<super>′</super> subsites of the cathepsin X active site and to gain a detailed understanding of the enzyme's substrate specificity.
Three libraries of compounds have been synthesized based on the parent compound 2-Abz-Phe-Arg-Phe(4NO<sub>2</sub>). In each library, the 20 natural...
...prime;</super> sites respectively, while keeping the other positions fixed. In reference to the parent compound, P2 is occupied by Phe, P1 by Arg, and

P1<super>′</super> by Phe... ...by docking 2-Abz-Phe-Arg-Phe(4NO<sub>2</sub>) and analogues to the cathepsin X active site in order to gain a detailed understanding of factors underlying substrate specificity. Knowledge...

4/3,K/57 (Item 1 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0377298 DBA Accession No.: 2005-23004 PATENT
Identification of a compound capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence and presence of the compound involving vector-mediated gene transfer and expression in host cell for therapy

Author: SALTZMAN A G; TANG Z; PALEJWALA V; CAVALLO J
Patent Assignee: AVENTIS PHARM INC 2005
Patent Number: WO 200565693 Patent Date: 20050721 WPI Accession No.: 2005-533570 ( 200554 )
Priority Application Number: US 533330 Application Date: 20031230
National Application Number: WO 2004US41815 Application Date: 20041214
Language: English
Identification of a compound capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence and presence of the compound involving vector-mediated gene transfer and expression in host cell for therapy
Abstract: DERWENT ABSTRACT: NOVELTY - Identification of a compound (I) capable of modulating the activity of cathepsin Z in a cell comprises measuring the cell's base level of cathepsin Z activity in the absence of a candidate compound; introducing the candidate compound; and measuring the cell's level of cathepsin Z activity in the presence of the candidate compound. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) the compound (I) capable of modulating activity of cathepsin Z; and (2) a pharmaceutical comprising (I) and excipient for treating an inflammatory. ACTIVITY - Antiinflammatory; Immunosuppressive; Antiarthritic; Antirheumatic; Neuroprotective. MECHANISM OF ACTION - Cathepsin Z modulator. Test details are described but no results given. USE - (I) is useful to treat...
Descriptors: recombinant cathepsin-Z prep., isol., vector-mediated gene transfer, expression in host cell, appl., inflammatory disease, autoimmune disease...

4/3,K/58 (Item 2 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0338230 DBA Accession No.: 2004-10522 PATENT
Use of polynucleotide sequence encoding Cathespin Y protein for identification of therapeutic agent useful for treating stroke e.g. ischemic stroke vector-mediated cathespin-Y gene transfer, expression in host cell and antisense oligonucleotide for drug screening and gene therapy

Author: LUBBERT H; ZWILLING S; ENGELS P
Patent Assignee: LUBBERT H; ZWILLING S; ENGELS P 2003
Patent Number: US 20030232740 Patent Date: 20031218 WPI Accession No.: 2004-142033 ( 200414 )
Priority Application Number: US 392809 Application Date: 20030319
National Application Number: US 392809 Application Date: 20030319
Language: English
Abstract: ...of potential therapeutic agent for treating stroke involves contacting a cell capable of expressing a Cathepsin Y gene or homologues or fragments with the potential therapeutic agent; detecting a level of expression of the Cathepsin Y gene in the test cell; comparing expression in the test cell to a reference cell... ...of potential therapeutic agent for treating stroke involves contacting a cell capable of expressing a Cathepsin Y gene or homologues or fragments with the potential therapeutic agent; detecting a level of expression of the Cathepsin Y gene in the test cell; comparing the level of expression of the Cathepsin Y gene in the test

cell to a level of expression of the Cathepsin Y gene in a reference cell whose disease stage is known; and identifying the difference in the expression level of the Cathepsin Y gene in the test cell and the reference cell. INDEPENDENT CLAIMS are included for the following: (a) a composition comprising a compound of formula (I) or its salt; (b) a composition comprising a nucleic acid sequence (S1) which is an antisense sequence compared to a nucleic acid sequence (S2) encoding Cathepsin Y, its homologue or fragment. (S2) Has sequence of 1140 or 1500 nucleotide bases as given... ...is 0, then R4 is other than -N(CH3)OCH3. ACTIVITY - Cerebroprotective. MECHANISM OF ACTION - Cathepsin Y protein inhibitor. Test details are described, but no results are given. USE - For identifying potential...

4/3,K/59 (Item 3 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0335363 DBA Accession No.: 2004-07655 PATENT
New antisense compound targeted to nucleic acid molecules encoding cathepsin Z, useful for treating diseases associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder involving vector-mediated gene transfer and expression in host cell for use in therapy

Author: DOBIE K W
Patent Assignee: ISIS PHARM INC 2003
Patent Number: US 20030224511 Patent Date: 20031204 WPI Accession No.: 2004-060543 ( 200406 )
Priority Application Number: US 159266 Application Date: 20020531
National Application Number: US 159266 Application Date: 20020531
Language: English
New antisense compound targeted to nucleic acid molecules encoding cathepsin Z, useful for treating diseases associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder involving vector-mediated gene transfer and expression...
Abstract: DERWENT ABSTRACT: NOVELTY - A compound (I) 8-80 nucleobases in length targeted to a nucleic acid molecule encoding cathepsin Z, is new. DETAILED DESCRIPTION - A compound (I) 8-80 nucleobases in length targeted to a nucleic acid molecule encoding cathepsin Z, is new. The compound specifically hybridizes with the nucleic acid molecule encoding cathepsin Z and inhibits the expression of cathepsin Z, or specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding cathepsin Z. INDEPENDENT CLAIMS are included for the following: (1) a composition comprising (I) and a pharmaceutical carrier or diluent; (2) a method of inhibiting the expression of cathepsin Z in cells or tissues comprising contacting the cells or tissues with (I); and (3) a method of treating an animal having a disease or condition associated with cathepsin Z comprising administering to the animal a therapeutic or prophylactic amount of (I) so that expression of cathepsin Z is inhibited. BIOTECHNOLOGY - Preparation: The antisense compounds are produced by solid phase synthesis. Preferred Compound: The compound is an antisense oligonucleotide, preferably a chimeric oligonucleotide. The antisense oligonucleotide comprises: (a) at least... ...Inhibitor Z. USE - The antisense oligonucleotides and compounds are useful for inhibiting the expression of cathepsin Z, and for treating diseases or conditions associated with expression of cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative disorder, such as cancer (all claimed). The antisense...
Descriptors: recombinant cathepsin-Z prep., isol., vector-mediated gene transfer, expression in host cell, antisense oligonucleotide, appl. encephalitis, virus...

4/3,K/60 (Item 4 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0334375 DBA Accession No.: 2004-06667 PATENT
Composition useful for treating pain e.g. neuropathic pain comprises polynucleotide sequence sense and antisense sequence for use in disease therapy and gene therapy

Author: LUBBERT H; ENGELS P; SCHMITZ B
Patent Assignee: LUBBERT H; ENGELS P; SCHMITZ B 2003
Patent Number: US 20030212003 Patent Date: 20031113 WPI Accession No.: 2004-041675 ( 200404 )
Priority Application Number: US 369386 Application Date: 20030214
National Application Number: US 369386 Application Date: 20030214
Language: English
Abstract: ...therapeutic agents for treating pain involving: (a) contacting a test cell capable of expressing a Cathepsin Y gene, its homologues or fragments with the potential therapeutic agent; (b) detecting a level of expression of the Cathepsin Y gene in the test cell; (c) comparing the level of expression of the Cathepsin Y gene in the test cell to that in a reference cell; and (d) identifying the difference in the expression levels of the Cathepsin Y gene in the test cell and reference cell; (2) identification of a therapeutic agent for treating pain involving: (a) incubating a sample comprising a Cathepsin Y protein, a test compound/agent and a polypeptide which is a target of Cathepsin Y protein proteolysis; (b) determining an aminoterminal amino acid of a peptide resulting from the proteolysis... ...nucleic acid sequence is an antisense sequence compared to a nucleic acid sequence that encodes Cathepsin Y and has a sequence of 1387 or 1500 nucleotide bases. BIOTECHNOLOGY - Preferred Method: The expression of the Cathepsin Y gene is determined by at least one method selected from PCR of a cDNA, hybridizing a sample DNA and detecting a Cathepsin Y protein. ACTIVITY - Analgesic; Antidiabetic; Neuroprotective; Virucide; Vulnerary; Cardiant. MECHANISM OF ACTION - Cathepsin Y protein inhibitor. No biological data given. USE - The compound is useful for treating pain e.g. neuropathic pain (claimed), diabetic neuropathy, post-herpetic neuralgia... ...reflex sympathetic dystrophy and causalgia, myocardial syndromes or idiopathic pain. ADVANTAGE - The composition efficiently downregulates Cathepsin Y activity and hence treats pain. EXAMPLE - No relevant example given. (22 pages)
Descriptors: polynucleotide composition, cathepsin Y gene, antisense sequence, polymerase chain reaction, appl. pain, neuropathic pain, diabetic neuropathy, post-herpetic neuralgia...

4/3,K/61 (Item 5 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0328457 DBA Accession No.: 2004-00749 PATENT
Developing medicament used for treating pain comprises using polynucleotide sequence encoding cathepsin Y involving vector-mediated gene transfer and expression in host cell for use in neuropathic pain therapy

Author: LUEBBERT H; SCHMITZ B
Patent Assignee: BIOFRONTERA PHARM AG 2003
Patent Number: EP 1336847 Patent Date: 20030820 WPI Accession No.: 2003-814978 ( 2003 )
Priority Application Number: EP 20023400 Application Date: 20020214
National Application Number: EP 20023400 Application Date: 20020214
Language: English
Developing medicament used for treating pain comprises using polynucleotide sequence encoding cathepsin Y involving vector-mediated gene transfer and expression in host cell for use in neuropathic pain...
Abstract: DERWENT ABSTRACT: NOVELTY - Developing a medicament for treating pain comprises using a polynucleotide sequence encoding cathepsin Y. DETAILED DESCRIPTION - Developing a medicament for treating pain, for diagnosing pain status outside of a... ...efficacy of pain treatment outside of a living body, comprises using a polynucleotide sequence encoding cathepsin Y or homologs or fragments or the corresponding protein or peptide. INDEPENDENT CLAIMS are also included for: (1) the use of a compound downregulating cathepsin Y expression or activity for manufacture of a medicament for treatment of pain; (2) a diagnostic... ...isolated nucleic acid sequence comprising an 'antisense' sequence compared to a nucleic acid sequence encoding cathepsin Y or a fragment of the nucleic acid sequence as a medicament; and (4) a transgenic animal where the gene encoding cathepsin Y is manipulated in the animal in comparison to the wild type. ACTIVITY - Analgesic. MECHANISM OF ACTION -

Cathepsin Y inhibitor. Tests are described, but no results are given. USE - Used for treating pain, particularly...
Descriptors: recombinant cathepsin-Y prep., isol., vector-mediated gene transfer, expression in host cell, polymerase chain reaction, appl. neuropathic...

4/3,K/62 (Item 6 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0313249 DBA Accession No.: 2003-14389 PATENT
New transgenic mice comprising a disruption in a cathepsin Z (CTSZ) useful as models for diseases or conditions associated with phenotypes relating to a disruption in a CTSZ gene, and in identifying drugs for treating a disease vector-mediated mutant gene transfer and expression in embryonic stem cell for transgenic mouse construction for use as an animal model in disease therapy

Author: WISOTZKEY R G; KIRK C J
Patent Assignee: DELTAGEN INC 2003
Patent Number: WO 200326403 Patent Date: 20030403 WPI Accession No.: 2003-354621 ( 200333 )
Priority Application Number: US 324639 Application Date: 20010924
National Application Number: WO 2002US30506 Application Date: 20020924
Language: English
New transgenic mice comprising a disruption in a cathepsin Z (CTSZ) useful as models for diseases or conditions associated with phenotypes relating to a disruption...
Abstract: DERWENT ABSTRACT: NOVELTY - A transgenic mouse comprising a disruption in a cathepsin Z (CTSZ) gene, where there is no native expression of endogenous CTSZ gene, is new. DETAILED... ...a pharmaceutical composition for a condition associated with a function of CTSZ, comprises identifying a compound that modulates CTSZ, synthesizing the identified compound, and incorporating the compound into a pharmaceutical carrier. USE - The transgenic mouse is useful as a model for diseases... ...symptoms; and in testing and developing new treatments relating to behavioral phenotypes. EXAMPLE - Disruptions in cathepsin Z (CTSZ) genes were produced by homologous recombination. Transgenic mice comprising disruptions in CTSZ genes were...
Descriptors: transgenic mouse construction, vector-mediated mutant cathepsin- Z gene transfer, expression in embryonic stem cell, phenotyping, animal model, antagonist, agonist, database, homologous recombination...

4/3,K/63 (Item 7 from file: 357) Links
Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rights reserved.
0257611 DBA Accession No.: 2000-12101 PATENT
New human cathepsin-Y protein, a gene encoding it and its application - diagnosis, therapy, gene therapy and drug screening

Corporate Source: Japan.
Patent Assignee: Fuji-Pharm. 2000
Patent Number: JP 2000157263 Patent Date: 20000613 WPI Accession No.: 2000-468198 ( 2041 )
Priority Application Number: JP 98352110 Application Date: 19981126
National Application Number: JP 98352110 Application Date: 19981126
Language: Japanese
New human cathepsin-Y protein, a gene encoding it and its application
Abstract: A human-derived cathepsin-Y protein (I) or a new human-derived cathepsin-Y protein which has at least 49% homology to the protein sequence of (I) has a... ...I) or its salts, peptides, etc., the DNA or the antibody; a drug containing a compound promoting or inhibiting biological activity of one of the claimed proteins, their partial peptides or...
Descriptors: human recombinant cathepsin-Y prep., cysteine protease act., monoclonal antibody, vector expression in host cell, DNA probe hybridization, appl...

```
?  e au=saltzman, alan?
Ref   Items  Index-term
E1        1  AU=SALTZMAN, ALAN GLENN
E2        2  AU=SALTZMAN, ALAN R
E3        0  AU=SALTZMAN, ALAN?
E4        1  AU=SALTZMAN, ALICE
E5        1  AU=SALTZMAN, ALVIN R.
E6        8  AU=SALTZMAN, AMY
E7        1  AU=SALTZMAN, ANDREA
E8        1  AU=SALTZMAN, ANDREW K
E9        5  AU=SALTZMAN, ANDREW K.
E10       1  AU=SALTZMAN, ANN L.
E11       1  AU=SALTZMAN, AR
E12       3  AU=SALTZMAN, ARNEET L
E13       3  AU=SALTZMAN, ARNEET L.
E14      39  AU=SALTZMAN, ARTHUR
E15       1  AU=SALTZMAN, ARTHUR MICHAEL
E16      22  AU=SALTZMAN, B
E17       7  AU=SALTZMAN, B (ED)
E18       1  AU=SALTZMAN, B E
E19      62  AU=SALTZMAN, B.
E20       1  AU=SALTZMAN, B. (BROWN UNIVERSITY, PROVIDENCE, RI
E21       1  AU=SALTZMAN, B. C.
E22      34  AU=SALTZMAN, B. E.
E23       3  AU=SALTZMAN, B. N.
E24       8  AU=SALTZMAN, B. R.
E25       3  AU=SALTZMAN, B. S.
          Enter PAGE for more

?  s e2
S5          2   AU='SALTZMAN, ALAN R'

?  rd
>>>W:  Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S6          2   RD  (UNIQUE ITEMS)

?  t s6/3,k/1-2
>>>W:  KWIC option is not available in file(s): 399
 6/3,K/1 (Item 1 from file: 98)  Links
General Sci Abs
(c) 2007 The HW Wilson Co. All rights reserved.
03787731    H.W. Wilson Record Number: BGSI98037731
Advances in Health Sciences Education: Theory and Practice.

Augmented Title: review of triannual journal edited by Henk Schmidt et al., Kluwer
Academic Publishers
Saltzman, Alan R
Byrd, Gary D
JAMA ( JAMA ) v. 279 no13 (Apr. 1 '98) p. 1045
  ISSN: 0098-7484
Language: English
Country Of Publication: United States
Saltzman, Alan R


 6/3,K/2 (Item 1 from file: 143)  Links
Biol. & Agric. Index
(c) 2007 The HW Wilson Co. All rights reserved.
0539292    H.W. Wilson Record Number: BBAI95034200
```

Influence of cardiac action on gas mixing in closed-chest dogs

Zhang, Shaoping
Saltzman, Alan R; Klocke, Robert A
Journal of Applied Physiology v. 79 (July '95) p. 113-20
Document Type: Feature Article ISSN: 8750-7587
Saltzman, Alan R...

```
?  e au=tang, zhihua
Ref   Items  Index-term
E1       60  AU=TANG, ZHIHUA
E2        3  AU=TANG, ZHIHUAN
E3       23  AU=TANG, ZHIHUI
E4        1  AU=TANG, ZHIJI
E5       43  AU=TANG, ZHIJIAN
E6        1  AU=TANG, ZHIJIAN (JASON)
E7        9  AU=TANG, ZHIJIAO
E8        8  AU=TANG, ZHIJIE
E9        8  AU=TANG, ZHIJING
E10      16  AU=TANG, ZHIJUN
E11      11  AU=TANG, ZHIKAI
E12       3  AU=TANG, ZHILAN
E13       2  AU=TANG, ZHILEI
E14       7  AU=TANG, ZHILI
E15     199  AU=TANG, ZHILIAN
E16      23  AU=TANG, ZHILIE
E17       1  AU=TANG, ZHILIN
E18       1  AU=TANG, ZHILING
E19       1  AU=TANG, ZHILIU
E20       7  AU=TANG, ZHILONG
E21       2  AU=TANG, ZHILU
E22      24  AU=TANG, ZHIMIN
E23      18  AU=TANG, ZHIMING
E24       3  AU=TANG, ZHINENG
E25       1  AU=TANG, ZHINGANG
          Enter PAGE for more

?  s e1-e3
           60   AU=TANG, ZHIHUA
            3   AU=TANG, ZHIHUAN
           23   AU=TANG, ZHIHUI
S7         86   S E1-E3

?  s s7
S8         86   S S7

?  s s8 and cathepsin
           86   S8
        88555   CATHEPSIN
S9          1   S S8 AND CATHEPSIN

?  t s9/3,k/1
>>>W:  KWIC option is not available in file(s): 399
 9/3,K/1 (Item 1 from file: 399)  Links
CA SEARCH(R)
```

(c) 2007 American Chemical Society. All rights reserved.

143109795 CA: 143(7)109795k PATENT
Cathepsin Z inhibitors for treatment of rheumatoid arthritis and other autoimmune diseases
Inventor (Author): Saltzman, Alan G.; Tang, Zhihua; Palejwala, Vaseem; Cavallo, Jean

```
Location: USA
Assignee: Aventis Pharmaceuticals Inc.
Patent: PCT International ; WO 200565693 A2      Date: 20050721
Application: WO 2004US41815 (20041214) *US 2003PV533330 (20031230)
Pages: 28 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class:   A61K-031/70A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA;
CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG;
MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;
SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB;
GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI;
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG


?  e au=palejwala, vaseem
Ref   Items  Index-term
E1        8  AU=PALEJWALA, V. A.
E2       11  AU=PALEJWALA, VA
E3        5  AU=PALEJWALA, VASEEM
E4       17  AU=PALEJWALA, VASEEM A
E5       13  AU=PALEJWALA, VASEEM A.
E6        2  AU=PALEJWALLA M M
E7        3  AU=PALEK
E8      595  AU=PALEK J
E9      130  AU=PALEK J.
E10       1  AU=PALEK JIFI
E11      27  AU=PALEK JIRI
E12       2  AU=PALEK L
E13       1  AU=PALEK L E
E14       1  AU=PALEK LUKAS
E15       1  AU=PALEK M
E16      33  AU=PALEK V
E17       4  AU=PALEK V.
E18       1  AU=PALEK, , JIRI
E19      39  AU=PALEK, B.
E20      22  AU=PALEK, J
E21      39  AU=PALEK, J.
E22     102  AU=PALEK, JIRI
E23       1  AU=PALEK, LEONARD E.
E24      40  AU=PALEK, LUKAS
E25       2  AU=PALEK, M.
          Enter PAGE for more

?  s e1-e5
           8   AU=PALEJWALA, V. A.
          11   AU=PALEJWALA, VA
           5   AU=PALEJWALA, VASEEM
          17   AU=PALEJWALA, VASEEM A
          13   AU=PALEJWALA, VASEEM A.
S10       54   S E1-E5

?  s s10 and cathepsin
          54   S10
       88555   CATHEPSIN
S11        1   S S10 AND CATHEPSIN
```

```
?  t s11/3,k/1
>>>W:  KWIC option is not available in file(s): 399
 11/3,K/1 (Item 1 from file: 399)  Links
CA SEARCH(R)
```
(c) 2007 American Chemical Society. All rights reserved.

143109795 CA: 143(7)109795k PATENT
Cathepsin Z inhibitors for treatment of rheumatoid arthritis and other autoimmune diseases
Inventor (Author): Saltzman, Alan G.; Tang, Zhihua; Palejwala, Vaseem; Cavallo, Jean

Location: USA
Assignee: Aventis Pharmaceuticals Inc.
Patent: PCT International ; WO 200565693 A2 Date: 20050721
Application: WO 2004US41815 (20041214) *US 2003PV533330 (20031230)
Pages: 28 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class: A61K-031/70A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

```
?  e au=cavallo, jean
Ref   Items  Index-term
E1       16  AU=CAVALLO, JD
E2        1  AU=CAVALLO, JD*
E3        2  AU=CAVALLO, JEAN
E4       18  AU=CAVALLO, JEAN-DIDIER
E5        1  AU=CAVALLO, JIM
E6        1  AU=CAVALLO, JL
E7        5  AU=CAVALLO, JO
E8        1  AU=CAVALLO, JO ANN
E9        1  AU=CAVALLO, JOHN
E10       3  AU=CAVALLO, JOHN A
E11       2  AU=CAVALLO, JOHN A.
E12       2  AU=CAVALLO, JOHN J.
E13       2  AU=CAVALLO, JOHN L
E14      11  AU=CAVALLO, JOHN L.
E15       2  AU=CAVALLO, JOHN LOUIS
E16       2  AU=CAVALLO, JOHN MICHAEL
E17       1  AU=CAVALLO, JON
E18       2  AU=CAVALLO, JON R
E19       7  AU=CAVALLO, JON R.
E20       1  AU=CAVALLO, JOSEPH PETER
E21       3  AU=CAVALLO, K.
E22       1  AU=CAVALLO, K. M.
E23       2  AU=CAVALLO, KATHLEEN H.
E24       1  AU=CAVALLO, KATIE
E25       6  AU=CAVALLO, L
          Enter PAGE for more

?  s e2-e3
```

```
            1   AU=CAVALLO, JD*
            2   AU=CAVALLO, JEAN
S12         3   S E2-E3

?  s s12 and cathepsin
            3   S12
        88555   CATHEPSIN
S13         1   S S12 AND CATHEPSIN

?  t s13/3,k/1
>>>W:  KWIC option is not available in file(s): 399
 13/3,K/1 (Item 1 from file: 399)  Links
CA SEARCH(R)
(c) 2007 American Chemical Society. All rights reserved.

143109795        CA: 143(7)109795k          PATENT
Cathepsin Z inhibitors for treatment of rheumatoid arthritis and other autoimmune
diseases
Inventor (Author): Saltzman, Alan G.; Tang, Zhihua; Palejwala, Vaseem; Cavallo, Jean

Location: USA
Assignee: Aventis Pharmaceuticals Inc.
Patent: PCT International ; WO 200565693 A2      Date: 20050721
Application: WO 2004US41815 (20041214) *US 2003PV533330 (20031230)
Pages: 28 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class:   A61K-031/70A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA;
CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG;
MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;
SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB;
GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI;
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

?
```